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SUMMARY
Background
Statins are inhibitors of the rate-limiting enzyme, 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) reductase, in cholesterol biosynthesis. As such, they have been widely used 
in clinical practice as cholesterol lowering agents to reduce morbidity and mortality from 
coronary artery disease. There is evidence from clinical studies and in vitro experiments 
that statins have additional anti-inflammatory properties in atherosclerotic disease, which 
are unrelated to their lipid lowering activity. 
Clinical studies have previously suggested that statins might show a beneficial clinical 
effect in inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis. 
Furthermore, preliminary data obtained in models of pulmonary inflammation suggest 
that the effects manifest in rheumatoid patients can be achieved also in asthma.  A proof 
of concept study was designed to test the hypothesis that atorvastatin improves asthma 
control and airway inflammation in adults with asthma. 
Methods
Fifty four adults with allergic asthma were recruited to a 22-week crossover randomised 
controlled trial comparing the effect on asthma control and airway inflammation of oral 
atorvastatin 40 mg daily with that of a matched placebo. Each treatment was administered 
for 8 weeks separated by a 6-week washout period. The primary outcome was morning 
peak expiratory flow. Secondary outcomes included spirometry, asthma control 
questionnaire (ACQ) score, asthma quality of life questionnaire (AQLQ), provocation 
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concentration to methacholine (PC20) and inflammatory markers: exhaled nitric oxide, 
sputum differential cell count, sputum supernatant and serum inflammatory markers such 
as interleukin-6 (IL-6), IL-5, IL-8, sICAM-1, TNF-α, leukotriene B4 (LTB4) and high 
sensitivity C-reactive protein (hsCRP), and blood lymphocyte proliferation. 
Results
At 8 weeks, the change in mean morning PEF, as compared with baseline, did not differ 
between the atorvastatin and placebo treatment periods [mean difference -0.5 L/min, 95% 
CI -10.6 to 9.6, p=0.921]. No statistically significant effect of atorvastatin was seen in 
evening PEF, or methacholine responsiveness (PC20). Out of all spirometry results, only 
post-salbutamol FVC showed a statistically significant result, which was slightly lower in 
the atorvastatin group [treatment difference -0.1L, 95% CI -0.2 to 0.0, p=0.037]. There 
was also no change in ACQ or AQLQ. 
No change was seen in exhaled nitric oxide. The total cell counts recovered from sputum 
were similar after atorvastatin compared to after placebo treatment. After 8 weeks, the 
mean absolute and relative sputum macrophage count was significantly reduced after 
atorvastatin compared to placebo [mean absolute difference -44.9x104 cells, 95% CI -
80.1 to -9.7, p=0.029]. There was a reciprocal increase in the relative proportion of 
sputum neutrophils [mean proportion difference 13.1%, 95% CI 1.8 to 24.4, p=0.025], 
but there were no significant changes in the absolute count of these cells or the counts 
and proportions of the other sputum cell phenotypes under atorvastatin treatment.
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The sputum concentrations of inflammatory cytokines and mediators were similar after
atorvastatin compared to after placebo treatment other than LTB4 which was significantly 
reduced [mean difference -88.1 pg/mL, 95% CI -156.4 to -19.9, p=0.014].
No significant difference was seen in the concentration of any serum marker of 
inflammation between atorvastatin and placebo treatment periods. The change in hsCRP 
was of borderline significance [mean difference -0.65 mg/L, 95% CI -1.38 to 0.09, 
p=0.082], but there were no changes in sICAM-1, TNF-α, IL-5, IL-6 and IL-8. There was 
no significant difference in lymphocyte proliferation. 
The biochemical effects of atorvastatin therapy were reflected in significant reduction in 
concentration of serum lipids; cholesterol (mean difference -1.71 mmol/l, 95% CI -1.94 
to -1.48 p<0.0001), and HDL-cholesterol (mean difference -0.14 mmol/l, 95% CI -0.26 to 
-0.02 p=0.026), but not triglycerides. There were significant, albeit modest, increases in 
mean bilirubin, AST and ALT. There was no difference in compliance, assessed by 
number of tablets returned and by biochemical results.
There was no correlation between changes in LTB4 or IL-8 and sputum macrophage 
count, sputum neutrophil count, or PEF. The only correlation observed between the 
variables that were compared was between sputum macrophages and neutrophils.
Adverse event rates were similar in patients taking atorvastatin compared with placebo. 
Equal numbers of patients were lost to follow-up in both arms of the study. One patient 
died of unrelated causes while taking the placebo medication.
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Conclusions
There were no clinically important improvements in a range of clinical indices of asthma 
control after eight weeks of treatment with atorvastatin despite expected changes in 
serum lipids. There were however changes in airway inflammation and in particular, a 
reduction in the absolute sputum macrophage count after atorvastatin compared to 
placebo and an associated reduction in sputum LTB4 and a trend towards lower CRP.
The lack of any evidence of clinical benefit of atorvastatin in allergic asthma confirms 
and extends the findings of a smaller randomised placebo controlled crossover trial of 
simvastatin in 16 subjects with asthma, which showed no change in clinical outcomes or 
inflammatory markers. 
It is unlikely that altering duration of treatment, washout period or type of statin used 
would have changed the outcome of the study. However, as all patients were receiving 
inhaled corticosteroid as part of their asthma therapy, it is possible that this may have 
masked any modest anti-inflammatory effects of the statin. Baseline asthma inflammation 
may also have been too low to show any significant improvement.
Despite the postulated anti-inflammatory actions of statins, it seems that they may not be 
appropriate for the inflammatory phenotype associated with atopic asthma. The reduction 
in alveolar macrophage count found in patients with allergic asthma may however have 
relevance to the treatment of chronic lung diseases such as COPD in which alveolar 
macrophage function has been implicated in the pathogenesis.
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11. INTRODUCTION
1.1 Asthma
1.1.1 Definition
Asthma is a clinical syndrome characterised by increased responsiveness of the tracheo-
bronchial tree to a variety of stimuli. The major symptoms of asthma are paroxysms of 
dyspnoea, wheezing and cough, which may vary from mild and almost undetectable to 
severe and unremitting. This is caused by airway smooth muscle hyperresponsiveness, 
which is the excessive narrowing of the airway lumen caused by stimuli that would cause 
little or no narrowing in the normal individual. The primary physiological manifestation 
of this hyperresponsiveness is variable airways obstruction. 
Asthma is defined by the Global Initiative for Asthma (GINA) as:
“a chronic inflammatory disorder of the airways in which many cells and cellular
elements play a role. The chronic inflammation causes an associated increase in airway 
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing, particularly at night or in the early morning. These episodes are 
usually associated with widespread but variable airflow obstruction that is often 
reversible either spontaneously or with treatment.” 1
1.1.2 Pathogenesis
Asthma is an inflammatory condition of the airways with both acute and chronic phases. 
An immunoglobulin E (IgE)-type response to common inhaled allergens is the most 
2common form of the disease in children 2, and is called atopic asthma. The frequency 
with which asthma is associated with atopy depends on the test used (table 1.1).
Table 1.1 Relationship of asthma and atopy
Test Population Percentage asthma
associated with atopy
Reference
Skin prick testing Adults 1-34 3
Serum IgE Adults 13-67 3
Skin prick test Children 65 4
In non-atopic asthma, it is likely that there is an immunological basis for disease, as the 
pathological features and the inflammation observed are similar in atopic and non-atopic 
asthma 5. 
1.1.2.1 Cells of the respiratory immune system
1.1.2.1.a Eosinophils
Bronchial eosinophilia is seen in both atopic and non-atopic asthma, and there is a 
correlation between sputum eosinophil concentration and asthma exacerbation rates6.
Eosinophil influx from capillaries into the lungs is controlled by vascular cell adhesion 
molecule-1 (VCAM-1), eotaxin, granulocyte-macrophage colony-stimulating factor (GM-
CSF), interleukin-4 (IL-4) and IL-5 5. When in the lung the eosinophils can be stimulated 
to release these same proinflammatory mediators, as well as cytotoxic mediators and 
growth factors, thus amplifying the inflammation. This leads to vascular leakage, 
3hypersecretion of mucus, smooth muscle contraction, shedding of epithelial cells and 
bronchial hyperresponsiveness. Eosinophils also regulate airway inflammation and may 
initiate the process of tissue repair termed ‘remodelling’ by the release of cytokines 7 and 
growth factors (see section 1.1.2.4.a below). Corticosteroids, a commonly form of asthma 
therapy, induce eosinophil apoptosis and phagocytic removal by macrophages 8, which in 
part explains their therapeutic effect.
1.1.2.1.b T Lymphocytes
Raised bronchial mucosal lymphocyte numbers are seen in all forms of asthma 9. The 
majority of T-lymphocytes bear CD4-receptors whereas CD8-positive cells are more 
rarely identified, even during exacerbations of asthma 10. 
A variety of different factors have been shown to control whether naive CD4+ T cells 
develop into TH1 or TH2 subsets depending on the mediators in their environment (Figure 
1.1). The most potent signals in influencing this process are cytokines. If naïve CD4+ T
cells are activated by antigen processed and presented by antigen-presenting cells 
(APCs), and in the presence of IL-12, a TH1-dominated population will develop, whereas 
if IL-4 is present in the environment, TH2 cells are induced. In the respiratory tract, many 
studies now suggest that TH2 responses are preferentially stimulated 11. The cytokines 
secreted by TH2 lymphocytes are thought to play a key role in the initiation and 
perpetuation of this airway inflammation 5. However, in stable chronic asthmatics TH0 or 
4TH1 cells may also be seen in the airways reflecting chronicity 12. The cells that line the 
bronchial airways create the cytokine microenvironment that controls CD4+ TH subset 
differentiation. Mast cells secrete IL-4, IL-5, and IL-13 in response to cross-linking of 
receptor-bound IgE antibody by antigen. In this manner, the early production of cytokines 
may initiate a shift in the immune responses toward TH2. Lymphocytes residing near the 
respiratory tract and secreting IL-4 also influence the cytokine milieu and shift a T-cell 
response toward TH2 13. 
5Figure 1.1 T helper (CD4+) cells in atopic diseases. Allergen is processed by antigen-presenting cells (dendritic 
cells) and presented via class II major histocompatibility complex (MHC class II) to T-cell receptors (TCR) on 
uncommitted T helper cells (Thp). Accessory molecules B7-2 and CD28 amplify this interaction. THp cells 
differentiate into TH1 cells in response to IL-12, which, under the influence of IL-12 and IL-18, can release 
interferon-γ (IFN-γ). Thp cells under the influence of IL-4 differentiate into TH2 cells, which release IL-4, IL-13 
and IL-5. IFN-γ inhibits TH2 cell differentiation and in this system IL-12, IL-18 and IFN-γ all result in inhibition 
of TH2 cells and the release of TH2 cytokines. 
Ig, immunoglobulin; IL, interleukin.  Reprinted from Barnes and Lim 5 with permission from Elsevier.
61.1.2.1.b.i T Lymphocyte activation
T cell immune responses are initiated in secondary lymphoid organs, where naïve T cells 
(TH0) encounter antigen-presenting cells (APCs, also known as dendritic cells). The 
interaction between T lymphocytes and APCs creates a specific physical site, termed the 
"immunological synapse", at which specific ligands and costimulatory molecules trigger 
and sustain the T cell activation process. Leucocyte Function-associated Antigen-1 (LFA-
1) mediates adhesion between T cells and APCs. It also functions to lower T cell 
activation thresholds 14. 
The importance of this initial cellular adherence step is demonstrated by the use of 
monoclonal antibodies that inhibit the function of LFA-1 that have also been effective in 
reducing airway eosinophilia in a murine model of atopic asthma 15 and sputum 
eosinophilia after allergen challenge in asthmatic patients 16.
1.1.2.1.c Macrophages
Alveolar macrophages primarily function to remove particles and apoptotic cells in a 
non-inflammatory manner. However, when appropriately stimulated they can also 
process inhaled allergen, which is then presented in a modified and recognisable form to 
primed T lymphocytes 17. The macrophage itself then becomes the target of a positive 
feedback loop by producing macrophage-activation lymphokines, which heighten its 
capacity to regulate the immunogenic stimulus. They are activated in asthma 18, in 
particular night-time asthma 19. Macrophages are responsive to steroid treatment, with 
7decreased MIP-1α, IFN-γ and granulocyte macrophage – colony stimulating factor (GM-
CSF), and increased IL-10, IL-1β 20 and histone deacteylase (HDAC) 21 release after 
steroid treatment.
1.1.2.1.d Neutrophils
Biopsy, BAL and sputum samples from severe asthmatics often have a high neutrophil 
count, and a comparatively low eosinophil count 22 particularly during an exacerbation 23. 
Indeed, there is an inverse association between FEV1 and the proportion of sputum 
neutrophils 24. As corticosteroids appear to inhibit neutrophil phagocytosis and prolong 
survival 8, this may in part explain steroid resistance in severe asthma. The eosinophils, 
which respond to steroids by becoming apoptotic, disappear from the inflamed airway, 
and the neutrophil may be drawn in and act as a “substitute granulocyte” 25. However, 
there is considerable variation between patients. 
1.1.2.2 Inflammatory mediators
1.1.2.2.a Cytokines
Cytokines are a large group of glycol-protein mediators that allow communication 
between cells. They play a critical role in determining the nature of the inflammatory 
response and its persistence. To date, more than 50 different mediators have been 
identified in asthma 5. Some of these (e.g. IL-1, IL-6, TNF-α) are involved in many 
inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease 11. 
8Others are more specific to atopy. Airway epithelial cells, smooth muscle cells, 
endothelial cells, and fibroblasts are all capable of synthesizing and releasing 
inflammatory mediators including cytokines. Cytokines may also play an important role 
in antigen presentation and may enhance or suppress the ability of macrophages to act as 
antigen-presenting cells 5.
The functions of some specific cytokines in the context of asthma are outlined in table 
1.2. This is illustrative and not comprehensive.
Table 1.2 Some functions associated with selected cytokines in asthma
Cytokine General function Function associated with asthma
Immunoregulatory cytokines
IL-4 B cell activation  
Monocyte and macrophage 
activation  
T cell growth factor
Increased ICAM-1 expression
Promotes immunoglobulin class 
switching from IgG to IgE.
↑ Eosinophil growth
Down-regulates IFN-γ mediated TH1 
responses
Promotes AHR (+)
IL-5 Eosinophil activation 
Mast cell and basophil 
differentiation and maturation 
Endothelial adhesion, priming 
for chemoattractants 
Cofactor for IgE synthesis
Eosinophil maturation, ↓ apoptosis
↓T H2 cells
Promotes AHR (++)
9Cytokine General function Function associated with asthma
IL-8 Primes for eosinophil 
chemotaxis
Neutrophil activator
Neutrophil and T cell 
chemoattractant
Down-regulates IgE production
IL-17 T cell proliferation
Activates epithelia, endothelial 
cells, fibroblasts
Promotes airway neutrophilia
IFN-γ Activates endothelial cells, 
epithelial cells, alveolar 
macrophages/
monocytes
Inhibition IgE isotype switch 
Eosinophil activation (late 
acting)
Macrophage activation
↓ Eosinophil influx after allergen
↓ TH2 cells
↓ IgE
↓ AHR
Pro-inflammatory cytokines
IL-1 B cell growth factor
Neutrophil chemoattractant 
T cell and epithelial cell 
activation 
Increased expression of 
endothelial adhesion molecule 
on many cell types
↑Adhesion to vascular endothelium
Eosinophil accumulation in vivo
Growth factor for TH2 cells
Promotes AHR (+)
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Cytokine General function Function associated with asthma
TNF-α Activates epithelium, 
endothelium, antigen-
presenting cells, 
monocytes/macrophages
Promotes AHR (+)
IL-6 B cell growth factor
Macrophage and eosinophil 
activator
T cell growth factor
↑ IgE
GM-CSF Proliferation and maturation of 
haematopoetic cells 
Endothelial cell migration
Mast cell, macrophage, 
epithelial cell, eosinophil and 
neutrophil differentiation, 
activation, and in vitro survival
Eosinophil apoptosis, chemotaxis and 
activation
Promotes AHR (+)
LTB4 Neutrophil and monocyte 
activator and chemoattractant
Recruits neutrophils and monocytes 
into airway
CCL2 Monocyte, lymphocyte and 
basophil recruitment
Mast cell/basophil 
degranulation
Recruits monocytes and lymphocytes 
into airway
Macrophage 
inflammatory 
protein
(MIP-1α)
Monocyte and naïve T cell 
chemoattractant 
Activates basophils and mast 
cells
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Cytokine General function Function associated with asthma
Inhibitory cytokines
IL-10 ↓ Monocyte and macrophage 
activation 
↑ B cells
↑ Mast cell growth
Inhibits TH1 cytokine production 
on APC 
↓ Eosinophil survival
↓ IgE
↓ TH1 and TH2
↓ AHR
IL-1receptor 
antagonist 
(IL-1ra)
↓ TH2 proliferation ↓ IgE
↓ AHR
IL-4 and IL-5 are key cytokines in asthma, and are over-expressed in asthmatic airways. 
IL-4 in particular drives antibody class switching to IgE and TH2 differentiation 5. IL-4 
increases the expression of vascular cell adhesion molecule-1 (VCAM-1) on endothelial 
and airway epithelial cells, and this may be important in eosinophil and lymphocyte 
trafficking 5. Recent work suggests that specifically targeting IL-4 may provide effective 
new asthma treatments, although the results of early clinical studies have been 
disappointing 26. IL-13 is structurally similar to IL-4, and both are recognised by a 
common receptor chain, and may act as alternative switches for TH2 activation 5.
Interleukin-5 (IL-5) is essential for the production, maturation, activation and survival of 
eosinophils and is also important in eosinophil chemoattraction 5. A clinical trial of a 
single dose of monoclonal antibody to IL-5 showed decreased blood eosinophils for up to 
12
16 weeks and reduced sputum eosinophils after inhaled allergen challenge, but there was 
no improvement in clinical outcomes 27.
IL-1 is also important in activating T lymphocytes and is an important co-stimulator of 
the expansion of TH2 cells after antigen presentation. For example, IL-4 is expressed by 
TH2 clones, once they have been exposed to IL-1 5.
1.1.2.2.b Apoptosis
Apoptosis is a process of programmed cell death, whereby cells when they have finished 
their role or become senescent express membrane molecules e.g. Fas which are 
recognised by macrophages which remove the apoptotic cells by a non-inflammatory 
mechanism. This is a dynamic process which controls the cell distribution at inflamed 
sites, limits the progression of inflammation, and promotes resolution 28. Thus, on-going 
inflammation may be due to alterations in the regulation of cell apoptosis leading to a 
chronic and self-perpetuating inflammatory cell survival and accumulation. Activated 
cells tend to live longer in sites in active inflammation 29 as a consequence of reduced 
apoptosis 30. Increased eosinophil survival in asthma is associated with reduced 
apoptosis 30. GM-CSF, IL-3, IL-5, and RANTES (regulated upon activation, normal T-
cell expressed and secreted), which are over expressed in asthmatic airways, act to inhibit 
apoptosis 31. Apoptosis may also be delayed by expression of CD40, a receptor molecule 
expressed on eosinophils strongly associated with inflammation 32. Anti-asthmatic 
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treatments with anti-inflammatory properties may work by promoting apoptosis 33 or 
reducing cell survival 34. 
1.1.2.3 Acute inflammation in asthma
An acute episode of asthma may be triggered by exposure to allergens, viruses, or indoor 
or outdoor pollutants. From experimental models of atopic asthma, reactions can be 
divided into early phase and late phase, with this late chronic phase often involving 
processes of tissue repair called remodelling of the airways 35.
1.1.2.3.a Early phase
Early phase airway reactions against inhaled allergens are triggered by activation of cells 
bearing allergen-specific IgE. After activation of airway mast cells and macrophages, 
there is release of proinflammatory mediators such as histamine, and eicosanoids 35. 
These induce contraction of airways smooth muscle, mucus secretion and vasodilatation 
and exudation of plasma into the airways. Plasma proteins may also be responsible for 
the formation of characteristic bronchial plugs of exudates mixed with mucus produced in 
increasing amounts in asthma, and inflammatory and epithelial cells 36. Together, these 
effects contribute to airflow obstruction.
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1.1.2.3.b Late phase  
Several hours, usually 6 to 9hr, after allergen exposure, the late-phase inflammatory 
reaction occurs. This involves the recruitment and activation of eosinophils, CD4+ T cells, 
basophils, neutrophils, and macrophages. Adhesion molecules such as tumour necrosis 
factor a (TNF-a) and sVCAM are released, as are proinflammatory mediators such as 
histamine, prostaglandin D2 (PGD2), and thromboxane B2 36 and cytokines like IL-1b, 
IL-4 and IL-5, which are involved in the recruitment and activation of inflammatory cells. 
T cells are activated after allergen challenge, releasing TH2 cytokines, which may be a 
key mechanism of the late-phase response 35. 
Cytokines such as IL-5 and GM-CSF enhance eosinophil recruitment, and expression of 
adhesion molecules. Chemokines such as RANTES and eotaxin  also act on eosinophils 
and T cells to enhance their recruitment and possibly their activation. IL-16 and 
macrophage inflammatory protein 1α (MIP-1α) are found in BAL fluid of antigen-
challenged asthmatics and may also participate in the process 35.
1.1.2.4 Chronic inflammation in asthma
Inflammation in chronic asthma appears to be far more complex than a simple 
eosinophilic inflammation. All cells of the airways, including T-cells, eosinophils, mast 
cells, macrophages, epithelial cells, fibroblasts, and even bronchial smooth muscle cells 
are involved in chronic asthma and become activated. 
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This chronic inflammation may result in structural changes in the airway, such as fibrosis 
(particularly under the epithelium), increased thickness of the airway smooth muscle 
layer (hyperplasia and hypertrophy), hyperplasia of mucus- secreting goblet cells, and 
new vessel formation (angiogenesis) 35. There may also be changes in the innervation of 
the airways 5.Some of these changes may be irreversible, leading to fixed narrowing of 
the airways, a process known as “remodelling” 35.
1.1.2.4.a Remodelling
The highly complex and inter-dependent interactions involved in remodelling are 
summarised in figure 1.2. Cells implicated in remodelling include epithelial cells 
(recruiting and prolonging the survival of inflammatory cells), eosinophils (involved in 
fibrosis), neutrophils, and smooth muscle cells (hyperplasia and altered myosin 
function) 35. 
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Figure 1.2 Mechanisms of acute and chronic inflammation in asthma and remodelling processes. Reproduced 
from Bousquet et al 35, copyright American Thoracic Society 2000
1.1.2.5 Systemic inflammation in asthma
It follows that inflammation in the lungs might be associated with systemic inflammation. 
Certainly, respiratory symptoms associated with infection, such as those seen in chronic 
obstructive pulmonary disease (COPD) are associated with a raised CRP, indicative of 
systemic inflammation 37. However some studies have shown that CRP is normal in 
atopic asthma 38, which suggests a different immuno-pathogenesis.
1.1.3 Diagnosis
1.1.3.1 Clinical diagnosis
Diagnosis of asthma is made on the basis of wheezing, chest tightness and episodic 
breathlessness. There may be a family history, and/or a seasonal pattern to symptoms. 
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Measurements of symptoms and lung function are important for assessing the 
characteristics of the patient's asthma.
1.1.3.2 Physical examination
Because asthma is an episodic disorder, physical examination may be normal. The most 
commonly found abnormality on chest auscultation is wheeze, however normal chest 
auscultation does not rule out a significant limitation of airflow.
1.1.3.3 Objective testing
Patients often have a poor perception of their own disease, especially in those with long-
standing or severe disease 39. In contrast, measurement of lung function, such as the 
reversibility of lung function, provides a direct, quantitative, assessment of airflow 
limitation. Measuring the variability in lung function provides an indirect assessment of 
airway hyper-responsiveness.
The most commonly used forms of assessment of airway function are the measurement of 
forced expiratory volume in 1 second (FEV1) and its accompanying forced vital capacity 
(FVC), and the measurement of peak expiratory flow (PEF). Both of these measurements 
rely on the fact that airflow limitation is directly related to the luminal size of the airways 
(airway calibre) and the elastic properties of the surrounding lung tissue (alveoli). 
Measurement of FEV1 and FVC is undertaken during a forced expiratory manoeuvre 
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using a spirometer. Specific technique for spirometry is discussed in the methodology 
chapter.
Because a reduced FEV1 can be caused by diseases other than those causing airflow 
limitation, a useful assessment of airflow limitation can be obtained as the ratio of FEV1
to FVC. In the normal lung, flow limitation on forced expiration results in FEV1/FVC 
ratios of greater than 80 percent and in children possibly greater than 90 percent. Any 
values less than these are suggestive of airflow limitation 1.
When making a diagnosis of asthma, a 12% improvement in FEV1 after inhalation of a 
bronchodilator, or in response to a trial of glucocorticosteroid therapy is sought 1.
Ideally lung function should be measured first thing in the morning when values are 
usually close to their lowest and last thing at night when values are usually at their 
highest. 
1.1.3.3.a Airway Hyperresponsiveness
Airway hyperresponsiveness can be assessed directly by stimulating airway smooth 
muscle with irritants (e.g. methacholine and histamine). Measurement of airway 
hyperresponsiveness has been standardized for histamine and methacholine administered 
via aerosol inhalation by tidal breathing or administered in predetermined amounts via a 
dosimeter. The provocative concentration reduces FEV1 by 20 percent from baseline 
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(PC20 or PD20). Nocturnal and/or early morning symptoms with a diurnal variation in 
peak expiratory flow (PEF) (which correlates well with FEV1) of 20 percent or more are 
highly characteristic of asthma 1. 
Key features of the diagnosis of asthma are detailed in table 1.3. 
20
Table 1.3 Diagnosis of asthma in adults 1, 40
Consider the diagnosis of asthma in patients with some or all of the following:
Symptoms Signs
Episodic/variable None (common)
Shortness of breath Wheeze – diffuse, bilateral, 
Wheeze expiratory (± inspiratory)
Chest tightness  Tachypnoea
Cough
Helpful additional information
Personal or family history of asthma or atopy (eczema, allergic rhinitis)
History of worsening after use of aspirin/non-steroidal anti-inflammatory drug ingestion, use 
of β blockers (including glaucoma drops)
Recognised triggers – pollens, dust, animals, exercise, viral infections, chemicals, irritants 
Pattern and severity of symptoms and exacerbations 
Objective measurements
>20% diurnal variation on ≥ 3 days in a week for two weeks on Peak Expiratory Flow diary 
or FEV1 ≥ 12% (and 200ml) increase after short acting β2 agonist (e.g. salbutamol 400 μg by 
MDI + spacer or 2.5mg by nebuliser) 1
or FEV1 ≥ 15% (and 200ml) increase after trial of steroid tablets (prednisolone 30mg/day for 
14 days) 40
or FEV1 ≥ 15% decrease after 15 minutes of exercise (running)
40
Histamine or methacholine challenge in difficult cases 
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1.1.4 Asthma control and quality of life
1.1.4.1 Assessment of asthma control
The goals of asthma control (defined by the Global Initiative for Asthma, GINA) 1 are: 
Minimal (ideally no) chronic symptoms, including nocturnal symptoms
Minimal (infrequent) exacerbations
No emergency visits
Minimal (ideally no) need for p.r.n. (as-needed) ß2-agonist
No limitations on activities, including exercise
PEF circadian variation of less than 20 percent
(Near) normal PEF
Minimal (or no) adverse effects from medicine.
A telephone survey of 2,803 patients in seven European countries found that less than 
25% of patients manage this ideal 41. Reasons for this can include poor adherence to 
guidelines, problems with communications, inadequate education and poor motivation. 
Therefore, there is room for improvement, and new treatments can help with this 
objective. Patients have also shown a preference for tablet-based medication rather than 
inhaler if possible 42, an issue which might help compliance.
1.1.4.1.a Asthma control score
An asthma control questionnaire (ACQ) was developed by Juniper et al 43 (see appendix 
3). In patients whose asthma was stable between clinic visits, reliability of ACQ was 
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high. The questionnaire includes a survey or important clinical symptoms and short 
acting β2-agonist use and well as FEV1 43.
1.1.4.2 Quality of Life
Health related quality of life (HRQL) can be measured through generic questionnaires 
such as the Medical Outcome Survey Short-Form 36 (SF-36) 44.  The strength of generic 
instruments is that they can be compared across different medical conditions. However, 
because of their breadth, they have very little depth, and in many conditions, including 
asthma, generic instruments can be unresponsive to small but clinically important 
changes in HRQL 45. An alternative is to use disease specific questionnaires, such as that 
developed by Juniper et al. 46 (see appendix 2). This questionnaire examines different 
aspects of asthma quality of life – symptoms, activities, emotional well-being and 
environmental factors – as well as providing an overall score. The developing team 
determined a Minimal Important Difference (MID) for change in HRQL score, which 
again was based on patient perceptions. A change of 0.5 is considered to be a clinically 
significant level 47.
1.1.5 Assessment of airway inflammation
In addition to assessing clinical control of asthma, it can be helpful to measure the extent to 
which the airways are inflamed. There are several techniques that can be used for this. Non-
invasive methods such as measuring cells or mediators in exhaled breath 
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condensate 48, exhaled nitric oxide 49 and induced sputum 50 are commonly used, and they are 
well tolerated by patients. More invasive methods such as bronchoscopy with biopsy provide 
more information with higher attendant risk.
1.1.5.1Invasive investigations
1.1.5.1.a Bronchoscopy
Bronchial biopsy is an invasive technique to directly sample bronchial tissue through 
bronchoscopy. This enables comparison between animal models and human airway 
disease. By obtaining a sample of actual lung tissue, one may directly examine cellular 
pathological events, for example, apoptosis, shedding, and expression of adhesion 
molecules 51. Remodelling, expression of specific types of cell and their prevalence ratios 
can also be directly assessed. Bronchoalveolar lavage (BAL) or airway brushing can also 
be performed during bronchoscopy. This allows direct sampling of the local environment.
1.1.5.2 Non-invasive investigations
1.1.5.2.a Exhaled Gases
1.1.5.2.a.i Nitric oxide
The presence of exhaled nitric oxide (NO) in the exhaled breath of both animals and 
humans was first described in 1991 52. This was followed by the discovery that exhaled 
NO levels are higher in asthma compared to normal subjects 53, and fall with treatment 
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with corticosteroids 54. There is a correlation between exhaled NO and sputum eosinophil 
levels 54 (see section 1.1.5.2.b below).
Exhaled NO comes from the nasal mucosa and the lower airways. It is synthesised by 
inducible NO synthases (iNOS or NOS2), and from non-enzymatic sources from 
reduction of NO metabolites 54. Other diseases can be associated with higher exhaled NO, 
shown in table 1.4 below. Exhaled NO is now being introduced as a method of assessing 
the response of asthma to treatment 55.
Table 1.4 Factors affecting exhaled nitric oxide 
Increased NO Decreased NO
Breath holding 53 Cigarette smoking 53
Exercise/hyperventilation 53 Pulmonary Hypertension 53
L-arginine (oral) 53 Kartagener’s syndrome 53
Upper respiratory tract infections 53 NOS inhibitors 53
Asthma 53 Glucocorticoids 53
Allergen challenge (late response) 53 HIV infection 56
Bronchiectasis 53
Cystic fibrosis 53
Lower respiratory tract infection 53
Systemic lupus erythematosis 57
Liver cirrhosis 58
25
1.1.5.2.a.ii Carbon monoxide
Levels of exhaled carbon monoxide (CO) rise in atopy and asthma, and rise further 
during an acute asthmatic reaction independently of airway caliber 59. There is also an 
association between exhaled CO and AHR 60. 
1.1.5.2.b Induced sputum
Induced sputum as a method for assessment of airway inflammation was introduced in 
1958 by Bickerman, using inhalation of hypertonic saline in aerosol form 61. Early studies 
found that inhalation of saline could induce bronchospasm in poorly controlled asthmatic 
subjects, so changes were made to the technique 62. The modern technique has been 
shown to be very safe, although bronchospasm can still occur 63. It is possible to obtain 
spontaneous sputum from some patients, especially those with more severe disease, but 
the sample tends to have fewer viable cells 64, and thus be of less value.
Individuals with asthma demonstrate increases in sputum markers of inflammatory cell 
activation or increased vascular permeability, such as tryptase, IL-5, and fibrinogen  as 
well as sputum cell counts for eosinophils, mast cells and neutrophils 65. One example of 
the value of induced sputum as a biomarker in asthma is that there are changes in sputum 
eosinophil count seen after treatment with prednisolone, correlating with clinical 
improvement 66.
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1.1.5.2.c Exhaled breath condensate
Condensation of some volatiles in gases in exhaled breath can be achieved simply by 
cooling the tubing through which the patient is exhaling. Successful collection has been 
reported with a variety of devices with different designs 67. Most widely used designs 
include immersion of a Teflon-lined tubing in an ice-filled bucket and a specially 
designed double-wall glass condenser system. The collected fluid represents the volatile 
part of aerosolized pulmonary extracellular-lining fluid. The pH of breath condensate 
fluid of patients with acute asthma has been shown to be over two log orders lower than 
in control subjects, suggesting that this may be a good indicator of altered airway 
environment which may be part of the inflammation 68. Markers in exhaled breath that 
may prove to be clinically useful in the future include aldehydes, glutathione 69, carbon 
monoxide, hydrogen peroxide, ethane 70, and nitrate or nitrites 71.
1.1.5.2.d Methacholine or histamine hyperreactivity
Tests of airway hyperresponsiveness are non-specific in isolation, as positive test results 
have been described in patients with allergic rhinitis, cystic fibrosis, bronchitis, and 
chronic obstructive pulmonary disease. However, a change in methacholine 
responsiveness is used to assess response to anti-inflammatory medications such as 
inhaled corticosteroids, or specific immunotherapy 72.
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1.1.5.2.e Blood tests
1.1.5.2.e.i IgE
A study of children with raised IgE levels (at least 10 times the mean) showed a strong 
link with asthma symptoms 4. Both total IgE and IgE against Dermatophagoides farinae
(house dust mite) have been shown to be strongly associated with asthma 73. 
1.1.5.2.e.ii Eosinophils
There is a link between raised serum eosinophils and asthma symptoms in children 74. 
However, in severe asthma the bronchial eosinophils tend to be reduced relative to raised 
neutrophils 24, so it is unlikely that their peripheral eosinophil count would be an accurate 
reflection of disease.
1.1.5.2.e.iii C-Reactive Protein
C-reactive protein (CRP) is the prototype acute phase protein and is a major systemic 
inflammatory marker synthesised by hepatocytes in response to IL-6 75. CRP is a very 
non-specific marker of inflammation: levels may be transiently elevated for 2 to 3 weeks 
after a major infection or trauma, and is transiently raised after exercise 76. CRP may also 
be of limited value among patients with chronic inflammatory conditions such as 
rheumatoid arthritis and SLE.  Finally, adipocytes also release IL-6, and obesity itself is 
related to a raised CRP 77. Some studies have shown that CRP is elevated in asthmatic 
subjects 78, although this association was weakened when obesity was controlled for. 
Other studies have suggested that CRP is similar between asthmatic and non-asthmatic 
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non-smokers 38. However, if CRP is measured using very sensitive techniques (high 
sensitivity or hs-CRP), a significant difference can be seen between asthmatic and 
healthy people (mean±SD 1.33±1.48mg/L compared with 0.21±0.30mg/L) 79. This 
difference is not seen in patients taking inhaled corticosteroids. Steroid-naive patients 
also showed a negative correlation between clinical indices such as FEV1 and hs-CRP, 
and a positive correlation relative to sputum eosinophils 79.  
1.1.6 Asthma treatment
1.1.6.1 Pharmacological treatments
Some of the drugs that are effective in asthma can only be used via inhalation because 
they are not absorbed when given orally. Medications taken for asthma fall into two 
groups, relievers and preventors. Relievers are rapid-acting bronchodilators that act to 
relieve bronchoconstriction and its accompanying acute symptoms such as wheezing, 
chest tightness, and cough. Inhaled β2 agonists such as salbutamol are bronchodilators, 
and act principally to dilate the airways by relaxing airway smooth muscle. They reverse 
bronchoconstriction and related symptoms of acute asthma, but do not reverse airway 
inflammation or reduce airway hyperresponsiveness 80. Long-acting β2 agonists (LABAs), 
such as formoterol, salmeterol provide relief of symptoms in addition to a reduction in 
exacerbations 81.
Preventors are medications taken on a long-term basis to keep persistent asthma under
control. Of all single medications, inhaled glucocorticosteroids (ICS) are at present the most 
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effective controllers 1. Oral steroid medication is indicated as treatment of an acute 
exacerbation of asthma not responding to other treatment, or for longer term treatment of 
unresponsive asthma 40. Leucotriene receptor antagonists are another oral medication that can 
improve asthma control 40. More recently, Omalizumab (a recombinant humanised 
monoclonal antibody against IgE) has been shown to be useful in patients with atopic asthma 
and concomitant allergic rhinitis 82. 
1.1.7 Summary
Asthma is a highly complex inflammatory disorder with many potential therapeutic 
approaches. Treatments aim to modify many aspects of the disease, usually with the 
intention of decreasing inflammation, the most commonly used being corticosteroids. 
Future developments in asthma medication will focus on alternative anti-inflammatory 
agents.
1.2 Atheroma and Inflammation – parallels for asthma
Atherosclerosis has been described as “a chronic inflammation induced and perturbed by 
lipid accumulation” 83. The primary site of inflammation is in the arteries. T lymphocytes 
and monocytes are early progenitors of this inflammation 84. The T lymphocytes involved 
show a predominantly TH1 cytokine picture, with expression of IL-2 and IFN-γ in a large 
proportion of plaques 83. A much lower proportion of plaques show TH2 cytokines such as 
IL-4. The natural consequence of atherosclerosis is plaque rupture, which can cause 
myocardial ischaemia or infarctions or cerebrovascular events, and can lead to death. 
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Post mortem studies of patients who have died suddenly of coronary ischaemia suggest 
that the typical causal lesion is often a small, unnoticed plaque, causing minimal clinical 
symptoms. These plaques have a thin or fragmented fibrous cap, which has a poor 
connective tissue skeleton (see table 1.5). This cap ruptures, exposing the blood in the 
lumen to the procoagulant effects of a lipid-rich core infiltrated with inflammatory 
cells 85-87. Cytokines released by the lipid core attract smooth muscle cells into the 
subintimal space.  Both cell types trigger further matrix break down within the lesion by 
releasing metalloproteases 88.  This process is exacerbated by IFNγ secretion, which 
suppresses collagen formation by intimal smooth muscle cells 89 and in addition may lead 
to their apoptosis 88.
Table 1.5 Characteristic features of the vulnerable atherosclerotic plaque (from Sattar & Gaw 85).
Thin, fragmented fibrous cap
Underdeveloped connective tissue skeleton
Lipid enrichment
Inflammatory cell infiltration
Evidence of proteolytic enzyme release
Apoptosis of smooth muscle cells
1.2.1 Inflammatory markers and coronary heart disease 
Systemic levels of acute phase markers such as white cell count, serum amyloid A (SAA) and 
C-reactive protein (CRP) have been shown to predict the risk of coronary heart disease 
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(CHD) events independently in men and women 90 - 93. Markers such as VCAM-1 may be 
released by vascular endothelium in very early stages of atherosclerosis 94.
The answer to how circulating cytokines enhance CHD risk likely lies in the dual 
functions of cytokines, for in addition to their role in regulating immune responses, 
cytokines mediate numerous metabolic effects. One consequence of this functional 
pleiotropy is that the intensity of the metabolic adaptations parallels other cytokine 
effects 85  Cytokine-induced metabolic effects, such as temporary changes in lipids and 
peripheral insulin resistance, function as part of the physiological reaction to infection 
and acute inflammation, to ensure the transport of specific metabolic fuels to and from 
essential organs 95. In the short term, these changes are beneficial. However, when these 
same cytokines are chronically elevated, even modestly as in the case of obese 
individuals, the effects are harmful, and may promote accelerated atherogenesis. Indeed, 
CRP concentrations in population studies correlate with levels of many classical and 
novel CHD risk factors 96.
1.2.2 Statins
Statins are a class of cholesterol-lowering drugs that reduce cholesterol biosynthesis 
through competitive inhibition of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase (Figure 1.3) Statins occupy a portion of the binding site in HMG-
CoA, thus blocking access to the active site 97. They were initially introduced to the 
market in 1987 and there are now several commercially available drugs with similar 
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properties groups under the umbrella term “statin” (table 1.6). In 2004 atorvastatin was 
the best selling drug in the world 98. Their main clinical application is in cardiovascular 
disease, where they have been consistently shown to decrease mortality from ischaemic 
heart disease 99 - 102 and stroke 103, 104. These studies also showed that treatment with 
statins provided greater protection than predicted from cholesterol reduction 105, therefore 
further anti-inflammatory functions of these drugs were suggested, for example 
preventing essential substitution (e.g. prenylation) of signalling molecules.  
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Figure 1.3 Cholesterol biosynthesis pathway showing potential effects of inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase by statins, causing decreased prenylation of signalling 
molecules, as well as derivatives from mevalonate and cholesterol. 
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Table 1.6 The statin family of drugs
Drug name Dose range (mg) Comment
Atorvastatin 10 – 80 Completely synthetic origin
Fluvastatin 20 – 80
Lovastatin Not prescribed in the UK The original medication, derived from Aspergillus terreus.
No longer prescribed in the UK
Mevistatin Not prescribed in the UK Original molecule derived from Penicillium citrinum. 
Never used clinically due to side effects
Pitavastatin Not prescribed in the UK Also known as Itavastatin. Not yet commercially available
Pravastatin 10 – 40
Rosuvastatin 5 – 20 New drug
Simvastatin 10 – 80 Discovered from Aspergillus terreus
Cerivastatin Not prescribed in the UK Removed from the market in 2001 due to severe 
adverse reactions
Evidence has accumulated that statins lower C-reactive protein (CRP) 106 – 109, a key 
indicator of inflammation, which itself is an independent risk factor for cardiovascular 
mortality and morbidity 110, 111. This reduction in CRP is likely a consequence of the 
ability of statins to reduce the production of IL-6 112, 113; the cytokine which activates the 
acute-phase CRP response 75. Based on these observations it has been proposed that the 
35
clinical effectiveness of statins might be due to a combination of functions including 
cholesterol reduction, anti-inflammatory, antithrombotic and immunomodulatory effects. 
1.2.3 Effect of statins in vascular endothelium
Statin therapy has been shown to have impact upon many processes in atheroma, helping 
to reduce the likelihood of atherosclerotic plaque rupture, or limiting thrombus formation 
should rupture occur.  Comparative investigations suggest that the lipid soluble statins are 
capable of modulating vascular smooth muscle cell growth, independently of their 
cholesterol lowering capability 114.  The statins may also directly suppress platelet 
activation, limiting platelet thrombus formation 115. In addition, they may stabilise lesions 
through a change in the composition of the plaque 116, 117, and a reduction in the number 
of inflammatory cells within the plaque 118. 
1.2.3.1 Plaque stability
Ultrasound studies have shown that statin therapy does not result in extensive plaque 
regression 119. This seems to contradict the findings of large intervention trials, which 
indicated that the plaques of treated patients carried a lower risk for acute coronary 
events 99, 101, 120, 121. It has been shown from experimental work in primates 122 and in a 
clinical trial of patients undergoing carotid endarterectomy that statins have a plaque-
stabilising effect 123. Histological examination in the trial showed that the lesions in the 
treated patients contained a significantly lower concentration of lipids (-66%), less 
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oxidized LDL (-40%), and lower macrophage and T-cell counts (-41% and -54%, 
respectively) than did arteries from untreated control individuals. 
1.2.4 Mechanism of action
Statins have several possible mechanisms of action that may be inter-related which result 
in the reduction of inflammation. These include a) modulating the cholesterol content, 
and thus reducing the stability of lipid raft formation and subsequent effects on the 
activation and regulation of immune cells, and b) preventing the prenylation of signalling 
molecules and subsequent down-regulation of gene expression; both resulting in reduced 
cytokine, chemokine and adhesion molecule expression, with effects on cell apoptosis or 
proliferation. 
There are additional less well described anti-inflammatory properties of statins including 
antioxidant effects which have been described for some statins related to their ability to 
scavenge oxygen-derived free radicals 124.
1.2.4.1 Lipid raft formation
Lipid rafts are small cell membrane structures, or microdomains, rich in cholesterol and 
glycosphingolipid, which house intracellular enzymes, mainly kinases. These lipid rafts 
can be translocated by the actin cytoskeleton, which controls their specific redistribution, 
clustering and stabilisation within the cell membrane. When these rafts are assembled 
they form critical sites for processes such as cell movement, intracellular transport or 
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signal transduction. Lipid rafts act as platforms, bringing together molecules essential for 
the activation of immune cells, but also separating such molecules when the conditions 
for activation are not appropriate. Several strands of evidence suggest that the inhibition 
of cholesterol synthesis by statins disrupts these lipid rafts and thereby influences the 
function of lymphocytes 125, 126 (figure 1.4). A central component of the interaction 
between lymphocytes and antigen presenting cells, which results in T-cell activation, is 
interferon-γ (IFN-γ) induced up-regulation and assembly of the major histocompatibility 
complex class-II (MHC-II). Statins reduce IFN-γ production by TH1 cells 127 and thus act 
as repressors of MHC-II-mediated T-cell activation 128, 129. This effect may, however, 
decrease over time 130. 
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Figure 1.4 Lipid rafts and statins. The T-cell receptor (TCR) and costimulatory molecules, including lymphocyte 
function-associated antigen 1 (LFA-1), CD28, CD4, and CD40 ligand (CD40L), are recruited to lipid rafts after activation. 
Statins interfere with the activation of T cells by depleting membrane cholesterol and disrupting the integrity of lipid rafts. 
Statin treatment causes the exclusion from lipid microdomains of raft-associated molecules such as the Lck protein tyrosine 
kinase, the inhibition of actin polymerization, and the formation of a stable immunologic synapse and therefore disrupts T-
cell activation From Ehrenstein, et al. 125 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
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1.2.4.2 Prenylation and regulation of cytokine synthesis
Altered cytokine synthesis observed with statin therapy may be a consequence of altered 
lipid raft formation.  However, there is an alternative or additional pathway of cytokine 
synthesis that may be affected by statins.  The mevalonate synthetic pathway mediated by 
HMG-CoA reductase is crucial for the biosynthesis of isoprenoids (Figure 1.3, above), 
which are essential for normal cellular proliferation and activity. Farnesyl pyrophosphate
is a later intermediate on this pathway and serves as a precursor for the synthesis of 
various isoprenoids, for example geranylgeranyl or farnesyl groups, which prenylate 
proteins through covalent links. These can anchor these proteins to lipid rafts. Many 
prenylated proteins play important roles in the regulation of cell growth, cell secretion 
and signal transduction. Thus, by inhibiting prenylation, statins affect many cell 
processes involved in inflammation.
1.2.5 Anti-inflammatory effects of statins on non-respiratory cells and diseases 
These two complementary mechanisms of prenylation and lipid raft stability allow statins 
to affect the function of many different cells and to attenuate inflammation in 
experimental models of disease.  
1.2.5.1 Cell adhesion molecules
Statins interfere with cell binding by reducing leukocyte–endothelial cell adhesion 131, 132. 
This occurs because statins attenuate the up-regulation of P-selectin normally seen on 
activated endothelial cells 133, and they also interfere with monocyte 134 and lymphocyte 
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attachment to endothelium by suppressing intercellular adhesion molecule-1 (ICAM-1) 
and lymphocyte-function-associated antigen 1 (LFA-1) interactions 135 (figure 1.5). 
Statins have been shown to decrease the expression of the receptor for chemoattractant 
chemokine ligand 2 (CCL2) expression on endothelial cells in rats 136, 137 and thereby 
reduce monocyte adhesion to vascular endothelium. Interference with the same 
chemokine in mice causes them to be unable to mount a TH2 cell response 138.
Figure 1.5 Interruption of leucocyte–endothelium interaction. Leucocyte function-associated antigen 1 (LFA1) 
is important for lymphocyte binding to endothelial cells and for lymphocyte activation. Various statins directly 
inhibit this endothelial interaction by attaching to LFA1, thereby blocking its binding to intercellular adhesion 
molecule 1 (ICAM1). From Terblanche et al 139. Reprinted with permission from Elsevier.
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1.2.5.2 Cytokine and mediator release
Statins alter protein expression, which is reflected in altered cytokine release. In vitro 
experiments looking at spontaneous and lipopolysaccharide-induced secretion of 
interleukin (IL)-6 and tumour necrosis factor (TNF)-α in human cell lines showed 
reduced output due to statins in both cases 112, 140. Fluvastatin and simvastatin but not 
pravastatin reduce production of IL-6 and interleukin-1 β (IL-1β) in human umbilical 
vein endothelial cells (HUVECs) 141. Atorvastatin has also been shown to inhibit 
production of TNF-a 142. Lovastatin induces T H2 production of IL-4, IL-5 and IL-10 in 
vitro 127. Increased prostacyclin 143 and decreased endothelin 144 production are seen in 
human endothelial cells after statin treatment.
1.2.5.3 Cellular apoptosis or proliferation
Statins increase apoptosis as demonstrated in human vascular endothelial cells 145, and in 
plasma cell lines from patients with multiple myeloma 146. Statins can then enhance the 
clearance of apoptotic cells by human and mouse macrophages, a statin-specific effect 
reversible with mevalonate, through modulation of Rho-GTPases 147, 148. Lovastatin and 
simvastatin have also been shown to block Fc receptor-mediated phagocytosis by 
cultured human monocytes 149.
Proliferation of T lymphocytes and B lymphocytes is inhibited by statins 150, 151, and 
statins can alter the ratio of TH1 to TH2 lymphocytes; cerivastatin, simvastatin, lovastatin, 
and atorvastatin can promote TH2 polarisation through suppression of TH1 lymphocyte 
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development and augmentation of TH2 lymphocyte development from naive CD4+ T cells 
when primed in vitro 152. Statins also reduce the proliferation of cardiac fibroblasts in rat 
and rabbit models 153.
1.2.5.4 Antioxidant effects
Metabolites of atorvastatin have been shown to possess potent antioxidative 
properties 154, 155, and protect very low density lipoprotein (VLDL), low density 
lipoprotein (LDL) and high density lipoprotein (HDL) from oxidation 156.  Simvastatin 
acts as an antioxidant in  rat liver microsomes 157 and vascular smooth muscle 158, and 
human lipoprotein particles 159, which may contribute to its anti-atherogenic effect. 
1.2.5.5 Experimental models of disease
Statins have diverse effects on many chronic animal models of auto-immune disease. In 
models of systemic lupus erythematosus (SLE) the administration of atorvastatin resulted 
in a significant reduction in serum IgG anti-dsDNA antibodies and decreased proteinuria, 
reduced glomerular immunoglobulin deposition and glomerular injury. Disease 
improvement was paralleled by decreased expression of MHC class II on monocytes and 
B lymphocytes. T cell proliferation was impaired by atorvastatin in vitro and in vivo and 
a significant decrease in glomerular MHC class II expression was also observed 160. 
Cerivastatin and simvastatin have also been shown to inhibit human neutrophil response 
to ANCA in vitro 161.
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In experiments with collagen-induced arthritis in mice, simvastatin was given 
intraperitoneally either before (prophylactically) or after (therapeutically) induction of 
arthritis and a marked reduction in serum IL-6 and IFN-γ was seen, with a significant 
histological improvement 162 (figure 1.6).
Figure 1.6 Simvastatin in collagen-induced arthritis. Simvastatin administration to mice with after onset 
collagen-induced arthritis resulted in significantly reduced joint pathology. A–D, Mice were treated with 
phosphate-buffered saline or simvastatin (40 mg/kg) following detection of arthritis. After 14 days of 
simvastatin administration, arthritic paws were removed and stained with Haemotoxylin & Eosin or toluidine 
blue. Profound cartilage surface erosion and loss of proteoglycan was observed in PBS controls (arrows), 
whereas simvastatin recipients exhibited  significantly reduced histologic evidence of destruction. From Leung 
et al 162 Copyright 2003 The American Association of Immunologists, Inc. 
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In a mouse model of autoimmune retinal disease, treatment with 20 mg/kg/day 
intraperitoneal lovastatin over 7 days, suppressed clinical ocular pathology, retinal vascular 
leakage, and leukocytic infiltration into the retina 163. Efficacy was reversed by co 
administration of mevalonolactone, the downstream product of HMG-CoA reductase.
1.2.5.6 Clinical studies
A double-blind, randomised, placebo-controlled trial examined the efficacy of atorvastatin 40 
mg daily for six months in rheumatoid arthritis. At the end of that period, patients who had 
received statin were found to have decreased plasma levels of lipids, fibrinogen and 
viscosity. Disease activity score improved significantly on atorvastatin treatment compared 
with placebo. CRP and erythrocyte sedimentation rate reduced by 50% and 28% respectively, 
relative to placebo 164.
A trial of atorvastatin during tetanus toxoid (TT) vaccination showed a marked increase in 
anti-TT antibodies 15 days post-vaccination, with a suppression of lymphocyte and platelet 
count 165. This complex immunological picture raises more questions about the effect of 
statins on the immune system.
1.2.5.7 Different statins may have different anti-inflammatory properties
It has recently become apparent that the different families of statins may have different 
biochemical functions. Kiener and colleagues 166 showed that lipophilic statins such as 
atorvastatin and simvastatin have a much greater effect on inflammatory responses in 
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human and mouse models than the hydrophilic pravastatin. Similarly, when looking at 
sensitisation of human smooth muscle cells to apoptotic agents, lovastatin and 
simvastatin showed a powerful sensitising effect, whereas atorvastatin showed less of an 
effect, and pravastatin had no activity 167. There is also a dose-response effect seen for 
example where cerivastatin is much more potent than fluvastatin in blocking NF-κB 
activation in human blood monocytes 168. Some statins have differing effects on protein 
expression, for example in monocytes stimulated by lipopolysaccharide (LPS), 
pravastatin and fluvastatin may induce production of TNF-a, IFN-γ, and IL-18 169, 170, 
whereas atorvastatin and simvastatin inhibit production of TNFα 112, 113, 142, 171. 
It is therefore important to recognise that all statins may not have the same therapeutic 
potential. For example, a clinical study in 27 healthy volunteers found significant 
differences between the ex vivo immunological responses after atorvastatin and 
simvastatin therapy. Atorvastatin led to a significant down-regulation of the expression of 
human leukocyte antigen (HLA)-DR and of the CD38 activation marker on peripheral T 
cells, whereas simvastatin up-regulated both these molecules. In contrast, superantigen-
mediated T cell activation was inhibited by simvastatin and enhanced by atorvastatin 172. 
However, initial experimental work in inflammatory lung disease has used both 
simvastatin 173 and pravastatin 174 with clear effect.
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1.2.6 Potential therapeutic role for statins in respiratory disease
The therapeutic effect of statins on cardiovascular and auto-immune disease seem to be 
broadly anti-inflammatory, which are also likely to apply to lung diseases in which there 
is an inflammatory component (figure 1.7). 
Figure 1.7 Potential anti-inflammatory effects of statins on different structural and inflammatory cells within 
the lungs.
47
1.2.6.1 Possible effects of statins on cellular inflammatory processes in the lung
There are several inflammatory processes in the lung that may be susceptible to the
effects of statins.
Statins could affect the chemokine and adhesion molecule-directed migration of 
inflammatory cells from blood into the airways 169, 175 - 177. Since both eosinophils and 
macrophages express the adhesion molecule LFA-1, this offers a potential target for 
modification of airway inflammation. Treatments other than statins targeted at reducing 
the expression of LFA-1 have been effective in decreasing airway eosinophilia in a 
mouse model of atopic asthma 15 and have reduced sputum eosinophilia after allergen 
challenge in asthmatic patients 16. Since statins can inhibit LFA-1/ICAM-1 interaction, as 
seen in HIV 135, there is potential for statins to have an equivalent effect in asthma, where 
the pathophysiology is associated with eosinophil accumulation. Lovastatin has recently 
been shown to inhibit human alveolar epithelial production of IL-8 178, which might also 
contribute a beneficial effect of statins in the treatment of neutrophil associated 
inflammatory diseases of the lungs.
The observation that statins increase eosinophil apoptosis in humans 179 suggests a further 
therapeutic role. The mechanism of this is likely due to the rapid reduction of cellular 
expression of CD40 after statin administration and this strongly inhibits eosinophil 
survival 32. Similarly, the neutrophilia associated with a mouse model of acute lung injury 
is markedly reduced with lovastatin treatment 180, and this modulation of neutrophil 
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apoptosis may prove beneficial in other inflammatory lung diseases, such as smokers 
with asthma or COPD where neutrophils are present and where corticosteroid treatment 
may be of limited benefit. In addition to induction of apoptosis, statins, in this case 
lovastatin, also enhance the clearance of apoptotic cells by human and mouse 
macrophages, a statin-specific effect reversible with mevalonate 147.
Statins could affect the activation and proliferation of a variety of cells associated with 
lung inflammation. For example, statins suppress TH1 cell activation, and IFN-γ 
production, as seen in a recent trial in rheumatoid arthritis 164, and by analogy this 
treatment could decrease the IFN-γ dependent pathology of chronic asthma and 
pulmonary tuberculosis. Similarly, statins decrease natural killer (NK) cell activity in 
treated transplant patients 181 and this might be relevant to the pathogenesis of asthma in 
which NK cells may have a pathogenic role 182, 183. The decrease in expression of MHC-II 
induced by statins has been observed on monocytes, macrophages, and on B lymphocytes 
in mice 160, which implies a widespread down-regulatory effect on presentation and 
immune response to inhaled or lung-associated antigens. 
Statins may also have a role in attenuating the tissue repair and remodelling 
consequences of chronic aberrant immune activation and inflammation. For example 
statins inhibit the proliferation of airway smooth muscle in human cell lines 184 and lower 
the expression of the profibrogenic cytokine transforming growth factor (TGF)-b1 185. 
Statins also reduce the tissue damage and cellular changes associated with cigarette 
49
smoking. The mechanism of this appears to be related to statins reducing the production 
of matrix metalloprotease (MMP)-9 and airway remodelling in smoking rats 186, 187, and 
rabbits 188 and in human macrophages 189 and monocytes 142 from smokers. Other MMPs 
may also be reduced 188 - 192. By targeting this key aspect of remodelling, this indicates a 
potential therapeutic role for statins in fibrotic lung diseases. 
Finally, it is worth bearing in mind the different pharmacological properties between 
statins. For example, lovastatin seems to increase lymphocyte secretion of IL-4 and IL-5 
in a mouse model of multiple sclerosis 127, and therefore this particular statin may be of 
limited use in asthma, where these cytokines are directly implicated in the pathogenesis.
1.2.6.2 Statin treatment of human and experimental respiratory diseases
1.2.6.2.a Age-related deterioration in lung function
A cohort study of 803 patients suggested that statins significantly reduced the deleterious 
effect of age on lung function, with patients taking a statin exhibiting a mean decline in 
FEV1 of 10.9mL/year, compared with 23.9mL/year in patients who were not 193. This 
protective effect was reduced in smokers. 
1.2.6.2.b Asthma
In a mouse model of atopic airways disease, the potential benefits of statin therapy on 
inflammatory airway disease were demonstrated 173. In this model, airway eosinophilia 
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was elicited using ovalbumin (OVA) as the allergen. Simvastatin given before each OVA 
challenge caused a reduction in inflammatory cell infiltrate and eosinophilia in broncho-
alveolar fluid, and a decrease in the OVA-specific production of IFN-γ, IL-4 and IL-5 by 
thoracic node lymphocytes in vitro (figure 1.8). The same anti-inflammatory effects of 
pravastatin have been reported in a similar experimental model of atopic airway 
inflammation 174. The anti-inflammatory properties of statins observed in animal models 
of atopic asthma 173 and in smoking-induced lung disease 186 suggests that statin treatment 
could improve asthma control in smokers with asthma who are insensitive to treatment 
with corticosteroids 194.
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Figure 1.8 Histological evidence of decreased lung inflammation in mice treated with simvastatin. A, Naive 
mouse, given saline challenge. B, ovalbumin antigen challenged mouse; peribronchial and perivascular 
inflammatory infiltrates are seen, with eosinophils present and mucosal hyperplasia. C, ovalbumin-challenged 
mouse plus treatment with simvastatin; a reduction in inflammatory infiltrates is seen compared with B.
Hematoxylin & Eosin staining. Reproduced from MacKay et al. 173 Copyright 2004 The American Association 
of Immunologists, Inc.
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Separately, fluvastatin has been shown to inhibit proliferation of human peripheral blood 
mononuclear cells (PBMC) from asthmatic patients, and to reduce expression of IL-5 and 
IFN-γ, in response to both allergen-specific (house dust mite) and non-allergen specific 
stimulation 195. 
1.2.6.2.c Emphysema and COPD
In rat and mouse models of emphysema 186, 196 found that simvastatin inhibited lung 
parenchymal destruction, reduced mRNA expression of IFN-γ, TNF-α and MMP-12, and 
peribronchial and perivascular inflammatory cell infiltration. Induction of MMP-9, a 
major inflammatory mediator, was reduced in the same model when the experiment was 
repeated using human lung microvascular endothelial cells in vitro 186. A nested case-
control study in humans has also suggested that statins may decrease respiratory mortality 
in patients with COPD 197.
1.2.6.2.d Pulmonary hypertension
Statins induce Rac 1 expression while suppressing Rho A in a rat model of pulmonary 
hypertension 198, and induce apoptosis of pulmonary vascular cells 198, 199. A rat model 
also shows improved pulmonary artery pressure, ventricular and blood vessel 
remodelling, and polycythaemia 200, suggesting a significant survival advantage following 
treatment with simvastatin 186, 201. An open-label clinical case series of patients with 
53
pulmonary hypertension showed that simvastatin delays disease progression and may 
improve survival 202. 
1.2.6.2.e Idiopathic pulmonary fibrosis (IPF)
Early experimental data suggests that simvastatin could modify critical determinants of the 
profibrogenic machinery responsible for the aggressive clinical profile of IPF, and could 
potentially prevent adverse lung parenchymal remodelling associated with persistent 
myofibroblast formation 203. This hypothesis has recently been tested in a clinical trial of 
lovastatin in IPF but preliminary data showed no improvement in survival 204.
1.2.6.2.f Acute lung injury
In a model of acute lung injury, mice treated with simvastatin showed decreased lung 
permeability, along with significant reduction in NF-κB mediated gene transcription, 
suggesting a potential role for statins in the management of this disease 205. 
1.2.6.2.g Community acquired pneumonia
This concern for an adverse role for statins in reducing resistance to lung infection was partly 
addressed in a retrospective cohort study which showed that statins  were associated with a 
22% decrease in overall 30-day mortality (from 28% to 6%) from community-acquired 
pneumonia. This remained significant even after adjustment for potential confounders such as 
previous co-morbidity, which would normally be expected to increase mortality 206. A case-
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control study of diabetic patients concurred 207. However, there is still a need to monitor the 
effects of statin therapy prospectively on the immune response. Interestingly, a study of statin 
therapy of Chlamydia pneumoniae in mice suggested an increase in inflammatory cell 
infiltration into the lungs during acute infection 208.
1.2.6.2.h Lung transplantation
The outcomes in lung transplantation were compared between 39 patients taking statins 
for hyperlipidemia (mainly atorvastatin and pravastatin) and 161 who were not. Acute 
rejection was less frequent, bronchoalveolar lavage (BAL) showed lower total cellularity, 
as well as lower proportions of neutrophils and lymphocytes, and survival was 91% 
compared with 54% in controls 209.  
1.3 Summary
Asthma is a chronic, degenerative disease, with serious negative effects on quality of life. 
At present, many therapies exist, but many patients still do not have complete control. 
Statins may be a possible novel adjunct to current therapies: their anti-inflammatory 
credentials are well established. The evidence from animal models is strongly suggestive 
of a beneficial effect in terms on improving inflammation. The logical next step would be 
a proof of concept clinical trial.
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2. HYPOTHESIS
This randomised controlled trial will test the hypothesis that statins improve asthma 
control and airway inflammation of patients with chronic allergic asthma. 
2.1 Primary End Point
The primary end point is an improvement in morning PEF. It is expected that an 
improvement of 20l/min will be seen after 8 weeks of atorvastatin.
2.2 Secondary End Points
2.2.1 Clinical
It is expected that an improvement will be seen in indicators of asthma control, including:
Asthma control questionnaire score
Asthma Quality of Life Questionnaire 
PC20 methacholine
2.2.2 Inflammatory
Markers of inflammation in blood and sputum are expected to show a reduction 
inflammation. This would be seen in a reduction in inflammatory cells in sputum cell 
count, such as macrophages, neutrophils and eosinophils. This would be accompanied by 
a reduction in inflammatory cytokines in sputum supernatant and serum. In particular, a 
reduction in CRP and IL-6 would be expected. 
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3. RANDOMISED CONTROLLED TRIAL
3.1 Recruitment
54 adult allergic asthmatic patients were recruited from hospital respiratory clinics and 
from general practice.  Potentially eligible patients were identified by scrutiny of hospital 
records and from computerised General Practice records.  Their hospital doctor or GP 
then invited them to take part and volunteers were screened for eligibility in the research 
unit. 
3.1.1 GPASS
The General Practice Administration system for Scotland (GPASS) is the national 
Primary Care System and is one of Britain's leading general practice systems. It is used in 
over 890 Scottish practices (www.show.scot.nhs.uk/gpass/), and allows searching of 
patient records by a number of parameters, including age, diagnosis and/or prescriptions. 
A shortcoming of any patient record system is that the information on the database has 
been entered by a number of people and many of them may not have any clinical 
background. Consequently, it is prudent to keep the original search wide. For example, a 
search based on prescription is more likely to be accurate than a search based on 
documented diagnosis.
Once a list of broadly suitable patients was produced, the details of each patient were 
examined for other exclusion criteria. The resultant list was then left for the GP and 
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practice nurse to examine so that they could remove any patients they deemed unsuitable, 
e.g. housebound patients. 
3.1.1.1 Search strategy
A search was performed for patients age between 18 and 70 who had been prescribed a 
b2-agonist inhaler and an inhaled corticosteroid in the last year, see figure 3.1
Figure 3.1 GPASS search strategy for patients 
GROUP  (and) -
Registration age in years is between 18 and 70 inclusive
And
Prescription drug BNF code is 301011 (SELECTIVE BETA2 AGONISTS)
And
Prescription weeks since issued is less than or equal to 52 
And
GROUP (and) -
Prescription drug BNF code is 302000 (CORTICOSTEROIDS)
And
Prescription weeks since issued is less than or equal to 52
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3.2 Subjects
3.2.1 Inclusion criteria
The inclusion criteria are shown in figure 3.2. 
Figure 3.2 Inclusion criteria
Diagnosis of asthma:
Objective: 
Confirmed by methacholine airway hyperresponsiveness (PC20 ≤ 8 mg/mL) or
by evidence of variable airflow obstruction with an increase in FEV1 of > 12% following nebulised 
salbutamol (2.5 mg) 210 or
Diurnal peak flow variability of > 20% for 3 days in a week (with a minimum change of 60 L)
during the run-in period of the study 40
AND
Symptomatic: 
Episodic wheezing, chest tightness and/or dyspnoea 211
AND 
Asthma control questionnaire score of ≥ 1 (range 0-7) prior to randomisation or
Use of inhaled beta2-agonist on 5 or more days in the week before randomisation or
FEV1 reversibility >12% or diurnal peak flow variability of  >20% during the run-in period 
of the study for at least 3 days of a week
Age range 18-70 years
Duration of asthma ≥ 1 year and on stable medication for 4 weeks
Receiving regular inhaled steroid treatment (≤ 1000 mcg Beclomethasone equivalent daily) 
and no other medication for their asthma other than a short-acting bronchodilator
Stable asthma medication for at least 4 weeks prior to randomisation
Written informed consent
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3.2.2 Exclusion criteria
Exclusion criteria are listed in figure 3.3.
Figure 3.3 Exclusion criteria
Current smokers or ex-smokers of < 1 year or ex-smokers who have smoked > 5 pack years
Patients with unstable asthma; defined as the presence of 1 or more of the following events, 
due to asthma, in the month prior to randomisation: 
 Emergency/”out of hours” visit of patients to the GP
 GP visit to patient at home
 A & E hospital attendance
 Hospital admission
Patients in whom cardiovascular risk requires statin therapy
Any known sensitivity or adverse reaction to statin, or previous evidence of myopathy or
myositis plus creatinine kinase and liver function tests > x2 upper limit of normal range
Non-atopic asthma; defined as skin test wheal ≤ 3mm over negative control saline
Pregnancy or lactation
Patients who require medications known to interact with statins, such as azole antifungal agents, 
erythromycin, clarithromycin, cyclosporine, gemfibrozil, verapamil and amiodarone
Inability to fully comprehend the patient information sheet
Inability to demonstrate correct use of peak flow meter after instruction
Patients who showed specific IgE sensitivity or were skin test positive to grass pollen 
allergen were not recruited from mid May to the end of July (grass allergen season in 
UK) if they were symptomatic of hayfever.
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3.3 Structure of Study
The study was a 24-week randomised double blind crossover study comparing the effect 
on asthma control of oral atorvastatin therapy (40 mg daily) with that of a matched 
placebo. Each treatment was administered for 8 weeks separated by a 6-week washout 
period and a 2-week run-in period prior to randomisation. Randomisation was performed 
in sequential blocks of four. 
Patients were assessed on 9 visits (13 occasions, as some visits were performed over 2 
days) (figure 3.4):
Screening visit 
Obtain written informed consent 
General medical history & physical examination
ACQ
Spirometry and reversibility testing
Blood sampling 
Skin prick testing
Issue diary card and peak flow meter 
Adjustment of asthma medication to BTS guidelines if required. If any changes were 
made, randomisation visit was deferred an extra two weeks to allow four weeks on stable 
medication
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Randomisation visit
Baseline clinical measurements
2 weeks after screening visit (or 4 weeks if any change made to baseline asthma 
medication)
ACQ
AQLQ 43(See appendix 2)
ATS Score to assess severity of asthma
Spirometry and reversibility testing
Induced sputum
Exhaled NO
Methacholine responsiveness
Randomise patient if all criteria met
Issue medication container A.
Issue diary card 
Follow up visits (Phase A)
2 and 4 weeks after randomisation
Spirometry and reversibility testing
Issue new diary
End of medication A visit (Phase A)
8 weeks after randomisation
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ACQ
AQLQ 43(See appendix 2)
ATS Score to assess severity of asthma
Spirometry and reversibility testing
Induced sputum
Exhaled NO
Blood sampling
Methacholine responsiveness
Issue new diary
End of washout visit (Phase B)
At least 6 weeks after end of medication A
ACQ
AQLQ 43(See appendix 2)
ATS Score to assess severity of asthma
Spirometry and reversibility testing
Induced sputum
Exhaled NO
Blood sampling
Methacholine responsiveness
Issue medication container B
Issue new diary
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Follow up visits (Phase B)
2 and 4 weeks after starting medication B
Spirometry and reversibility testing
Issue new diary
End of medication B visit (Phase B)
8 weeks after starting medication B
ACQ
AQLQ 43(See appendix 2)
ATS Score to assess severity of asthma
Spirometry and reversibility testing
Induced sputum
Exhaled NO
Blood sampling
Methacholine responsiveness
Patients recorded morning and evening PEF measurements and daily symptoms 
throughout the study. 
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3.3.1 Pregnancy testing
Pregnancy test was performed in all women of child-bearing age before all methacholine 
tests and subjects were informed about adequate contraception during and for one month 
after the study.
3.3.2 Exacerbations during washout phase
If a subject had an exacerbation during the wash-out phase of the study, visit 6 was 
delayed until the patient had been stable for 4 weeks.
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Figure 3.4 Flow chart for structure of study
Screening visit
Baseline tests performed
↓ 2 weeks 
Enrolment visit, 
Entry criteria into the study 
confirmed
↓ Minimum 2 weeks
Randomisation
 ↓
Phase A 
TREATMENT A
Treatment & control group
Tablets taken for 8 weeks
(Atorvastatin or Placebo)
 ↓
Follow up visits at 
weeks 2,4 & 8
↓
Washout phase
(No tablets)
6 weeks
↓
Follow up visit 
(confirm patient well enough 
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for
second phase)
↓
Phase B 
TREATMENT B
Treatment & control group
Tablets for a further 8 weeks
(Active or Blank tablets)
↓
Follow up visits at 
weeks 16 & 18
↓
22 week visit
End of study
3.4. Statistical analysis
3.4.1 Power calculations
A sample size of 44 has 90% power to detect a difference in means of 20L/min in peak 
expiratory flow (PEF) (primary endpoint), assuming a standard deviation of differences 
of 40L/min, using a paired t-test with a 0.05 two-sided significance level. A total of 54 
patients were recruited to ensure that 44 patients completed the study.
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3.4.2 Analysis Sets
As this was a crossover study, patients only contribute to an analysis if the data point 
from both treatment periods was available. The Full Analysis Set therefore consists of 
those patients who attended the final visit of treatment Period B. All of the available data 
is present in the Full Analysis Set.
3.4.2.1 Baseline Data 
The baseline demographic and other characteristics are presented by sequence group (i.e. 
AB or BA treatment sequences), and in total, using the minimum, maximum, mean and 
standard deviation for continuous variables, and counts and percentages for categorical 
variables. 
3.4.3 Endpoints
3.4.3.1 General Principles
Each of the two treatment periods lasts for eight weeks, and Week 8 data was analysed 
with statistical tests. The Week 0, Week 2 and Week 4 visits were summarised where 
data was available, but was not analysed by statistical tests. In all trials the later data is 
usually most important, but this is particularly true of crossover studies, where the end of 
Period B is the furthest from the washout period. The summaries of the earlier visits were 
considered as extra information for general interest regarding the timing of the treatment 
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effect, and are not considered to cause problems with multiplicity. Descriptions of 
endpoints are summarised in Table 3.1.
Results were analysed as the difference between means (treatment difference) or medians 
of endpoints, without controlling for baseline variables, as these are considered irrelevant 
in crossover trials. Comparison is therefore not made between baseline values of 
variables.
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Table 3.1 Description of end points
End point Derived from Time of measurement
Primary end point
Mean morning peak flow 
(PEF)
Patient diary cards Just before the Week 8 visits of each 
treatment period
Secondary end points
Mean evening peak flow 
(PEF)
Patient diary cards Just before the Week 8 visits of each 
treatment period.
Daily Asthma Control Score Patient diary cards Just before the Week 8 visits of each 
treatment period.
Mean number of puffs of relief 
β2 agonist as measured in the 
morning
Patient diary cards Just before the Week 8 visits of each 
treatment period.
Mean number of puffs of relief 
β2 agonist as measured in the 
evening
Patient diary cards Just before the Week 8 visits of each 
treatment period.
Exacerbation rates Patient diary cards Just before the Week 8 visits of each 
treatment period.
Asthma Control Score Clinic questionnaire Week 8 visit of each treatment period
ATS Score Clinic questionnaire Week 8 visit of each treatment period
Asthma Quality of Life 
Questionnaire
Clinic questionnaire Week 8 visit of each treatment period
Use of Oral Steroids Patient diary cards Throughout study
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End point Derived from Time of measurement
Pre-salbutamol: 
FEV1
PEF
FVC
FEF25-75
FEV1 percentage predicted
PEF percentage predicted
FVC percentage predicted
FEF25-75 percentage predicted
Clinic Spirometry Week 8 visit of each treatment period
Post-salbutamol:
FEV1
PEF
FVC
FEF25-75
FEV1 percentage predicted
PEF percentage predicted
FVC percentage predicted
FEF25-75 percentage predicted
PC20 methacholine
Clinic Spirometry Week 8 visit of each treatment period
Asthma Related Events
- Out of hours visits to GP
- GP home visits
- Visits to Accident and 
Emergency
- Hospitalisations
Patient diary cards Throughout study
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End point Derived from Time of measurement
Exhaled NO (FENO)
Exhaled CO
Clinic testing Week 8 visit of each treatment period
Immunological Tests in Blood:
- ICAM-1
- IL-6
- hsCRP
- TNF-α
- Lymphocyte proliferation
Clinic sample Week 8 visit of each treatment period
Lipids in Blood
- Cholesterol
- Triglycerides
- HDL cholesterol
Clinic sample Week 8 visit of each treatment period
Serum Biochemistry Safety 
Checks
Renal function:
- Urea
- Potassium
- Sodium
Liver function tests:
- Bilirubin
- AST 
- ALT
Clinic sample Week 8 visit of each treatment period
Sputum Cell Counts
- Total cell count
- Macrophages
Clinic sample Week 8 visit of each treatment period
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End point Derived from Time of measurement
- Neutrophils
- Eosinophils
- Lymphocytes
- Viability
- Epithelial cells
Macrophage activation indices 
(sputum):
- MPO
- LTB4
- IL-1b
- IL-1RA
- IL-6
- IL-8
- IL-17
- TNF-α
- IFN-γ
- GM-CSF
- MIP-1a
- CCL2
Clinic sample Week 8 visit of each treatment period
3.4.3.2 Treatment of Diary Cards
The diary cards had space for up to eight weeks’ data. However, we analysed only the 
last seven days data that were filled in prior to each visit. A card was declared null and 
void if there was no morning PEF data. The last day’s data was calculated by counting 
back to the last non-missing day. For each of morning PEF, evening PEF, daily control 
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scores and puffs of relief medication separately, the number of non-missing days in the 
seven-day period up to (and including) the identified last day of data was counted. At 
least three days’ data for each variable had to be available separately for that variable to 
be considered as evaluable. The means of the seven days were calculated for each of the 
evaluable variables. 
3.4.3.3 Treatment of ACQ Scores (Clinic & Diary Versions)
For the standard clinic version of the ACQ score there are seven questions each scored on 
a seven-point scale (0=good control, 6=poor control). The overall score is the mean of the 
seven responses.
The daily diary ACQ is slightly different. The morning PEF data is used instead of FEV1, 
and converted to a percentage predicted value which is scored like the FEV1 version on 
the standard version (i.e. >95% = 0, 95%-90% = 1, 80%-89% = 2, 70%-79% = 3, 60%-
69% = 4, 50%-59% = 5 <50% = 6). Beta2 agonists puffs are totalled for the morning and 
afternoon (to calculate the number of puffs used in last 24 hours). The scores for this are: 
0 puffs, 1-2 puffs = 1, 3-4 puffs = 2, 5-8 puffs = 3, 9-12 puffs = 4, 13-16 puffs = 5, >16 
puffs = 6. Once this is done the mean of the seven questions can be calculated.
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3.4.3.4 Treatment of Use of Oral Steroids
The use of oral steroids was calculated by examining the CRF at each study visit, to see if 
a patient used oral steroids at any time during the treatment period (i.e. unlike the other 
endpoints Week 2 and Week 4 visits were included as well).
3.4.3.5 Treatment of Asthma Related Events
The total number of these events (out of hours visits to GP, GP home visits, visits to 
accident and emergency, hospitalisations) was calculated across each of the visits in a 
treatment period (i.e. Weeks 2, 4 and 8). The totals were also calculated separately for 
each of the four different types of event. 
3.4.4 Analysis Techniques
The main analyses were carried out by Normal Linear Models that include parameters for 
patient, period and treatment. 
3.4.5 Software
All analyses were carried out using SAS version 9 (SAS Institute, Cary, NC).  
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3.5 Location of work
All the clinical work for the study was undertaken at the Asthma Research Centre, 
Department of Respiratory Medicine, Gartnavel General Hospital, Glasgow. Sputum and 
blood analysis were performed within the department of Immunology, Western 
Infirmary, Glasgow and Department of Biochemistry, Royal Infirmary, Glasgow. 
Statistical analyses were performed in conjunction with the Robertson Centre for 
Biostatistics at the University of Glasgow.
3.6 Patient Safety
3.6.1 Drug interactions and side effects associated with atorvastatin
Statins should be administered with caution if there is a history of liver disease, a history 
of alcohol excess, renal impairment/failure or hypothyroidism. In the screening process 
the renal and hepatic function were assessed using routine biochemistry testing. Patients 
with a history of hereditary muscular disorders or previous history of muscular toxicity 
whilst using statin medication subjects were excluded from this study.
 
Side effects with statins are rare 212, but include headache, myalgia, abdominal pain, 
flatulence, diarrhoea, nausea, vomiting, insomnia, anorexia, alopecia, peripheral 
neuropathy, urticaria, pruritis, impotence, chest pain, hypoglycaemia or 
hyperglycaemia 213. Atorvastatin has recently been identified as causing nightmares 214, a 
feature also seen in other statins. 
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Patients concurrently taking digoxin, oral contraceptives, amlodipine, colestipol, antacids 
or warfarin were closely monitored (and appropriate blood levels measured) as 
atorvastatin may enhance or decrease the effect of these drugs.  It is also been shown that 
the level of atorvastatin in the body may be reduced if the patient is on any of the drugs 
listed above 212.  Patients on azole antifungal agents, erythromycin, clarithromycin, 
azithromycin, cyclosporine, gemfibrozil, verapamil and amiodarone were excluded from 
this study and general practitioners were asked to omit the study medication if any of 
these medications were required during the course of the study.
As per the recommendations of the MHRA 215, subjects were asked to avoid fresh 
grapefruit juice while on the study and to report muscle pain, weakness or cramps and to 
stop treatment if this was severe. Creatine kinase (CK) levels were checked and treatment 
did not re-commence if levels were elevated >2 times normal.
3.6.2 Unused medication
All unused medication was returned to the pharmaceutical company (Pfizer) for 
destruction at the end of the study.  
3.6.3 Current anti-asthma drug treatment
Patients were asked to continue on their usual anti-asthma drug therapy throughout the 
study.
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3.6.4 Adverse Events
An adverse event (AE) is defined by the UK Medicines for Human Use (Clinical Trials) 
Regulations 2004 (SI 2004/1031) as:
An exacerbation, or unexpected increase in the frequency or intensity of a pre-
existing condition (other than asthma), including intermittent or episodic conditions.
Significant or unexpected worsening or exacerbation of asthma
A suspected drug interaction
Any clinically significant laboratory abnormality
Adverse events are graded according to their severity as follows:
Mild: Awareness of signs or symptoms, but easily tolerated.  There is no loss of time 
from normal activities.   Symptoms resolve easily with no medical treatment (other than 
short-acting bronchodilators).  Signs and symptoms are transient.  
Moderate: Discomfort severe enough to cause interference with the patient’s usual 
activities.  Symptomatic treatment is possible.
Severe: Incapacitating with inability to do work or usual activities, signs and 
symptoms may be of a systemic or require medical intervention and/ or treatment.  
Hospitalisation may be required.  
A reasonably related event is one that is in the opinion of the investigator, possibly, 
probably or definitely related to the study product.  
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3.6.4.1 Serious Adverse Events
A serious adverse event (SAE) is any adverse event, which results in:
Death
Is life-threatening (this refers to an event in which the patient was at risk of death at
the time of the event; it does not refer to an event that hypothetically might have 
caused death if it were more severe)
In-patient hospitalisation or prolongation of inpatient hospitalisation. (Hospitalisation 
for a pre-existing condition, including elective procedures, which has not worsened, 
does not constitute a serious adverse event)
Persistent or significant disability/incapacity that interferes with the person’s ability 
to conduct normal activities of daily living
Congenital anomaly or birth defect
In addition, an important medical event may be considered a SAE when, based on 
appropriate medical judgment, it may jeopardise the subject and/or may require medical 
or surgical intervention to prevent one of the outcomes listed.  
Any SAE that was ongoing on completion of the trial would have been followed until it 
resolved or stabilised,
returned to baseline condition or value (if baseline value is available) or 
could be attributed to agent(s) other than the study agent/ to factors unrelated to study 
conduct
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3.6.4.2 Suspected Unexpected Serious Adverse Reactions (SUSAR)
SUSARs are suspected adverse reactions related to an investigational medicinal product 
that are both unexpected and serious.  
3.6.4.3 Method for the reporting of Adverse Events
Serious Adverse Events: were collected in the CRF and a SAE form completed for each 
one. These were held in the site file and formed part of the Annual Safety Report which was 
sent to the MHRA, Ethics and the sponsor.
Serious Adverse Reactions (SARs): are reactions judged by the chief investigator to be 
related to the study drug, although listed in the protocol as expected drug reactions. These 
were collected in the CRF and a SAE form completed for each one. All SARs were held in 
the site file and formed part of the Annual Safety Report sent out as above.
Suspected Unexpected Serious Adverse Reactions: are reactions judged by the chief 
investigator to be related to the study drug, and are unexpected study drug reactions 
according to the protocol. If they occur, they are collected in the CRF and an SAE form 
completed for each one. SUSARs should be sent to the MHRA, ethics committee and the 
sponsor within 7 days for all fatal or life-threatening SUSARs and 15 days for all others.
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3.6.5 Clinical Trial Obligations
3.6.5.1 Ethics and the MHRA
In 2004, the introduction of EU directive 2001/20/EC means that in order to conduct a 
clinical trial of a medicinal product, the following must be obtained:
3.6.5.2 Sponsorship
A sponsor is an individual, company, institution or organisation which takes 
responsibility for the initiation, management or financing of a clinical trial. For this trial, 
the North Glasgow University Directorate NHS Trust Research and Development agreed 
to act as sponsor.
3.6.5.3 Ethical approval
An ethics committee is an independent body consisting of health care professionals and 
non-medical members. The function of an ethics committee is to provide an opinion 
before a clinical trial starts having been given details of the following particulars:
• The relevance of a clinical trial and the trial design
• Evaluation of the expected benefits and risks
• The protocol
• Suitability of the investigator and supporting staff
• The investigator’s brochure
• The quality of facilities available
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• The process for obtaining informed consent and the alternative procedures for doing so 
on behalf of those incapable of giving informed consent
• Details of any indemnity or compensation in the event of injury or death attributable to 
the clinical trial
• Insurance to cover the liability and the investigator and sponsor
• Details of payments to be made to investigators and participants in the trial
• Arrangements for the recruitment of clinical trial subjects
Only if the opinion of the ethics committee on all the above points is favourable will the 
trial be permitted to start. The legislation requires that the decision from the ethics 
committee must be supplied within 60 days of the date of receipt of the application. If the 
ethics committee requires further information to make a final judgment as to its opinion, 
the time taken for that further information to be supplied by the applicant is not included 
in the 60-day schedule. 
To ensure the effective functioning of ethics committees, a new UK Ethics Committee 
Authority (UKECA) has been created to establish, recognise and monitor ethics 
committees. The executive procedures of the UKECA are carried out by the Central 
Office of Research Ethics Committee (COREC).
Ethics committee approval was granted on the 18th January 2005. 
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3.6.5.4 MHRA Approval
Applying to the MHRA for Clinical Trial Approval (CTA) is a complex undertaking. The 
amount of information required for the application was substantial. With assistance from 
Karen Dunlop at Pfizer, we eventually, in March 2005, submitted:
Application form
Protocol
Investigational Medicinal Product (IMP) brochure
The MHRA then has 30 days to consider its response, during which time it may ask one 
lot of questions. If it does so, the 30 day clock is “on hold” until a reply is obtained 
(figure 3.5).
We received no questions, and on day 30 (9th April 2005), we received permission to 
proceed.
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Figure 3.5 Flowchart for Application to MHRA for Clinical Trial Authorisation (CTA)
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3.6.5.5 Amendments
Where a change must be made to the protocol, this must first be approved by the ethics 
committee and the MHRA, unless the change relates to patient safety, in which case the 
amendment may be submitted after the change has taken place. Normally the MHRA will 
issue approval subject to ethics committee agreement. Copies of both agreements are then 
forwarded to the sponsor. Patients were asked to re-consent if there were any 
amendments to the protocol. 
3.6.5.6 Annual Safety Reports
It is the legal responsibility of the sponsor to submit, once a year throughout the clinical 
trial, (or on request), a safety report to the MHRA and the Ethics Committee, taking into 
account all new available safety information produce along the reporting period.  Safety 
reports were issued on the 18th January 2006 and at the close of the study on the 27th
February 2007.
3.6.5.7 Other obligations
3.6.5.7.a Trial registration
In line with recent requirements by International Committee of Medical Journal Editor 
(ICMJE) journals 216 - 218, clinical trials hoping for future publication are required to be 
registered on an international, searchable database. In addition, this database must hold 
specific information about the trial, as specified by a WHO registration advisory group 219
(see table 3.2, below). For trials recruiting after the 1st of July 2005, the deadline for this 
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registration was the 13th September 2005 219. Trials must be registered before the first 
patient is recruited 218. Accordingly, the trial was registered with www.clinicaltrials.gov 
on 30th June 2005. Clinicaltrials.gov was established by the US National Institute of 
Health and is one of the largest research databases currently in existence 216.
Table 3.2 Minimum required information for Clinical Trial Database, as defined by the ICMJE 219
Item Comment
Unique trial number The unique trial number will be established by the primary 
registering entity (the registry)
Trial registration date The date of registration will be established by the primary 
registering entity
Secondary IDs May be assigned by sponsors or other interested parties (there 
may be none)
Funding source(s) Name of the organization(s) that provided funding for the study
Primary sponsor The main entity responsible for performing the research
Secondary sponsor(s) The secondary entities, if any, responsible for performing the 
research
Responsible contact 
person 
Public contact person for the trial, for patients interested in 
participating
Research contact 
person 
Person to contact for scientific inquiries about the trial
Title of the study Brief title chosen by the research group (can be omitted if the 
researchers wish)
Official scientific title of the 
study
This title must include the name of the intervention, the condition 
being studied, and the outcome (e.g. The International Study of 
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Item Comment
Digoxin and Death from Congestive Heart Failure)
Research ethics 
review 
Has the study at the time of registration received appropriate 
ethics committee approval (yes/no)? (It is assumed that all 
registered trials will be approved by an ethics board before 
commencing.)
Condition The medical condition being studied (e.g. asthma, myocardial 
infarction, depression)
Intervention(s) A description of the study and comparison/control intervention(s). 
(For a drug or other product registered for public sale anywhere 
in the world, this is the generic name; for an unregistered drug 
the generic name or company serial number is acceptable.) The 
duration of the intervention(s) must be specified
Key inclusion and 
exclusion criteria
Key patient characteristics that determine eligibility for 
participation in the study
Study type Database should provide drop-down lists for selection. This 
would include choices for randomized vs. nonrandomized, type 
of masking (e.g. double-blind, single-blind), type of controls (e.g. 
placebo, active), and group assignment, (e.g. parallel, crossover, 
factorial)
Anticipated trial start date Estimated enrolment date of the first participant
Target sample size The total number of subjects the investigators plan to enroll 
before closing the trial to new participants
Recruitment status Is this information available (yes/no)? (If yes, link to information.)
Primary outcome The primary outcome that the study was designed to evaluate. 
Description should include the time at which the outcome is 
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Item Comment
measured (e.g. blood pressure at 12 months)
Key secondary outcomes The secondary outcomes specified in the protocol. Description 
should include time of measurement (e.g. creatinine clearance at 
6 months)
3.6.5.7.b Confidentiality
All investigators ensured that patient confidentiality was maintained at all times adhering 
to the Data Protection Act (1998) and according to the Clinical Trials Directive 
2001/20/EC ‘Good Clinical Practice’ (G.C.P) guidelines.  
3.6.5.7.c Monitoring of the study
The study was intended to be monitored within 6 months of the first patient being 
recruited. However, due to staffing constraints within the Research and Development, full 
monitoring was delayed until July 2007. An audit of documentation was carried out in 
April 2006. 10% of all patient information documented in the case report file was 
checked and verified for completeness and adherence to the protocol.  The Chief 
Investigator and the research team reviewed recruitment on a fortnightly basis.  
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4. METHODOLOGY
4.1 Asthma-specific measurements
4.1.1 Diary card recordings 
A diary card was used (Appendix 1) to measure asthma symptoms 220, PEF recordings 
and inhaled beta2-agonist use. PEF measurements were be undertaken by patients at 
home using a mini-Wright peak flow meter (Clement Clarke, Harlow, UK). On return 
visits, the diary was analysed for variability and exacerbations (see below). The best of 
three measurements was recorded twice daily (prior to treatment with salbutamol) in the
diary. Peak flow variability was calculated from the difference between the highest and 
lowest daily reading divided by the mean PEF reading multiplied by 100 (amplitude % 
mean). 
One of the reasons that PEF is collected in clinical trials is that for the individual patient, 
regular daily measurements often provide the clinician with a much clearer picture of the 
patient’s clinical status that does a single measure of FEV1 or PEF made in the clinic. 
Frequent measurement of PEF provides valuable information about diurnal variation in 
airway calibre and evidence of day-to-day fluctuation in the patient’s status 221.
4.1.1.1 Asthma quality of life (AQLQ)
Quality of life was assessed using the Juniper Asthma Quality of Life Questionnaire 222, 
before and after taking each medication (on visits 2, 5, 6 and 9). A sample of this 
questionnaire is in Appendix 2.
89
4.1.1.2 Asthma Control
Asthma control was assessed using the Juniper Asthma Control Questionnaire (ACQ) 43
on each visit. The patient answered the first 6 questions, and the final question was 
completed by a member of the research team from spirometry. A sample of this 
questionnaire is in Appendix 3. 
4.1.2 Spirometry (FEV1, FVC), reversibility testing
Baseline pre-bronchodilator spirometric measurements were recorded from the best of 
three attempts using a dry wedge spirometer (Vitalograph, Buckingham, UK) (figure 
4.1), with measurements not varying by more than 5% or 0.2 mL. Spirometric 
measurements were made before and after nebulised salbutamol (2.5 mg). Measurements 
were performed at the same time of day (am or pm) for each patient. 
Figure 4.1 Spirometry
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4.1.3 Asthma severity
Asthma severity, or impairment, is defined by physiological and clinical parameters 223.
The degree of impairment is calculated as the sum of the scores for post-bronchodilator 
FEV1, reversibility of FEV1, or PC20, and medication need: 
· Postbronchodilator FEV1: this is scored from zero (no evidence of airflow 
limitation) to 4 (severe degree of airflow limitation, FEV1 < 50% predicted).
· Reversibility to salbutamol or hyperresponsiveness to methacholine (defined as 
PC20 <8 mg/mL: scored from zero (reversibility <10% or PC20>8 mg/mL) to 3 
(reversibility >30% or PC20<0.125 mg/mL).
· Minimum medication needed to control symptoms: from none (scored zero) to 
high dose systemic steroid daily (scored 4).
4.1.4 Exacerbations of asthma and Adverse Events 
Mild exacerbation was defined as one of the following for 2 consecutive days: 
· a drop in PEF > 20% below baseline value, 
· use of more than 3 additional puffs of reliever bronchodilator over 24 hours 
(excluding prophylactic puffs for exercise) as compared with baseline value, or 
· night awakening due to asthma. 
A severe exacerbation was defined as:
· any worsening of asthma control considered by the investigator or GP to require a 
short course of oral corticosteroids/hospitalization, or 
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· decrease in morning PEF to more than 30% below the baseline value on 2 
consecutive days 224.
The following were monitored to assess adverse events:
· Emergency or “out of hours” visit of patients to the GP; 
· GP visit to patient at home; 
· GP or investigator prescribing extra treatment; 
· A & E hospital attendance; 
· Hospital admission and length of stay. 
Patients recorded events that they would consider “out of the ordinary” for them, such as 
headaches, nausea or muscle cramps, that might be attributable aside-effects of the 
medications. These were also documented in the adverse events section.
4.1.5 Airway responsiveness
Recent guidelines for bronchial challenge testing with methacholine have been 
published 225. The tidal breathing method described is a version of Cockcroft’s 
technique 226, which has been shown to produce slightly better responses that the 
alternative breath-hold with dosimeter method 227. The nebuliser was calibrated before the 
study began (Appendix 4). After initial spirometry, patients received 2 minutes of 
nebulised 3% saline. Further spirometry was then performed. Patients received 2 minutes 
of increasing concentrations of methacholine, from 0.03mg/mL to 16 mg/mL. After each 
period, spirometry was preformed at 30 seconds and 90 seconds, with a third test at 180 
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seconds if a fall in FEV1 was recorded (figure 4.2). Once a drop in FEV1 of 20% from the 
lowest post-saline FEV1 was recorded, all measurement stopped and the patient was 
given a nebuliser of salbutamol to reverse the effects of the methacholine. The patient 
was then monitored until the FEV1 returned to normal.
Figure 4.2 Methacholine administration
Methacholine hyperreactivity is measured by the PC20, a function of the concentration 
required to bring about a drop in FEV1 of 20%. This is calculated using the following 
equation: 
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Where 
C1 = second to last methacholine concentration (i.e. the concentration preceding C2)
C2 = final methacholine concentration (the concentration resulting in a 20% or greater fall 
in FEV1)
R1 = percent fall in FEV1 after C1 and
R2 = percent fall in FEV1 after C2
This was inserted into a Microsoft Excel package for ease of calculation:
Post Saline FEV1
(mL)
2nd last FEV1
(mL)
Last FEV1
(mL)
Concentration
at 2nd last FEV1 
(mg/mL)
Concentration
at last FEV1
(mg/mL)
3190 2930 2520 4 8
1st % fall 2nd % fall
PC20 
(mg/mL)
8.15047 21.0031 7.5787
A value of methacholine hyperreactivity >16 mg/mL was read as 16 mg/mL. Bronchial 
hyper-reactivity is defined as a PC20 FEV1 of <8 mg/mL, so patients who had a level 
below this were suitable for inclusion in the trial.  Methacholine challenge testing was 
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only performed in subjects who had a baseline FEV1 of greater than 60% predicted. 
Patients who had a baseline FEV1 lower than this were still included in the trial, but 
without methacholine testing.
4.2 Measurement of atopy
Atopy is the predisposition to produce IgE antibody to common aeroallergens. This can 
be identified and quantified by either skin-prick testing or serum immunoassay. 
Allergen skin prick tests give a more sensitive and more repeatable diagnosis of atopy 
than measurement of serum IgE antibody 228, 229. At the screening visit, skin prick tests for 
allergy to cat dander, house dust mite (Dermatophagoides farinae) and mixed grass 
pollen (wheat, timothy grass, foxtail grass, rye-grass, meadow grass, cocksfoot) was 
performed (Soluprick, ALK, Horsholm, Denmark), with a positive control (histamine) 
and a negative control (saline and glycerine) 230.  A positive result was a wheal reaction 
after 15 minutes of 3mm greater than  the control wheal diameter 231. 
In the event of a negative skin prick test, but a strong history of atopy (e.g. hay fever), a 
serum sample was sent to the hospital immunology laboratory for IgE antibody testing. 
In addition, serum samples from each patient were saved for batch analysis at the end of 
the study. Total IgE and specific IgE to house dust mite, and grass pollen were assayed 
by automated fluorescent-immunoassay (Unicap 100, Pharmacia UK, Ltd, Milton 
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Keynes, UK,). Total IgE >120 International Units/L and specific IgE >0.35 Arbitrary 
Units/L were considered positive.
4.3 Induced sputum
Sputum was induced using an ultrasonic nebuliser (Sonix 2000, Medic Ltd, Harlow, 
Essex, UK), initially filled with 3% saline. Subjects inhaled the nebulised solution for 7 
minutes (nebuliser output 0.9 mL/min; mass median diameter 5.5 micrometer) following 
pre-treatment with 2.5mg nebulised salbutamol. After this, the nebuliser was filled with 
4% saline and the nebulised solution inhaled for a further 7 minutes (figure 4.3). Finally, 
the nebuliser was filled with 5% saline and the nebulised solution was inhaled for a final 
7 minutes. At each 7-minute interval the inhalation was stopped to allow expectoration 
into a polypropylene container, and for spirometry checks. The test was not performed on 
subjects with an FEV1 less than 1 L. If FEV1 fell by 20% or more, or if troublesome 
symptoms occurred, the test was stopped. If the FEV1 fell by 10-20%, the concentration 
of saline was not increased. The sample was kept on ice until processed for cell counts 
and centrifugation to harvest the soluble phase of sputum. This was always done within 2 
hours 50. Cell counts were performed and the supernatant stored for analysis of 
inflammatory mediators.
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Figure 4.3 Induced sputum technique
4.3.1 Analysis of sputum
Analysis was performed in a procedure similar to that described by Popov et al 232. 
Sputum was poured into a petri dish and mucous plugs were selected from surrounding 
saliva (figure 4.4). Plugs were transferred into a pre-weighed bijou bottle and weighed. 
A 1:10 dilution of dithiothreitol (DTT) (Calbiochem, Merck Biosciences Ltd, Beeston): 
Phosphate buffered saline (PBS) (VWR International Ltd, Poole) 4 times the weight of 
sputum was added to the sample and mixed in. A further 4 times the original weight of 
sputum of PBS was then added. The sample was then passed through a sterile nylon 
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(nitex) mesh to filter out clumps, into a pre-weighed centrifuge tube, which was then 
weighed again. An aliquot of 20 mL was removed then diluted 1:1 with 0.1% trypan blue 
(Sigma Aldrich Company Ltd, Gillingham). A manual total cell count and a viability 
count were then performed using a haemocytometer (figure 4.5). Samples were assessed 
at this point and excluded if they failed to meet the criteria listed in table 4.1.
Table 4.1 Sputum cell count – criteria for exclusion of sample
Parameter Threshold for exclusion
Cell viability <40%
Total cells to be counted <400
Proportion of squamous cells >80%
The sample was then centrifuged at 1000 rpm for 10 minutes, at 4 °C. Multiple 1 mL 
aliquots of supernatant were stored at –20 °C. If only 1 mL was available, it was split into 
2 x 0.5 mL.
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Figure 4.4 Selection of mucus plugs
Figure 4.5 Cell counting
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4.3.1.1 Differential cell counting by staining of cytocentrifuge cell smear preparations
The cell pellet was resuspended at a concentration of 0.6 x 106/mL in a volume of 200 mL 
which was kept on ice. 70 mL was pipetted into each funnel of a cytocentrifuge to obtain 
7 x 104/mL, insert into a cytospin holder. 2 slides (VWR International Ltd, Poole) were 
prepared for cytospins, using filter cards, funnels and cytoclips (Thermo Electron 
Corporation, Basingstoke) as per manufacturer’s instructions. They were then spun at 450 
rpm for 6 minutes (Shandon Cytospin 4 Cytocentrifuge, Thermo Electron Corporation, 
Basingstoke), then air dried for 1 – 2 hours. Samples were then fixed in methanol for 10 
minutes. Fixed slides were then stained using Romanowsky staining – Rapi Diff II Stain 
Pack (Triangle Biomedical Sciences Ltd, Skelmersdale).
A differential cell count of greater than 400 inflammatory cells was performed. In 
addition to this the squamous epithelial cell count was performed in order to estimate 
saliva contamination. 
4.3.1.2 Analysis of sputum biomarkers
4.3.1.2.i Microbead fluorescent assay: Luminex technology
The inflammatory cytokines IL-1β, IL-6, IL-8, TNF-α, GM-CSF IL-1RA, IL-17, IFN-γ, 
MIP-1α and CCL2  were measured using an assay kit (Biosource, Invitrogen, Paisley, 
UK).  The format of luminex allows the measurement of a combination of various 
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cytokines or other mediators at the same time in a small volume, which makes it 
particularly suitable for sputum samples.
Luminex technology consists of a uniform batch of polystyrene microbeads dyed 
internally with a combination of two fluorescent markers, which give this batch a unique 
spectral address for identifying that bead set on a fluorescent reader. Using different 
ratios of markers with different batches of beads allows them to be detected separately 
when they are mixed. A batch of beads with a characteristic marker identity is coated 
with a capture antibody specific for the cytokine or mediator of interest, thus each 
cytokine or mediator has a specific set of beads that can be identified simultaneously in a 
mix. 
The beads are prepared by washing twice using the supplied buffer; after this, they are 
ready to use.  The sputum supernatant samples are incubated with the antibody-coated 
beads on an orbital shaker for 2 hours.  Internal quality control and quantification is 
achieved using standard samples containing known amounts of these mediators. After 
this time, any unbound sample is washed from the well by washing 3 times with the 
supplied wash buffer, which is aspirated using a vacuum manifold.  A cocktail of 
cytokine-specific biotinylated detection antibodies are added and incubated for a further 
hour.  The plate is the washed 3 times to remove any unbound detection antibody, and 
streptavidin conjugated to the fluorescent protein, R-phycoerythrin, is added then 
incubated for 30 minutes.  An additional 3 washes later, the beads are analysed by 
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fluorimetry with the Bio-plex System instrument (Bio-Rad Laboratories, Hertfordshire, 
UK).  As the analyte forms an essential component of the sandwich between the 
microbead and the fluorescent reporter dye, the amount of fluorescence associated with 
each bead set can be directly attributed to the concentration of cytokine in each sample.  
Multiple beads are read for each analyte giving a mean value of fluorescence intensity, 
which is directly proportional to the concentration of the cytokine or mediator in each 
sputum supernatant sample.
Occasionally while using this test, the beads become stuck together. This unpredictable 
occurrence means that the beads are thus unable to be counted properly. These results are 
discarded and not included in the final analysis. 
Validity of this technique is examined using a technique known as “spiking”233. This 
involves adding a known amount of mediator to unprocessed sputum, processing the 
sputum as usual and then measuring recovery by immunoassay. Unspiked sputum is 
simultaneously processed and assayed so that percentage recovery can be calculated. This 
technique is however, extremely expensive and due to the limited resources of this study 
it was not possible to run spiking experiments specifically for these mediators. However, 
previous work in our department has shown good levels of recovery, consistent with 
those described by other centres233, 234. Despite this, measuring mediators in sputum 
supernatant remains difficult and controversial, and all results must be interpreted with 
considerable caution.
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4.3.1.2.ii Enzyme-linked immunoassay, ELISA
4.3.1.2.ii.a Leukotriene (LT)B4
This assay is based a competitive binding technique during which any LTB4 present in a 
sample competes with a set amount of alkaline phosphatase-labelled LTB4 conjugate for 
sites on a mouse monoclonal antibody (R&D Systems, Abingdon, UK).  The microplate 
has been coated with goat anti-mouse antibody, and during incubation the mouse 
monoclonal antibody will become bound to the coating antibody.  The sample and 
conjugate compete for binding sites on the antibody.  Following a wash step to remove 
excess conjugate and any unbound sample, a substrate solution is added to the wells in 
order to determine the bound enzyme activity.  Following colour development the 
absorbance is read immediately at 405 nm.  As the assay is a competitive ELISA, the 
intensity of the colour in a given well is inversely proportional to the concentration of 
LTB4 in that sample.
The sputum supernatants were diluted 1:2 with the supplied assay buffer before use in 
this assay. The microplate was marked into sections to contain the samples and standards, 
and wells for total activity, non-specific binding, maximum binding and substrate blank 
were also included.  Assay buffer was added to all wells, excluding the wells reserved for 
total activity and substrate blank.  The standards and samples were then added to the 
allocated wells, with the LTB4 conjugate being added directly afterwards.  The LTB4
conjugate was not added to the total activity or substrate blank wells.   LTB4 antibody 
solution was then added to the wells, excluding the non-specific binding, total activity 
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and substrate blank wells.  The plate was left to incubate at room temperature for 2 hours, 
on a horizontal orbital microplate shaker.  A wash removed any unbound sample or 
excess conjugate.  At this stage, LTB4 conjugate was added to the total activity wells.  
The substrate para-nitrophenyl phosphate was added, and allowed to incubate for 1 hour 
at room temperature on the benchtop.  When the colour had developed sufficiently, a 
solution of 1N sulphuric acid stopped the reaction and stabilized the colour in each well, 
and the plate was read immediately.
A standard curve was generated which allowed the calculation of the concentration of 
LTB4 in each sample, after the non-specific binding optical density was subtracted from 
each result.
LTB4 is a competitive ELISA, and requires the use of various internal controls mentioned 
above (total activity, non-specific binding, and substrate blanks) in duplicate, as the 
manufacturer states that results are only valid in the presence of these controls. This 
meant that a smaller total number of samples could be run in the analysis, so not all 
patient samples could be included.
4.3.1.2.ii.b Myeloperoxidase
Myeloperoxidase (MPO) was measured using a test kit developed for the quantitative 
measurement of natural human MPO (Cambridge Bioscience, Cambridge, UK).  The 
assay was based on the sandwich ELISA technique.  The sputum supernatants were 
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diluted 1:5 with the supplied dilution buffer before use in this assay. Samples and 
standards are incubated in microtitre wells coated with antibodies recognising human 
MPO.  During this incubation step, the solid-bound antibody captures any MPO present 
in the sample.  Unbound material present in the sputum supernatant sample is removed 
by washing.  Biotinylated second antibody to human MPO is then added to the wells.  If 
human MPO was present in the sample, the biotinylated-antibodies will bind to the 
captured MPO.  Excess biotinylated-antibodies are removed by washing.  Streptavidin-
peroxidase conjugate is applied to the wells.  This conjugate reacts specifically with the 
biotinylated-antibody bound onto the detected MPO.  Excess streptavidin-peroxidase 
conjugate is removed by washing, and the substrate, tetramethylbenzidine is added to the 
wells.  A coloured product develops, and the amount of colour that forms is directly 
proportional to the concentration of MPO present in the sample.  The enzymatic reaction 
is stopped by the addition of citric acid and the absorbance at 450 nm is measured with a 
spectrophotometer.  A standard curve is obtained by plotting the absorbance values 
versus the corresponding concentrations of defined standards.
4.4 Measurement of exhaled Nitric Oxide
Exhaled NO (FENO) is detected using chemiluminescence and detection depends on the 
photochemical reaction between NO and ozone generated in the analyser 235. The 
specificity of exhaled NO measurements by chemiluminescence has been confirmed by 
gas chromatography-mass spectrometry 236. FENO was measured on a chemiluminescence 
analyser (LR2149, Logan Research Ltd., Rochester, Kent).  In 2005 the American 
105
Thoracic Society and European Respiratory Society published joint guidelines for 
measurement of FENO 49. These superseded previous guidelines 237, 238.
Measurement of FENO requires slow expiration against resistance, which creates back 
pressure to close the soft palate and thus eliminates contamination of exhaled NO by 
nasal NO 239 (figure 4.6).
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Figure 4.6 Exhaled nitric oxide  testing
4.5 Allergen-driven blood  lymphocyte proliferative response in vitro.
Peripheral blood mononuclear cells were separated by density gradient centrifugation 
over lymphoprep, ficol-isopaque SG 1.088.  The mononuclear cells were harvested, 
washed, counted and at 106 cells/mL cultured in vitro with a growth medium of RPMI, 
10% autologous plasma, under penicillin and streptomycin cover for 3 days with or 
without mitogen (phytohaemagglutinin, PHA), or solid-phase anti-CD3/28 bound onto 
microbeads, in a humidified atmosphere at 37 °C with 5% CO2. Proliferation was 
measured by incorporation of tritiated thymidine (0.5 uCi) for 16 hours before harvest 
onto glass-fibre filters and counting in a beta counter. 
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4.6 Other immunological tests in blood 
Serum was analysed for C-reactive protein (CRP) concentration in the Routine Lipids 
section of the Biochemistry Department of Glasgow Royal Infirmary (high sensitivity 
assay, Roche/Hitachi, Roche Diagnostics GmbH, Mannheim, Germany). High sensitivity 
commercial ELISA kits were used for a variety of serum mediators according to 
manufacturers’ instructions (IL-6 and TNF-α, Quantikine; sICAM-1, Parameter; both R 
& D Systems Europe Ltd, Abingdon). 
4.7 Measurement of renal and liver safety parameters, and lipids in blood
Routine biochemistry laboratory samples were sent to the hospital laboratory for 
screening, at the end of treatment periods A and B, and before starting treatment period 
B. 
Blood for renal function (urea and electrolytes) and liver function tests (LFTs) were 
performed before and after each treatment period and creatinine kinase (CK) was 
performed at baseline. If a patient complained of muscle pain or excessive muscle 
fatigue, CK was repeated at that time. Cholesterol, triglycerides and HDL-cholesterol 
were measured in the Gartnavel General Biochemistry Laboratory at screening, at the end 
of treatment periods A and B, and before starting treatment period B. 
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4.8 Equivalent steroid dose
Equivalent steroid dose was calculated according to GINA guidelines 1 (see table 4.2). 
Patients with a beclomethasone equivalent of 1000mcg or less were eligible for the trial. 
Table 4.2 Equivalent inhaled corticosteroid doses (from GINA 1)
Drug Multiplication factor to calculate beclomethasone equivalent
Beclomethasone 1
Budesonide 1
Qvar 2
Fluticasone 2
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5. RESULTS
5.1 Introduction
4303 patients were invited to participate in the trial, from 39 practices and hospital 
outpatients. Of these, 439 expressed an interest in taking part. 140 were excluded prior to 
clinical screening by telephone, for reasons such as pregnancy or lactation, current statin 
medication, diagnoses of COPD, non-attendance at appointments or because they were 
unable to be contacted. Of the 137 subjects that attended screening at Gartnavel General 
Hospital, 54 were recruited to the trial between August 2005 and August 2006 (table 5.1).
Table 5.1 Reasons for exclusion of screened patients from study
Reason for exclusion from study Number of patients
Withdrew or unable to provide consent 20
Negative allergy test 24
Negative spirometry 16
Unsuitable medication 3
Declined to take part 20
5.2 Flow of participants
The progress of participants through the trial is shown in the CONSORT diagram (figure 
5.1).
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Figure 5.1 CONSORT diagram showing flow of patients through study
Patients invited n = 4303
Suitable for screening n = 299
Positive responses n = 439
Screened n = 137
Randomized n = 54
Competed trial n = 48
Analyzed for primary endpoint n = 46
Not eligible n = 140
Declined screening n = 81
Excluded n = 83
Lost to follow-up n = 3
Discontinued n = 3
Final diary missing n = 2
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5.3 Baseline characteristics
5.3.1 Demographics
Baseline demographic characteristics of the 54 subjects who underwent randomisation 
were similar (table 5.2). 
Patients taking atorvastatin before placebo were younger than the group taking placebo 
first, mean age 39.4 years compared with 45.9 years. This difference was non-significant 
(p=0.082). There were equal numbers of women in both groups (42.9% vs. 42.3%) and 
all patients were white. 10.7% in the atorvastatin and 11.5% in the placebo group were 
former smokers. The mean duration of asthma was 24.9 years.
Mean alcohol consumption was 8.2 units per week, this was similar in both groups. 
88.9% of patients had positive IgE serology (total IgE >120 IU/L or specific IgE for 
house dust mite or grass pollen >0.35 IU/L), similar in both groups (85% for atorvastatin, 
92.3% for placebo). Finally, mean equivalent beclomethasone dose was 476 mg (SD 
283), with no significant differences between groups.
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Table 5.2: Demography at baseline mean (SD) in all patients, and sub divided into those randomised to received 
atorvastatin then placebo, and those randomised to receive placebo then atorvastatin
Variable Total
(n=54)
Atorvastatin > 
Placebo
(n=28)
Placebo > 
Atorvastatin
(n=26)
t-test
(p value)
Male sex, n (%) 23 (42.59) 12 (42.9) 11 (42.3) 0.968
Ex-smoker, n (%) 6 (11.11) 3 (10.7) 3 (11.5) 0.923
Age in years (SD) 42.5 (13.7) 39.4 (13.4) 45.9 (13.5) 0.082
Asthma duration years
(SD)
24.9 (16.6) 24.1 (15.0) 25.7 (18.4) 0.730
Equivalent
beclomethasone dose,  
mg (SD)
476 (283) 441 (309) 513 (251) 0.351
Positive IgE testing, n (%) 48 (88.9) 24 (85.7) 24 (92.3) 0.438
Alcohol units (SD) 8.2 (8.0) 9.1 (8.3) 7.2 (7.7) 0.387
5.3.2 Baseline outcome measures
5.3.2.1 PEF
Baseline PEF measurements of randomised patients are listed in table 5.3.  Mean (SD) 
morning PEF measurements were 390.3 L/min (103.5) (Table 5.3). Values in the group 
commencing on atorvastatin and placebo were similar (395.6 L/min (107.8) vs. 384.6 
L/min (100.5)). Evening PEF measurements were also similar (overall mean 403.3 L/min 
(101.4), atorvastatin 408.9L/min (109.4), placebo 397.4 L/min (93.9)). 
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Table 5.3 Baseline PEF
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
Morning PEF 
(L/min)
54 390.3 103.5 28 395.6 107.8 26 384.6 100.5
Evening PEF 
(L/min)
52 403.3 101.4 27 408.9 109.4 25 397.4 93.9
5.3.2.2 Reliever inhaler use
Baseline use of reliever inhalers was similar between groups. Total mean (SD) number of 
puffs of reliever inhaler was 2.3 (2.0). 
Table 5.4 Baseline reliever inhaler use
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
Puffs of reliever 
inhaler used daily
51 2.3 2.0 27 2.1 2.1 24 2.5 2.0
5.3.2.3 Asthma severity 
Mean (SD) ATS severity score was 3.3 (1.3) (Table 5.5). There was no significant 
difference in score between groups.
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Table 5.5 Baseline ATS severity score
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
ATS severity score 54 3.3 1.3 28 3.1 0.9 26 3.5 1.5
5.3.2.4 Asthma Control Questionnaire (ACQ) Score
Mean (SD) ACQ score was 1.5 (0.8) at baseline (Table 5.6). There was no significant 
difference between groups.
Table 5.6 Baseline Asthma Control Score
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
ACQ 54 1.5 0.8 28 1.5 0.8 26 1.6 0.8
5.3.2.5 FEV1
Table 5.7. Mean (SD) FEV1 pre-salbutamol was 2.78 L (0.85) with no difference between 
groups, mean post-salbutamol was 3.18 L (0.84). This equates to a mean reversibility of 
14.9% (11.7). Mean percentage predicted FEV1was 85.7% (19.3), comparable between 
groups.
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Table 5.7 Baseline FEV1 and reversibility 
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std
Dev
n Mean Std 
Dev
FEV1 pre-salbutamol (L) 54 2.78 0.85 28 2.96 0.91 26 2.59 0.74
FEV1 post-salbutamol (L) 54 3.18 0.84 28 3.33 0.98 26 3.02 0.65
Predicted FEV1 (%) 54 85.7 19.3 28 86.9 17.3 26 84.4 21.6
FEV1 reversibility (%) 54 14.9 11.7 28 13.3 9.4 26 17.0 13.8
5.3.2.6 PEF (spirometry)
Mean (SD) PEF when measured at the clinic by spirometry was 426.6 L/min (130.4) pre-
salbutamol, and 499.8 L/min (133.4) post-salbutamol. Mean percentage predicted PEF 
(pre-salbutamol) was 92.3% (22.9), which was similar in both groups (Table 5.8).
Table 5.8 Baseline PEF (spirometry)
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
Spirometry PEF 
pre-salbutamol (L/min)
54 426.6 130.4 28 434.2 122.2 26 418.3 140.8
Spirometry PEF post-
salbutamol (L/min)
54 499.8 133.4 28 505.9 138.9 26 493.3 129.7
Predicted PEF (%) 54 92.3 22.9 28 91.7 19.2 26 93.0 26.7
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5.3.2.7 FVC
Mean (SD) FVC pre-salbutamol was 3.70L (1.10), post-salbutamol was 4.03L (1.04). 
Mean percentage predicted FVC was 95.8% (20.2) (Table 5.9). 
Table 5.9 Baseline FVC
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
FVC pre-
salbutamol (L)
54 3.70 1.10 28 3.98 1.26 26 3.41 0.82
FVC post-
salbutamol (L)
54 4.03 1.04 28 4.20 1.23 26 3.85 0.80
Predicted FVC (%) 54 95.8 20.2 28 98.5 20.6 26 92.8 19.6
5.3.2.8 FEF25-75
Mean (SD) FEF25-75 pre-salbutamol was 2.35 L/sec (1.09) (Table 5.10). Post-salbutamol 
was 2.87 L/sec (1.11). Mean percentage predicted FEF25-75 was 60.6% (25.0), which was 
comparable between groups.
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Table 5.10 Baseline FEF25-75
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
FEF25-75 pre-salbutamol 
(L/sec)
54 2.35 1.09 28 2.40 1.04 26 2.23 1.15
FEF25-75 post-salbutamol 
(L/sec) 
54 2.87 1.11 28 3.03 1.18 26 2.70 1.04
Predicted FEF25-75 
(%)
54 60.6 25.0 28 59.4 20.2 26 61.8 29.7
5.3.2.9 FEV1/FVC ratio
Mean (SD) pre-salbutamol FEV1/FVC ratio was 75.5% (9.8) (Table 5.11). Mean post-
salbutamol FEV1/FVC ratio was 79.1% (8.2). 
Table 5.11 Baseline FEV1/FVC ratio
Variable Total Atorvastatin > 
Placebo
Placebo > 
Atorvastatin
n Mean Std 
Dev
n Mean Std 
Dev
n Mean Std 
Dev
FEV1/FVC ratio 
pre-salbutamol (%)
54 75.5 9.8 28 75.2 8.8 26 75.7 10.9
FEV1/FVC ratio 
post-salbutamol (%)
54 79.1 8.2 28 79.6 8.0 26 78.6 8.6
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5.3.2.10 Methacholine responsiveness
Geometric mean (SD) methacholine responsiveness as measured by PC20 was 
2.23mg/mL (3.65) (Table 5.12). Initial results were slightly lower in the atorvastatin 
group compared with the placebo group [1.95 mg/mL (4.03) vs. 2.69 mg/mL (4.23)].
Table 5.12: Baseline methacholine responsiveness
Variable Total Atorvastatin > Placebo Placebo > Atorvastatin
n Geometric 
mean
Std 
Dev
n Geometric
mean
Std 
Dev
n Geometric 
mean
Std 
Dev
Methacholine 
responsiveness
(PC20, mg/mL)
43 2.23 3.65 22 1.95 4.03 21 2.69 4.23
5.3.2.11 Asthma Quality of Life Questionnaire (AQLQ) 
AQLQ score was similar between groups at baseline (Table 5.13). Total score was 5.55 
(range 1-7). Total score and sub-scores of symptoms (5.38), activities (5.88), emotional 
well-being (5.39) and environmental quality of life (5.34) showed no obvious differences 
between groups. 
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Table 5.13 Baseline AQLQ scores (One patient in the placebo arm completed their questionnaire incorrectly).
Variable Total Atorvastatin > Placebo Placebo > Atorvastatin
n Median IQR n Median IQR n Median IQR 
AQLQ 53 5.75 5.03, 6.19 28 5.77 4.92, 6.17 25 5.75 5.09, 6.28
AQLQ- symptoms 53 5.38 4.83, 6.08 28 5.50 4.58, 6.08 25 5.67 5.33, 6.08
AQLQ - activities 53 5.88 5.50, 6.45 28 6.18 5.38, 6.45 25 6.27 5.55, 6.55
AQLQ - emotions 53 5.39 4.60, 6.40 28 5.70 4.4, 6.3 25 5.80 4.80, 6.60
AQLQ - environment 53 5.34 4.75, 6.25 28 5.63 4.63, 6.13 25 5.50 4.75, 6.25
5.3.3 Inflammatory markers
The baseline values for various inflammatory markers in the groups randomised to start 
with either atorvastatin or placebo are described below. 
5.3.3.1 Sputum markers
5.3.3.1.a Sample quality
Median total filtrate volume was 18.5 mL (IQR 8.0 to 35.5). This was similar between 
groups. Additionally, indicators of sputum quality such as total cells recovered (2 
x106/mL, 0.9 to 6.7), and viability (77.0%, 65.5 to 85.5), were also comparable (Table 
5.14).
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Table 5.14 Baseline sputum sample quality. The lower number of samples in absolute number of cells counted 
represents samples discarded due to inadequate quality, as discussed in the methodology section.
Variable Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR 
Filtrate volume (mL) 36 18.5 8.0, 35.5 19 20.0 8.0, 41.0 17 17.0 8.0, 35.0
Total number of cells 
recovered from sample 
(x106/mL)
36 2.0 0.9, 6.7 19 1.8 0.9, 4.8 17 2.7 0.9, 7.0
Viability (%) 36 77.0 65.5, 85.5 19 75.0 67.0, 85.0 17 78.0 64.0, 88.0
Total cell count per ml 
sputum filtrate (x106/mL)
36 0.14 0.07, 0.28 19 0.14 0.07, 0.22 17 0.12 0.07, 0.34
Total viable cells 
recovered from sample 
(x106/mL)
36 1.4 0.8, 4.3 19 1.4 0.7, 3.0 17 1.9 0.9, 4.9
Absolute number of cells
counted per slide
30 576 501, 643 16 581 520, 671 14 566 481, 609
5.3.3.1.b Cell counts
No significant difference was seen between groups for all cell counts (Table 5.15). 
Median macrophages were 196.5 x104 cells per slide (IQR 101.3 to 235.0). Neutrophils 
were 129.8 x104 cells per slide (60.0 to 186.5), eosinophils were 6.4 x104 cells per slide 
(2.0 to 16.3) and lymphocytes were 2.5 x104 cells per slide (1.0 to 5.5). Bronchial 
epithelial cells accounted for 44.0 x104 cells per slide (12.0 to 60.3) and total non-
squamous cells were 405.3 x104 cells per slide (401.5 to 410.0).
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Table 5.15 Baseline values for sputum cell counts 
5.3.3.1.c Cell count proportions
There was no significant difference between patients starting with atorvastatin and those 
starting with placebo for any of the different cell types in sputum analysis (Table 5.16). 
Variable Total Atorvastatin Placebo
n Media
n
IQR n Median IQR n Median IQR 
Macrophages 
(x104 cells)
30 196.5 101.3, 235.0 16 191.0 167.3, 217.0 14 213.0 95.5, 254.0
Neutrophils
(x104 cells)
30 129.8 60.0, 186.5 16 129.8 57.5, 177.8 14 146.0 66.0, 268.0
Eosinophils
(x104 cells)
30 6.4 2.0, 16.3 16 4.9 1.3, 18.9 14 6.4 4.0, 13.5
Lymphocytes
(x104 cells)
30 2.5 1.0, 5.5 16 2.6 1.6, 8.3 14 2.5 1.0, 4.5
Bronchial 
epithelial cells
(x104 cells)
30 44.0 12.0, 60.3 16 50.8 23.5, 71.1 14 19.5 11.5, 50.0
Total non-
squamous cells
(x104 cells)
30 405.3 401.5, 410.0 16 407.8 402.5, 413.3 14 403.5 401.5, 409.5
Squamous 
epithelial cells
(x104 cells)
30 178.3 110.5, 257.0 16 181.3 118.0, 269.5 14 173.5 86.0, 212.0
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Median macrophages represented 49.5% (IQR 30.5 to 57.5) of total cell count. 
Neutrophils accounted for 35.5% (14.5 to 48.3), eosinophils 1.5% (0.6 to 5.0), 
lymphocytes 0.7% (0.3 to 1.1) and bronchial epithelial cells 10.8% (3.0 to 16.0). Median 
squamous cells as a proportion of absolute cell count were 30.8% (20.8 to 38.5). 
Table 5.16 Baseline values for sputum cell count proportions
Variable Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR 
Macrophage % 30 49.5 30.5, 57.5 16 47.3 40.5, 53.8 14 52.8 24.5, 61.5
Neutrophil % 30 35.5 14.5, 48.3 16 35.5 14.0, 43.8 14 35.8 14.8, 67.5
Eosinophil % 30 1.5 0.6, 5.0 16 1.1 0.3, 5.0 14 2.0 0.8, 3.0
Lymphocyte % 30 0.7 0.3, 1.1 16 0.8 0.5, 1.9 14 0.6 0.3, 1.0
Bronchial epithelial 
cells %
30 10.8 3.0, 16.0 16 12.5 5.5, 21.8 14 5.0 2.5, 13.5
Squamous cells as % 
of absolute count
30 30.8 20.8, 38.5 16 31.0 22.8, 39.8 14 30.0 20.0, 37.0
5.3.3.1.d Supernatant analysis
More variability was observed in the supernatant samples than other baseline values. 
Sputum LTB4 was higher in the atorvastatin group than the placebo group [atorvastatin 
median 216.8 ng/mL (IQR 66.5 to 303.5) vs. placebo median 162.0 ng/mL (73.5 to 
222.5), as was MPO [54.4 ng/mL (15.4 to 85.8) vs. 44.2 ng/mL (37.0 to 80.4)]. In 
contrast, IL-1b was higher in the placebo group [atorvastatin median 41.2 pg/mL (28.6 to 
123
91.9) vs. 162.8 pg/mL (61.9 to 223.2), as was IL-1RA [22.8 ng/mL (13.3 to 40.7) vs. 41.2 
ng/mL (25.8 to 52.6), IL-6 [30.6 pg/mL (15.0 to 59.2) vs. 91.9 pg/mL (21.7 to 161.2), IL-
17 [15.9 pg/mL (3.6 to 49.9) vs. 97.7 pg/mL (32.8 to 159.7), TNF-a [7.7 pg/mL (2.8 to 
17.7) vs. 43.3 pg/mL (9.2 to 61.0), IFNγ [9.7 pg/mL (3.3 to 23.9) vs. 40.8 pg/mL (19.2 to 
85.5), GM-CSF [126.9 pg/mL (77.6 to 184.2) vs. 304.0 pg/mL (134.3 to 488.3), MIP1α
[118.2 pg/mL (61.6 to 276.7) vs. 363.9 pg/mL (139.0 to 769.6), and CCL2 [195.1 pg/mL 
(123.2 to 368.5) vs. 332.5 pg/mL (220.7 to 616.9). Finally, IL-8 was similar between 
groups [1.4 ng/mL (0.7 to 9.6) vs. 2.0 ng/mL (1.0 to 4.7)] (Table 5.17).
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Table 5.17 Baseline values for sputum supernatant inflammatory markers
Variable Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR 
LTB4 (ng/mL) 37 179.0 73.5, 276.0 20 216.8 66.5, 303.5 17 162.0 73.5, 222.5
MPO (ng/mL) 37 47.8 32.6, 80.4 20 54.4 15.4, 85.8 17 44.2 37.0, 80.4
IL-1b (pg/mL) 37 76.4 38.9, 167.2 20 41.2 28.6, 91.9 17 162.8 61.9, 223.2
IL-1RA (ng/mL) 37 27.8 18.8, 47.0 20 22.8 13.3, 40.7 17 41.2 25.8, 52.6
IL-6 (pg/mL) 37 35.2 19.5, 105.6 20 30.6 15.0, 59.2 17 91.9 21.7, 161.2
IL-8 (ng/mL) 37 1.9 0.8, 5.8 20 1.4 0.7, 9.6 17 2.0 1.0, 4.7
IL-17 (pg/mL) 37 32.8 3.6, 137.9 20 15.9 3.6, 49.9 17 97.7 32.8, 159.7
TNF-α (pg/mL) 37 11.4 4.6, 46.5 20 7.7 2.8, 17.7 17 43.3 9.2, 61.0
IFN-γ (pg/mL) 37 19.8 4.9, 71.6 20 9.7 3.3, 23.9 17 40.8 19.2, 85.5
GM-CSF 
(pg/mL)
37 149.5 93.0, 367.9 20 126.9 77.6, 184.2 17 304.0 134.3, 488.3
MIP1α (pg/mL) 37 167.4 74.5, 483.8 20 118.2 61.6, 276.7 17 363.9 139.0, 769.6
CCL2 (pg/mL) 37 257.5 143.7, 477.3 20 195.1 123.2, 368.5 17 332.5 220.7, 616.9
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5.3.3.2 Serum markers
No obvious differences were seen between groups for CRP [median 1.2 mg/L (IQR 0.6 to 
2.6)], ICAM-1 [209.4 ng/mL (185.7 to 245.2)], TNF-a [1.1 pg/mL (0.7 to 1.8)], IL-6 [1.1 
pg/mL (0.7 to 3.1)], IL-1 [101.0 pg/mL (7.6 to 172.1)] or IL-8 [14.3 pg/mL (0.6 to 24.0)]. 
IL-5 was higher in the atorvastatin group than the placebo group [median 11.2 pg/mL 
(1.9 to 20.2) vs. 3.3 pg/mL (1.9 to 31.2)]; as was IL-10 [median 49.5 pg/mL (10.5 to 
102.5) vs. 33.9 pg/mL (10.5 to 77.4)] (table 5.18).
Table 5.18 Baseline values for serum inflammatory markers. Different sample sizes reflect availability of 
results for different tests, as discussed in the methodology
Variable Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR 
CRP (mg/L) 53 1.2 0.6, 2.6 28 1.3 0.9, 2.9 25 0.9 0.5, 2.3
ICAM-1 
(ng/mL)
54 209.4 185.7, 245.4 28 210.0 170.5, 244.8 26 209.4 191.2, 245.4
TNF-α (pg/mL) 54 1.1 0.7, 1.8 28 1.1 0.8, 1.9 26 1.0 0.7, 1.8
IL-6 (pg/mL) 54 1.1 0.7, 3.1 28 1.3 0.7, 3.0 26 1.1 0.7, 3.4
IL-1 (pg/mL) 47 101.0 7.6, 172.1 25 101.2 20.5, 164.9 22 99.5 7.6, 172.1
IL-5 (pg/mL) 47 7.3 1.9, 26.4 25 11.2 1.9, 20.2 22 3.3 1.9, 31.2
IL-8 (pg/mL) 47 14.3 0.6, 24.0 24 14.1 4.4, 22.9 23 14.3 0.6, 29.3
IL-10 (pg/mL) 46 36.1 10.5, 87.0 25 49.5 10.5, 102.5 21 33.9 10.5, 77.4
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5.3.3.3 Lymphocyte proliferation
There was no difference between groups for the control lymphocyte proliferation [median 
412 counts/min/well (IQR212 to 652). In contrast, testing using PHA gave lower results 
for the group starting with atorvastatin [36672 counts/min/well (2288 to 104773) vs. 
20721 counts/min/well (724 to 96458) for placebo], as did anti-CD3/28 [15681 
counts/min/well (2097 to 65625) vs. 7407 counts/min/well (487 to 50815)] (table 5.19). 
Table 5.19 Baseline values for lymphocyte proliferation
Variable Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR 
Control 
(counts/min/well)
47 412 212, 652 25 440 267, 641 22 340 210, 652
PHA 
(counts/min/well)
47 36518 894, 
104642
25 36672 2288, 
104773
22 20721 724, 96458
Anti-CD3/28 
(counts/min/well)
47 13880 658, 
65625
25 15681 2097, 65625 22 7407 487, 50815
5.3.3.4 Exhaled gases
Total baseline median (IQR) exhaled Nitric Oxide (FENO) was 18.33 ppb, (10.05 to 
33.07). Exhaled carbon monoxide (CO) median was 4.38 ppm (3.83 to 5.07) (Table 
5.20). There was no difference between groups.
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Table 5.20 Baseline values for exhaled gases
Variable Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR 
Exhaled NO 
(ppb)
53 18.33 10.05, 33.07 28 18.71 11.33, 44.1 25 17.1 9.13, 32.05
Exhaled CO 
(ppm)
53 4.38 3.83, 5.07 28 4.43 3.82, 5.13 25 4.35 3.93, 4.83
5.3.3.5 Biochemical indices
5.3.3.5.a Lipids
No difference between groups was seen in baseline serum triglycerides [median 1.3 
mmol/L (IQR 0.8 to 1.7)], cholesterol [5.1 mmol/L (4.5 to 5.9)] or HDL [1.3 mmol/L (1.1 
to 1.5)] (table 5.21).
Table 5.21 Baseline serum lipids. One value is missing for triglycerides in the atorvastatin group due to a lab 
error.
Variable Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR
Triglycerides (mmol/L) 52 1.3 0.8, 1.7 26 1.3 0.7, 1.7 26 1.2 0.8, 1.7
Cholesterol (mmol/L) 53 5.1 4.5, 5.9 27 5.0 4.3, 6.1 26 5.1 4.6, 5.8
HDL (mmol/L) 53 1.3 1.1, 1.5 27 1.3 1.1, 1.7 26 1.3 1.2, 1.5
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5.3.3.5.b Renal function
There was no difference in baseline urea [median 4.6 mmol/L (IQR 4.0 to 6.1)], 
potassium [4.0 mmol/L (3.9 to 4.2)] or sodium [140 mmol/L (138 to 141)] (table 5.22).
Table 5.22 Baseline values for renal function. One value is missing for potassium in the placebo group due to a 
haemolysed sample.
5.3.3.5.c Liver function
No difference was observed between groups in baseline values for bilirubin [median 9 
μmol/L (IQR 7 to 11)], AST [22 IU/L (19 to 27)] or ALT [21 IU/L (17 to 34)] (table 
5.23).
Variable
Total Atorvastatin Placebo
n Median IQR n Median IQR n Median IQR
Urea 
(mmol/L)
53 4.6 4.0, 6.1 27 4.6 4.1, 6.4 26 4.6 3.9, 6.1
Potassium 
(mmol/L)
52 4.0 3.9, 4.2 27 4.0 3.9, 4.2 25 4.1 3.9, 4.2
Sodium 
(mmol/L)
53 140 138, 141 27 140 139, 141 26 140 138, 141
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Table 5.23 Baseline values for liver function. One value is missing for AST in the placebo group due to a 
haemolysed sample
Variable Total Atorvastatin Placebo
n Media
n
IQR n Media
n
IQR n Media
n
IQR
Bilirubin (μmol/L) 53 9 7, 11 27 9 6, 11 26 9 8, 11
AST (IU/L) 52 22 19, 27 27 22 19, 26 25 23 18, 28
ALT (IU/L) 53 21 17, 34 27 20 17, 33 26 23 16,35
5.4 Loss to follow-up
3 patients (5.5%) were lost to follow-up. 3 prematurely discontinued, with a further 2 
patients failing to return their final diary. Thus for the primary end point, 14.8% were 
effectively lost to follow-up. Loss to follow up of 5% or lower is usually of little concern, 
whereas a loss of greater than 20% means that readers should be concerned about the 
possibility of bias. Losses between 5 and 20% can still be a source of bias 240.
5.5 Compliance
5.5.1 Peak flow measurements
Compliance with measuring PEF can be a problem in all clinical trials. We attempted to 
minimise this by emphasising the importance of diary card completion. In this study, the 
number of missing results was equal in both placebo and atorvastatin arms at analysis 
(table 5.24). 
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Table 5.24 Summary of incomplete data from peak flow diaries (morning PEF). Note 6 patients were 
prematurely excluded from the trial, 3 lost to follow-up and 3 discontinued.
Stage of trial Included results 
(n)
Missing results (n)
Atorvastatin Randomisation 49 4
Week 8 46 7
Placebo Randomisation 54 0
Week 8 47 7
5.5.2 Tablets
All patients were asked to return any unused medication and the container at the end of 
each course of treatment (2 per patient). 75.7% of containers were returned. Compliance 
was calculated by comparing the number of tablets returned with the number issued. 
Mean compliance was 94.5% for atorvastatin and 96.6% for placebo.
Compliance from medication was also inferred by alteration in serum cholesterol and 
LFTs, discussed in the results section, below.
5.6 Carry over effect
Crossover trials are elegant because they remove patient variation by allowing the patient 
to be compared with themselves. This makes them more efficient than a parallel group 
study 241. The principle drawback of a crossover trial is the possibility of a “carry over” 
effect. This is minimized by the use of a “washout period” (in the case of this study, six 
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weeks). Treatment-period interaction analysis shows no evidence of carry over effect for 
any outcome (Appendix 5).
5.7 Results – Clinical 
5.7.1 Peak expiratory flow
The primary outcome was morning PEF at 8 weeks. At 8 weeks, the difference in mean 
morning peak expiratory flow, for atorvastatin as compared with placebo, did not differ 
between groups [treatment difference -0.5 L/min, 95% CI -10.6 to 9.6, p=0.921]. There were 
no significant changes at 2 or 4 weeks (table 5.25 and 2.26, figure 5.2 and 5.3). There was 
also no difference in evening PEF [treatment difference 4.6 L/min, -5.8 to 14.9, p=0.377] 
(table 5.25 and 2.26, figure 5.4 and 5.5).
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Table 5.25 Morning and evening PEF at weeks 0, 2, 4 and 8
Variable Atorvastatin
Week 0 Week 2 Week 4 Week 8
n Mean SD n Mean SD n Mean SD n Mean SD
Δ Diary 
morning 
PEF, L/min
49 389.6 115.7 47 384.3 111.4 39 383.9 111.0 46 387.0 106.5
Δ Diary 
evening
PEF, L/min
48 402.6 114 47 392.6 110.5 39 389.3 112.1 46 395.3 101.0
Placebo
Week 0 Week 2 Week 4 Week 8
n Mean SD n Mean SD n Mean SD n Mean SD
Δ Diary 
morning 
PEF, L/min
54 386.4 106.9 52 387.1 110.0 45 380.5 105.8 47 393.9 114.2
Δ Diary 
evening
PEF, L/min
53 401.0 105.6 52 399.5 114.4 45 395.7 109.5 47 403.8 116.3
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Table 5.26 Morning and Evening PEF at week 8 for atorvastatin and placebo treatment, with treatment 
difference
Figure 5.2 Morning PEF at 2, 4 and 8 weeks for atorvastatin and placebo. Bars indicate standard deviation. No 
significant difference is seen between groups at any point. 
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Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Mean SD n Mean SD
Δ Diary morning 
PEF, L/min
46 387.0 106.5 47 393.9 114.2 -0.5 -10.6,  9.6 0.921
Δ Diary evening
PEF, L/min
46 395.3 101.0 47 403.8 116.3 4.6 -5.8, 14.9 0.377
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Figure 5.3 Box and whisker plot for morning PEF after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.921).
Figure 5.4 Evening PEF at 2, 4 and 8 weeks for atorvastatin and placebo. Bars indicated standard deviation. No 
significant difference is seen between groups at any point.
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Figure 5.5 Box and whisker plot for evening PEF after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.377).
5.7.2 Reliever inhaler use
There was no difference in reliever inhaler use at 2, 4 or 8 weeks [treatment difference at 
8 weeks 0.08 puffs of inhaler, 95% CI -0.41 to 0.57, p=0.745] (Table 5.27, Figure 5.6 and 
5.7).
Table 5.27 Reliever inhaler use at week 8 for atorvastatin and placebo treatment, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Mean SD n Mean SD
Puffs of reliever inhaler 47 2.1 2.0 47 2.1 1.9 0.08 -0.41, 0.57 0.745
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Figure 5.6 Reliever inhaler use at 0, 2, 4 and 8 weeks. Bars indicate standard deviation. No significant 
difference is seen between groups at any point.
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Figure 5.7 Box and whisker plot for use of reliever inhaler after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *.
Mean is indicated by +. No significant difference is seen between groups (p=0.745).
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5.7.3 Spirometry
5.7.3.1 FEV1
FEV1 did not show a statistically significant difference after 8 weeks of atorvastatin  
[treatment difference 0.01 L (95% CI -0.08 to 0.10), p=0.815 pre-salbutamol, and -0.05 L 
(-0.12 to 0.03), p=0.205, post-salbutamol](table 5.28 and figure 5.8 and 5.9). The values 
were also considered as percentage predicted for an adult of the same age and height. 
Mean FEV1 % predicted (pre-salbutamol), did not differ between the atorvastatin and the 
placebo group [treatment difference -0.05% (-3.0 to 2.9), p=0.973] (table 5.28 and figure 
5.10). There was a non-significant trend towards lower reversibility in the atorvastatin 
group [treatment difference -3.0% (-6.4 to 0.3) p=0.074] (table 5.28 and figure 5.11). 
Table 5.28 FEV1 results for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable
Atorvastatin Placebo Treatment 
difference
95% CI
P 
valuen Mean SD n Mean SD
FEV1 pre salbutamol, L 48 2.77 0.83 50 2.71 0.79 0.01 -0.08, 0.10 0.815
FEV1 post salbutamol, L 49 3.06 0.83 50 3.12 0.80 -0.05 -0.12, 0.03 0.205
FEV1 % predicted 48 83.0 17.3 50 82.6 18.2 -0.05 -3.0, 2.9 0.973
FEV1 reversibility, % 48 15.0 11.7 50 17.5 15.6 -3.0 -6.4, 0.3 0.074
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Figure 5.8 Box and whisker plot for FEV1 pre-salbutamol after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.815).
Figure 5.9 Box and whisker plot for FEV1 post-salbutamol after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.205).
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Figure 5.10 Box and whisker plot for percentage predicted FEV1 after 8 weeks for atorvastatin and placebo. 
The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by 
*. Mean is indicated by +. No significant difference is seen between groups (p=0.973).
Figure 5.11 Box and whisker plot for FEV1 reversibility after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. A trend of borderline significance is seen between groups (p=0.074).
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5.7.3.2 Spirometry PEF
There was no difference in PEF measured during spirometry pre-salbutamol [treatment 
difference 4.8 L/min (95% CI -11.9 to 21.6) p=0.563] (table 5.29, figure 5.12). Post-
salbutamol PEF was slightly lower in the atorvastatin group [treatment difference -12.4 
L/min (25.5 to -0.8) p=0.064] (table 5.29, figure 5.13). Percentage PEF predicted pre-
salbutamol did not vary between groups [treatment difference 0.2% (-3.3 to 3.6) p=0.927] 
(table 5.29, figure 5.14).
Table 5.29 Spirometry PEF results for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable
Atorvastatin Placebo Treatment 
difference
95% CI
P 
valuen Mean SD n Mean SD
PEF during spirometry, 
L/min, pre-salbutamol
48 427.1 129.6 50 417.8 127.9 4.8 -11.9, 21.6 0.563
PEF during spirometry, 
L/min, post-salbutamol
49 482.4 135.5 50 491.4 128.9 -12.4 -25.5, 0.8 0.064
PEF % predicted 48 92.0 22.1 50 90.6 23.5 0.2 -3.3, 3.6 0.927
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Figure 5.12 Box and whisker plot for spirometry PEF pre-salbutamol after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.563).
Figure 5.13 Box and whisker plot for spirometry PEF post-salbutamol after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. A trend of borderline significance is seen between groups (p=0.064).
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Figure 5.14 Box and whisker plot for percentage predicted spirometry PEF pre-salbutamol after 8 weeks for 
atorvastatin and placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. 
Outliers are identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.927).
5.7.3.3 FVC
No effect of atorvastatin was seen in pre-salbutamol mean (SD) FVC [treatment 
difference 0.0 L (95% CI -0.1 to 0.1), p=0.627] (table 5.30, figure 5.15). Post-salbutamol 
FVC was slightly lower in the atorvastatin group [treatment difference -0.1 L (-0.2 to 
0.0), p=0.037] (table 5.30, figure 5.16). Percentage FVC predicted pre-salbutamol did not 
vary between groups [treatment difference -1.3% (-4.5 to 2.0) p=0.431] (table 5.30, figure 
5.17).
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Table 5.30 FVC results for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Mean SD n Mean SD
FVC, pre-salbutamol, L 48 3.6 1.1 50 3.7 1.0 0.0 -0.1, 0.1 0.627
FVC, post-salbutamol, L 49 3.9 1.04 50 4.00 1.0 -0.1 -0.2, 0.0 0.037
FVC % predicted 48 92.9 16.5 50 93.8 18.1 -1.3 -4.5, 2.0 0.431
Figure 5.15 Box and whisker plot for FVC pre-salbutamol after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.627)
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Figure 5.16 Box and whisker plot for FVC post-salbutamol after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. A significant difference is seen between groups (p=0.037)
Figure 5.17 Box and whisker plot for percentage predicted FVC pre-salbutamol after 8 weeks for atorvastatin 
and placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.431).
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5.7.3.4 FEF25-75
No effect could be seen on mean FEF25-75 either pre-salbutamol [treatment difference 0.0 
L/sec (95% CI -0.2 to 0.2), p=0.871] (table 5.31, figure 5.18) or post-salbutamol 
[treatment difference 0.1 L/sec (-0.1 to 0.2), p=0.484] (table 5.31, figure 5.19). 
Percentage FEF25-75 predicted pre-salbutamol did not vary between groups [treatment 
difference 1.2% (-2.5 to 4.9) p=0.512] (table 5.31, figure 5.20).
Table 5.31 FEF25-75 results for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Mean SD n Mean SD
FEF 25-75 pre-
salbutamol, 
(L/sec)
48 2.3 1.0 48 2.3 1.2 0.0 -0.2, 0.2 0.871
FEF 25-75 post-
salbutamol, 
(L/sec)
49 2.9 1.2 48 2.8 1.2 0.1 -0.1, 0.2 0.484
FEF 25-75 % 
predicted
47 57.9 21.4 48 56.8 23.3 1.2 -2.5, 4.9 0.512
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Figure 5.18 Box and whisker plot for FEF25-75 pre-salbutamol after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.871).
Figure 5.19 Box and whisker plot for FEF25-75 post-salbutamol after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.484).
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Figure 5.20 Box and whisker plot for percentage predicted FEF25-75 pre-salbutamol after 8 weeks for 
atorvastatin and placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. 
Outliers are identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.521).
5.7.3.5 FEV1/FVC ratio
Finally, no effect was seen on the mean FEV1/FVC ratio, either pre-salbutamol [treatment 
difference -28.6% (95% CI -71.1 to 13.8) p=0.181] (table 5.32 and figure 5.21) or post-
salbutamol [treatment difference -20.9% (-65.1 to 23.3) p=0.346] (table 5.32 and figure 
5.22).
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Table 5.32 FEV1/FVC ratio results for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Mean SD n Mean SD
FEV1/FVC pre-salbutamol, % 48 75.4 10.7 50 102.1 139.1 -28.6 -71.1, 
13.8
0.181
FEV1/FVC post-salbutamol, % 49 85.8 44.9 50 106.7 140.1 -20.9 -65.1, 
23.3
0.346
Figure 5.21 Box and whisker plot for FEV1/FVC ratio pre-salbutamol after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.181).
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Figure 5.22 Box and whisker plot for FEV1/FVC ratio post-salbutamol after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.346).
5.7.4 Asthma severity
No effect was seen on mean ATS score [treatment difference -0.16 (95% CI –0.49 to 
0.17) p=0.323] (table 5.33 and figure 5.23). 
Table 5.33 ATS score results for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Mean SD n Mean SD
ATS 
score
48 3.2 1.6 50 3.4 1.4 -0.16 -0.49, 0.17 0.323
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Figure 5.23 Box and whisker plot for ATS score after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.323).
5.7.5 Asthma control questionnaire (ACQ) score
Statins showed no effect on ACQ score [treatment difference -0.03, (-0.28 to 0.21), 
p=0.783] (table 5.34, figure 5.24). 
Table 5.34 ACQ score results for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Mean SD n Mean SD
ACQ 49 1.4 0.9 50 1.5 0.8 -0.03 -0.28, 0.21 0.783
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Figure 5.24 Box and whisker plot for ACQ score after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.783).
5.7.6 Asthma quality of life (AQLQ)
Total AQLQ score was not significantly different between atorvastatin and placebo 
[treatment difference 0.1 (-0.1 to 0.3) p=0.284] (table 5.35, figure 5.25). Subdivision into 
symptoms [0.1 (-0.1 to 0.4) p=0.316], activities [0.1 (-0.1 to 0.3) p=0.226], emotional well-
being [0.1 (-0.2 to 0.4) p=0.540] and environment [0.1 (-0.2 to 0.3) p=0.590] did not show 
any difference between the categories (table 5.35, figure 5.26).
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Table 5.35 AQLQ results for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
AQLQ - total 48 5.9 5.4, 
6.6
49 5.9 5.4, 
6.4
0.1 -0.1, 0.3 0.284
AQLQ – symptoms 48 6.0 5.2, 
6.4
49 5.8 5.1, 
6.3
0.1 -0.1, 0.4 0.316
AQLQ –
activity
48 6.3 5.5, 
6.9
49 6.3 5.6, 
6.6
0.1 -0.1, 0.3 0.226
AQLQ – emotional 
well-being
48 6.0 4.9, 
6.8
49 5.8 5.0, 
6.4
0.1 -0.2, 0.4 0.540
AQLQ –
environment
48 5.9 5.0, 
6.5
49 5.8 5.0, 
6.5
0.1 -0.2, 0.3 0.590
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Figure 5.25 Box and whisker plot for AQLQ after 8 weeks for atorvastatin and placebo. The boxes represent 
the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is indicated 
by +. No significant difference is seen between groups (p=0.284).
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Figure 5.26 Box and whisker plots for AQLQ components after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (symptoms p=0.316, activity p=0.226, 
emotional well-being p=0.540, environment p=0.590).
5.7.7 Methacholine responsiveness
No difference was seen in methacholine responsiveness (PC20) between patients on 
atorvastatin and placebo [treatment difference 0.05 mg/mL (95% CI -1.60 to 1.70), 
p=0.949] (table 5.36 and figure 5.27).
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Table 5.36 Methacholine responsiveness results for atorvastatin compared with placebo after 8 weeks, with 
treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Geometric
mean
Std 
dev
n Geometric
mean
Std 
dev
Methacholine 
responsiveness 
(PC20) mg/mL
38 2.64 4.68 39 2.21 5.81 0.05 -1.60, 
1.70
0.949
Figure 5.27 Box and whisker plot for methacholine responsiveness after 8 weeks for atorvastatin and placebo. 
The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by 
*. Mean is indicated by +. No significant difference is seen between groups (p=0.949).
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5.8 Biochemical outcomes 
5.8.1 Lipids
No difference was seen between atorvastatin and placebo for triglycerides [treatment 
difference -0.2 mmol/L (95% CI -0.5 to 0.1), p=0.106] on serum lipid testing (table 5.37, 
figure 5.21). However, a significant change was seen in cholesterol [-1.7 mmol/L (-1.9 to 
-1.5) p<0.0001] and HDL [-0.1 mmol/L (-0.3 to -0.0) p=0.026] (table 5.37, figure 5.28). 
This suggests good compliance with medication and a clear effect on lipid profile within 
the timescale of the trial.
Table 5.37 Serum lipid results for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Triglycerides 
(mmol/L)
47 0.9 0.6, 1.3 47 1.1 0.8, 1.6 -0.2 -0.5, 0.1 0.106
Cholesterol 
(mmol/L)
47 3.3 2.9, 3.9 47 5.1 4.5, 5.7 -1.7 -1.9, 
-1.5
<0.001
HDL 
(mmol/L)
47 1.2 1.1, 1.5 47 1.4 1.1, 1.7 -0.1 -0.3,
-0.0
0.026
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Figure 5.28 Box and whisker plots for serum lipids after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. Significant differences are present for Cholesterol and HDL but not triglycerides (triglycerides 
p=0.106, cholesterol p<0.001, HDL p=0.026).
5.8.2 Urea and electrolytes
No effect was seen on urea [treatment difference 0.1 mmol/L (95% CI -0.2 to 0.4) 
p=0.586], potassium [-0.1 mmol/L (-0.3 to 0.0) p=0.104] or sodium [0.4 mmol/L (-0.5 to 
1.3) p=0.340] (table 5.38, figure 5.29) during the trial.
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Table 5.38 Urea and electrolyte results for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Urea (mmol/L) 46 5.1 4.0, 6.0 48 4.7 4.1, 5.8 0.1 -0.2, 0.4 0.586
Potassium 
(mmol/L)
46 4.0 3.8, 4.1 47 4.1 3.8, 4.3 -0.1 -0.3, 0.0 0.104
Sodium 
(mmol/L)
46 140.0 139.0, 141.0 48 139.0 138, 141 0.4 -0.5, 1.3 0.340
Figure 5.29 Box and whisker plot for urea and electrolytes after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant differences are seen (urea p=0.586, potassium p=0.104, sodium 
p=0.340).
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5.8.3 Liver function tests
Differences were statistically significant in serum bilirubin [treatment difference 1.8 
μmol/L (95% CI 0.7 to 2.9) p=0.002], AST [2.9 IU/L (0.8 to 4.9) p=0.007] and ALT [5.6 
IU/L (2.7 to 8.5) p<0.0001] (table 5.39, figure 5.30). This again suggests compliance 
with medication. These differences are clinically small and do not indicate any adverse 
events. 
Table 5.39 Liver function test results for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Bilirubin 
(μmol/L)
47 10 8, 13 47 8 6, 10 1.8 0.7, 2.9 0.002
AST (IU/l) 47 23 18, 27 47 20 16, 24 2.9 0.8, 4.9 0.007
ALT (IU/l) 47 26 18, 35 47 20 15, 33 5.6 2.7, 8.5 <0.001
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Figure 5.30 Box and whisker plot for liver function tests after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. Significant differences are present in all cases (bilirubin p=0.002, AST p=0.007, ALT p<0.001).
5.9 Patients who did not complete the trial
5.9.1 Loss to follow up
Three patients were lost to follow up. A further two patients did not complete their final 
diary, so their PEF data could not be used for analysis of the primary end point.
5.9.2 Patient withdrawals
Three patients were withdrawn prematurely from the trial. One patient had medication-
related side-effects (muscle cramps). One patient had a severe exacerbation of asthma 
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very early in the trial and elected to withdraw from the trial and commence long-acting 
beta agonists. The patient was followed-up clinically until symptoms had improved.
Unfortunately, one patient also died during this study. Following post mortem his death 
was attributed to alcohol excess and aspiration of gastric contents. There was no evidence 
to suggest that asthma played any part in his death.
5.10 Adverse events
5.10.1 Exacerbation rates
The rate of exacerbation is intended to measure the probability that a patient who is 
currently exacerbation-free will experience an exacerbation within a small time 
interval 2, 40. In a cross-over study, the important comparison is between exacerbation 
rates in the two separate arms of the study. Numbers of both mild and severe 
exacerbations were similar between the two groups (table 5.40).
Table 5.40 Mild and severe exacerbations for atorvastatin and placebo
Treatment Number of mild 
exacerbations (%)
Number of severe 
excerbations (%)
Atorvastatin (n=52) 33 (63.5) 1 (1.9)
Placebo (n=54) 38 (70.4) 1 (1.9)
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5.10.2 Asthma related adverse events
In addition to exacerbation rates, treatment with oral steroids, unscheduled GP visits, GP 
home visits, Accident & Emergency visits and hospital admissions for asthma or 
respiratory symptoms were measured. Frequency of these events was similar between 
groups (table 5.41).
Table 5.41 Asthma related adverse events
Event Total Atorvastatin Placebo
Oral steroid 
treatment
1 1 0
Unscheduled GP 
appointment
3 1 2
GP home visit 0 0 0
A&E visit 3 2 1
Hospital admission 0 0 0
Total asthma 
related adverse 
events
7 4 3
5.10.3 Possible drug related adverse events
Possible drug-related adverse events occurred on 38 occasions for patients taking 
atorvastatin and on 46 occasions for placebo. There were no striking differences between 
groups, including episodes of muscle cramps. All adverse events are listed in table 5.42.
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Table 5.42 Adverse events in trial, comparing atorvastatin with placebo. The different denominators reflect the 
fact that two patients left the trial before receiving atorvastatin.
Event name Atorvastatin 
Number of events (% total)
n=52
Placebo
Number of events (% total)
n=54
Any adverse event 38 (73.1) 46 (85.2)
Muscle cramp 3 (5.8) 5 (9.3)
GI upset 7 (13.5) 7 (13.0)
Hayfever 0 (0.0) 2 (3.7)
Headache 7 (13.5) 7 (13.0)
Insomnia 0 (0.0) 1 (1.9)
Joint pain 7 (13.5) 8 (14.8)
Pins and needles 1 (1.9) 2 (3.7)
Tiredness 1 (1.9) 4 (7.4)
UTI 1 (1.9) 2 (3.7)
Ankle swelling 1 (1.9) 0 (0.0)
Breast pain 0 (0.0) 1 (1.9)
Chest tightness 1 (1.9) 0 (0.0)
Cough 0 (0.0) 1 (1.9)
Death 0 (0.0) 1 (1.9)
Depression 1 (1.9) 0 (0.0)
Dermatitis 2 (3.8) 1 (1.9)
Dizziness 0 (0.0) 2 (3.7)
Conjunctivitis 1 (1.9) 1 (1.9)
Hernia 0 (0.0) 1 (1.9)
Mouth swelling 1 (1.9) 0 (0.0)
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Event name Atorvastatin 
Number of events (% total)
n=52
Placebo
Number of events (% total)
n=54
Nocturia 2 (3.8) 0 (0.0)
Nosebleed 0 (0.0) 2 (3.7)
Palpitations 1 (1.9) 0 (0.0)
Rectal bleeding 0 (0.0) 1 (1.9)
Rash 0 (0.0) 1 (1.9)
Sinusitis 1 (1.9) 1 (1.9)
Sore throat 2 (3.8) 2 (3.7)
Weak legs 0 (0.0) 1 (1.9)
5.11 Clinical results - Summary
A statistically significant difference was seen in post-salbutamol FVC, which was lower 
in the atorvastatin group. No other statistical or clinical difference can be seen between 
patients treated with eight weeks atorvastatin and placebo, although there was a non-
significant trend towards lower post-salbutamol PEF and lower reversibility in the 
atorvastatin-treated group. These findings are clinically insignificant but may indicate a 
subtle effect on lung function, or may simply be artefact. Serum biochemistry indicates 
compliance with medication. 
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5.12 Results – inflammatory markers
5.12.1 Sputum cell differential 
5.12.1.1 Sputum quality indicators
Results are summarised in table 5.44. Total sputum cell count was unchanged between 
the two groups [treatment difference -0.1 x106 cells (95% CI -0.1 to 0.0), p=0.090]. There 
was no difference in cell viability [treatment difference 1.6% (-5.8 to 8.9), p=0.669], nor 
in total number of cells recovered [treatment difference -2.4 x106 cells (-6.7 to 1.9) 
p=0.257] or total viable cells recovered [treatment difference -2.0 x106 (-5.2 to 1.2) 
p=0.209] (table 5.43). 4 samples in the atorvastatin group and 6 samples in the placebo 
group were of insufficient quality for further analysis (as defined by the criteria in section 
4.3.1, above).
Table 5.43 Sputum quality indicators for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
Total cell count per ml 
sputum filtrate (x106/mL)
40 0.1 0.1, 0.2 38 0.1 0.1, 0.3 -0.1 -0.1, 0.0 0.090
Viability (%) 40 71.0 66.0, 81.0 38 70.0 60.0, 80.0 1.6 -5.8, 8.9 0.669
Total number of cells 
recovered from sample 
(x106)
40 2.3 1.3, 4.2 38 2.5 1.1, 5.7 -2.4 -6.7, 1.9 0.257
Total viable cells recovered 
from sample (x106) 
40 1.7 0.9, 2.8 38 1.6 0.6, 4.7 -2.0 -5.2, 1.2 0.209
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5.12.1.2 Sputum cell count
5.12.1.2.a Macrophages
There was a marked reduction in total macrophage count in the atorvastatin treated group 
[treatment difference -44.9 x104 cells (-80.1 to 9.7), p=0.015]. This corresponds to a 
reduction in the proportion of macrophages in the cell count [treatment difference -10.9% 
(-20.5 to -1.2), p=0.029] (table 5.44, figure 5.31).
Table 5.44 Sputum macrophage cell count and proportion for atorvastatin compared with placebo after 8 weeks, 
with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
Macrophage 
cell count (x104
cells)
34 134.3 71.0, 201.0 32 171.25 135.0, 222.8 -44.9 -80.1, -9.7 0.015
Macrophage % 34 37.0 20.5, 52.5 32 45.3 36.5, 58.5 -10.9 -20.5, -1.2 0.029
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Figure 5.31 Box and whisker plot for macrophage cell count and proportion after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. Significant differences are seen between groups (cell count p=0.015, 
percentage p=0.029).
5.12.1.2.b Neutrophils
A small rise in neutrophil numbers were seen in the atorvastatin treated group [treatment 
difference 46.9 x104 cells (-2.1 to 95.9), p=0.060] (table 5.45, figure 5.32), with a 
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comparable shift in neutrophil percentage of total count [treatment difference 13.1% (1.8 
to 24.3), p=0.025].
Table 5.45 Sputum neutrophil cell count and proportion for atorvastatin compared with placebo after 8 weeks, 
with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Neutrophil 
cell count 
(x104
cells)
34 133.3 81.5, 234.0 32 100 50.3, 167.8 46.9 -2.1, 95.9 0.060
Neutrophil % 34 34.8 22.0, 65.0 32 25.0 15.0, 41.9 13.1 1.8, 24.3 0.025
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Figure 5.32 Box and whisker plot for neutrophil cell count and proportion after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. Cell count shows a trend towards significance (p=0.060), while 
percentage shows a significant difference between groups (p=0.025).
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5.12.1.2.c Eosinophils
No difference was seen in sputum eosinophil count [treatment difference -12.1 x104 cells 
(-32.8 to 8.7), p=0.242] (table 5.46, figure 5.33), or eosinophil percentage of total count 
[treatment difference -2.7% (-7.0 to 1.7), p=0.219].
Table 5.46 Sputum eosinophil cell count and proportion for atorvastatin compared with placebo after 8 weeks, 
with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Eosinophil cell 
count (x104 cells)
34 3.8 2.0, 10.5 32 5 1.0, 10.5 -12.1 -32.8, 8.7 0.242
Eosinophil % 34 1.0 0.5, 3.0 32 1.5 0.4, 3.0 -2.7 -7.0, 1.7 0.219
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Figure 5.33 Box and whisker plot for eosinophil cell count and proportion after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (cell count p=0.242, 
percentage p=0.219).
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5.12.1.2.d Lymphocytes
No difference was seen in sputum lymphocyte count [treatment difference 0.5 x104 cells 
(-0.8 to 1.7), p=0.455] (table 5.47, figure 5.34), or lymphocyte percentage of total count 
[treatment difference 0.2% (-0.1 to 0.5), p=0.271].
Table 5.47 Sputum lymphocyte cell count and proportion for atorvastatin compared with placebo after 8 weeks, 
with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Lymphocyte 
cell count x104
cells
34 2.0 1.0, 4.5 32 1.9 1.0, 5.0 0.5 -0.8, 1.7 0.455
Lymphocyte % 34 0.6 0.4, 1.0 32 0.5 0.3, 1.4 0.2 -0.1, 0.5 0.271
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Figure 5.34 Box and whisker plot for lymphocyte cell count and proportion after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (cell count p=0.455, 
percentage p=0.271).
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5.12.1.2.e Bronchial epithelial and squamous epithelial cells
No difference was seen in sputum bronchial epithelial cell count [treatment difference      
-3.4 x104 cells (-23.2 to 16.3), p=0.723], or percentage of total count [treatment 
difference 0.3% (-5.3 to 5.9), p=0.913] (table 5.48, figure 5.35). There was also no effect 
on squamous epithelial cell count [treatment difference -79.5 x104 cells (-201.6 to 42.6) 
p=0.191] or proportion [-5.5% (-17.0 to 6.0) p=0.333] (table 5.48, figure 5.36).
Table 5.48 Sputum bronchial epithelial and squamous epithelial cell counts and proportions for atorvastatin 
compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
Bronchial epithelial 
cell count (x104
cells)
34 38.8 17.0, 59.0 32 33.5 18.8, 69.3 -3.4 -23.2, 16.3 0.723
Bronchial epithelial 
cell %
34 10.3 4.0, 24.0 32 11.9 5.0, 17.8 0.3 -5.3, 5.9 0.913
Squamous 
epithelial 
cell count (x104
cells)
34 156.0 101.0, 325.5 32 288.0 162.8, 352.5 -79.5 -201.6, 
42.6
0.191
Squamous cells as 
% of absolute count
34 31.0 20.0, 46.5 32 41.8 25.3, 48.8 -5.5 -17.0, 6.0 0.333
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Figure 5.35 Box and whisker plot for bronchial epithelial cell count and proportion after 8 weeks for 
atorvastatin and placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. 
Outliers are identified by *. Mean is indicated by +. No significant difference is seen between groups (cell count 
p=0.723, percentage p=0.913).
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Figure 5.36 Box and whisker plot for squamous epithelial cell count and proportion after 8 weeks for 
atorvastatin and placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. 
Outliers are identified by *. Mean is indicated by +. No significant difference is seen between groups (cell count 
p=0.191, percentage p=0.333).
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5.12.2 Sputum cytokines
5.12.2.1 LTB4
Sputum supernatant LTB4 was significantly reduced in the atorvastatin treated group 
compared with placebo [treatment difference -88.1 pg/mL (95% CI -156.4 to -19.9) 
p=0.014] (table 5.49, figure 5.37).
Table 5.49 Sputum supernatant LTB4 for atorvastatin compared with placebo after 8 weeks, with treatment 
difference. Lower sample numbers reflect the fact that the total number of assays that could be run was limited 
by the necessity of internal controls, as discussed in the methodology section.
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
LTB4 
(pg/mL)
37 50.4 27.6, 
79.8
33 68.2 28.6, 
130.2
-88.1 -156.4, -19.9 0.014
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Figure 5.37 Box and whisker plot for sputum supernatant LTB4 after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. A significant difference is seen between groups (p=0.014).
5.12.2.2 MPO
There was no significant difference in sputum supernatant MPO in the group treated with 
atorvastatin compared with placebo [treatment difference -32.6 ng/mL (95% CI -112.8 to 
47.7) p=0.414] (table 5.50, figure 5.38).
Table 5.50 Sputum supernatant MPO for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
MPO 
(ng/ml)
41 87.5 51.0, 
193.0
38 112.3 56.5, 
206.0
-32.6 -112.8, 
47.7
0.414
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Figure 5.38 Box and whisker plot for sputum supernatant MPO after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.414).
5.12.2.3 IL-1β
There was no significant difference in sputum supernatant IL-1β in the group treated with 
atorvastatin compared with placebo [treatment difference -35.8 ng/mL (95% CI -156.2 to 
84.6) p=0.548] (table 5.51, figure 5.39).
Table 5.51 Sputum supernatant IL-1β for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valueN Median IQR n Median IQR
IL-1β
(pg/mL)
41 89.7 34.9, 
178.14
38 92.6 34.7, 
353.5
-35.8 -156.2, 
84.6
0.548
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Figure 5.39 Box and whisker plot for sputum supernatant IL-1β after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.548).
5.12.2.4 IL-1RA
There was no significant difference in sputum supernatant IL-1RA in the group treated 
with atorvastatin compared with placebo [treatment difference -3.4 ng/mL (95% CI -9.3 
to 2.5) p=0.252] (table 5.52, figure 5.40).
Table 5.52 Sputum supernatant IL-1RA for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% 
CI
P 
valuen Median IQR n Median IQR
IL-1RA 
(ng/mL)
41 28.5 17.0, 
46.0
38 35.4 19.3, 
52.6
-3.4 -9.3, 
2.5
0.252
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Figure 5.40 Box and whisker plot for sputum supernatant IL-1RA after 8 weeks for atorvastatin and placebo. 
The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by 
*. Mean is indicated by +. No significant difference is seen between groups (p=0.252).
5.12.2.5 IL-6, IL-8 and IL-17
There was no significant difference in sputum supernatant IL-6 in the group treated with 
atorvastatin compared with placebo [treatment difference -42.9 pg/mL (95% CI -118.7 to 
33.0) p=0.258] (table 5.53, figure 5.41). IL-8 also showed no difference [-1607.3 pg/mL 
(-5678.1 to 2463.7) p=0.426] (table 5.53, figure 5.42). IL-17 was similarly unaffected 
[-30.5 pg/mL (-163.2 to 102.1) p=0.642] (table 5.53, figure 5.43). 
182
Table 5.53 Sputum supernatant IL-6, IL-8 and IL-17 for atorvastatin compared with placebo after 8 weeks, with 
treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
IL-6 
(pg/mL)
41 36.4 12.1, 75.6 38 48.1 12.9, 
121.0
-42.9 -118.7, 33.0 0.258
IL-8 
(pg/mL)
41 1474.2 544.0, 
3615.7
38 1462.6 557.3, 
5072.1
-1607.3 -5678.2, 
2463.7
0.426
IL-17 
(pg/mL)
41 41.8 3.6, 120.3 38 39.7 3.7, 342.3 -30.5 -163.2, 
102.1
0.642
Figure 5.41 Box and whisker plot for sputum supernatant IL-6 after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.258).
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Figure 5.42 Box and whisker plot for sputum supernatant IL-8 after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.426).
Figure 5.43 Box and whisker plot for sputum supernatant IL-17 after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.642).
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5.12.2.6 TNF-α
There was no significant difference in sputum supernatant TNF-α in the group treated 
with atorvastatin compared with placebo [treatment difference -30.3 pg/mL (95% CI 
-111.6 to 51.0) p=0.453] (table 5.54, figure 5.44). 
Table 5.54 Sputum supernatant TNF-α for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
TNFα 
(pg/mL)
41 12.5 4.7, 
45.3
38 16.2 4.4, 
123.0
-30.3 -111.6, 
51.0
0.453
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Figure 5.44 Box and whisker plot for sputum supernatant TNF-α after 8 weeks for atorvastatin and placebo. 
The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by 
*. Mean is indicated by +. No significant difference is seen between groups (p=0.453).
5.12.2.7 IFN-γ
There was no significant difference in sputum supernatant IFN-γ in the group treated with 
atorvastatin compared with placebo [treatment difference -38.4 pg/mL (95% CI -175.4 to 
98.6) p=0.571] (table 5.55, figure 5.45). 
Table 5.55 Sputum supernatant IFN-γ for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
IFN-γ 
(pg/mL)
41 23.9 3.8, 
678.0
38 21.5 3.1, 
155.5
-38.4 -175.4, 
98.6
0.571
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Figure 5.45 Box and whisker plot for sputum supernatant IFN-γ after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.571).
5.12.2.8 GM-CSF
There was no significant difference in sputum supernatant GM-CSF in the group treated 
with atorvastatin compared with placebo [treatment difference -44.2 pg/mL (95% CI 
-262.5 to 174.1) p=0.682] (table 5.56, figure 5.46). 
Table 5.56 Sputum supernatant GM-CSF for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P 
valuen Median IQR n Median IQR
GM-CSF 
(pg/mL)
41 144.5 87.4, 287.5 38 159.4 99.7, 
664.7
-44.2 -262.5, 
174.1
0.682
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Figure 5.46 Box and whisker plot for sputum supernatant GM-CSF after 8 weeks for atorvastatin and placebo. 
The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by 
*. Mean is indicated by +. No significant difference is seen between groups (p=0.682).
5.12.2.9 MIP-1α
There was no significant difference in sputum supernatant MIP-1α in the group treated 
with atorvastatin compared with placebo [treatment difference -513.2 pg/mL (95% CI 
-1588.4 to 562.0) p=0.337] (table 5.57, figure 5.47). 
Table 5.57 Sputum supernatant MIP-1α for atorvastatin compared with placebo after 8 weeks, with treatment 
difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
MIP-1α 
(pg/mL)
41 195.1 64.1, 
466.8
38 176.4 63.0, 897.4 -513.2 -1588.4, 562.0 0.337
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Figure 5.47 Box and whisker plot for sputum supernatant MIP-1α after 8 weeks for atorvastatin and placebo. 
The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by 
*. Mean is indicated by +. No significant difference is seen between groups (p=0.337).
5.12.2.10 CCL2
There was no significant difference in sputum supernatant CCL2 in the group treated 
with atorvastatin compared with placebo [treatment difference -137.3 pg/mL (95% CI 
-612.7 to 338.2) p=0.560] (table 5.58, figure 5.48). 
Table 5.58 Sputum supernatant CCL2 for atorvastatin compared with placebo after 8 weeks, with treatment 
difference. 
Variable Atorvastatin Placebo Treatmen
t 
differenc
e
95% CI P value
n Median IQR n Median IQR
CCL2 
(pg/mL)
41 256.5 124.9, 495.6 38 300.9 124.9, 963.7 -137.3 -612.7, 
338.2
0.560
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Figure 5.48 Box and whisker plot for sputum supernatant CCL2 after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.560).
5.12.3 Serum markers of inflammation
5.12.3.1 CRP
Serum CRP showed a trend towards decrease in the treatment group, although the result 
was not significantly different between atorvastatin and placebo after 8 weeks [treatment 
difference -0.7 mg/L (95% CI -1.4 to -0.1), p=0.082] (table 5.59, figure 5.49).
Table 5.59 Serum CRP for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
CRP (mg/L) 47 0.6 0.5, 1.5 44 1.1 0.6, 2.5 -0.7 -1.4, 0.1 0.082
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Figure 5.49 Box and whisker plot for serum CRP after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.086).
5.12.3.2 ICAM-1
No significant difference was seen in serum ICAM-1 between atorvastatin and placebo 
after 8 weeks [treatment difference -6.5 ng/mL (-21.4 to -8.4) p=0.382] (table 5.60, figure 
5.50).
Table 5.60 Serum ICAM-1 for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
ICAM-1 
(ng/mL)
47 200.9 173.3, 
221.8
46 204.6 164.1, 
239.5
-6.5 -21.4, 
8.4
0.382
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Figure 5.50 Box and whisker plot for serum ICAM-1 after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.382).
5.12.3.3 TNF-α
No significant difference was seen in serum TNF-α between atorvastatin and placebo 
after 8 weeks [treatment difference -0.5 pg/mL (-2.5 to -1.4), p=0.584] (table 5.61, figure 
5.51).
Table 5.61 Serum TNF-α for atorvastatin compared with placebo after 8 weeks, with treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
TNF-α
(pg/mL)
47 1.0 0.6, 
1.9
46 1.2 0.8, 
1.9
-0.5 -2.5, 1.4 0.584
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Figure 5.51 Box and whisker plot for serum TNF-α after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.584).
5.12.3.3 IL-1, IL-5, IL-6, IL-8 and IL-10
No significant difference was seen between atorvastatin and placebo after 8 weeks in 
serum IL-1 [treatment difference -10.2 pg/mL (-42.2 to 21.7), p=0.519] (table 5.62, figure 
5.52), IL-5 [treatment difference -3.4 pg/mL (-11.3 to 4.5), p=0.378] (table 5.62, figure 
5.53), IL-6 [treatment difference 0.0 pg/mL (-1.9 to 1.9), p=0.982] (table 5.62, figure 
5.54), IL-8 [treatment difference -515.5 pg/mL (-1524.0 to 493.9), p=0.304] (table 5.62, 
figure 5.55), or IL-10 [treatment difference -5.8 pg/mL (-26.5 to 15.0), p=0.573] (table 
5.62, figure 5.56).
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Table 5.62 Serum IL-1, IL-5, IL-6, IL-8 and IL-10 for atorvastatin compared with placebo after 8 weeks, with 
treatment difference. Different samples sizes are due to beads sticking during analysis, as mentioned in the 
methodology section.
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
IL-1 
(pg/mL)
40 96.6 52.3, 142.5 42 97.1 56.1, 
153.3
-10.2 -42.2, 21.7 0.519
IL-5 
(pg/mL)
40 1.9 1.9, 21.6 31 1.9 1.9, 28.0 -3.4 -11.3, 4.5 0.378
IL-6 
(pg/mL)
47 1.3 0.74, 3.12 46 1.2 0.7, 3.6 0.0 -1.9, 1.9 0.982
IL-8 
(pg/mL)
40 0.7 0.6, 12.2 36 8.1 0.6, 17.5 -515.5 -1524.0, 
493.9
0.304
IL-10 
(pg/mL)
40 34.6 10.5, 70.9 39 38.5 10.5, 68.6 -5.8 -26.5, 15.0 0.573
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Figure 5.52 Box and whisker plot for serum IL-1 after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.519).
Figure 5.53 Box and whisker plot for serum IL-5 after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.378).
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Figure 5.54 Box and whisker plot for serum IL-6 after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.982).
Figure 5.55 Box and whisker plot for serum IL-8 after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.304).
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Figure 5.56 Box and whisker plot for serum IL-10 after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.573).
5.12.4 Lymphocyte proliferation
No significant difference was seen in lymphocyte proliferation between atorvastatin and 
placebo for control [treatment difference 107 counts/min/well (95% CI -89 to 303) 
p=0.276] (table 5.63, figure 5.57), PHA [treatment difference 4688 counts/min/well 
(-13351 to 22728) p=0.602] (table 5.63, figure 5.58) or anti-CD3/28 [treatment difference 
3983 counts/min/well (-7681 to 15647) p=0.494] (table 5.63, figure 5.59).
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Table 5.63 Lymphocyte proliferation results for atorvastatin compared with placebo after 8 weeks, with 
treatment difference
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Control
(counts/min/
well)
46 380 223, 691 46 329 186, 549 107 -89, 303 0.276
PHA
(counts/min/
well)
46 5165 792, 43814 46 3422 375, 38951 4688 -13351, 
22728
0.602
Anti-CD3/28
(counts/min/
well)
46 1544 494, 27139 46 1375 379,19088 3983 -7681, 15647 0.494
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Figure 5.57 Box and whisker plot for lymphocyte proliferation (control) after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.276).
Figure 5.58 Box and whisker plot for lymphocyte proliferation (PHA) after 8 weeks for atorvastatin and 
placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.602).
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Figure 5.59 Box and whisker plot for lymphocyte proliferation (Anti-CD3/28) after 8 weeks for atorvastatin 
and placebo. The boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are 
identified by *. Mean is indicated by +. No significant difference is seen between groups (p=0.494).
5.12.5 Exhaled gases
No difference was seen between atorvastatin and placebo for concentration of exhaled 
NO [treatment difference -1.6 ppb (95% CI -7.1 to 4.0), p=0.559] (table 5.64, figure 
5.60), or CO [treatment difference -0.2 ppm (-0.6 to 0.3), p=0.438)] (table5.64, figure 
5.61).
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Table 5.64 Exhaled nitric oxide and carbon monoxide results for atorvastatin compared with placebo after 8 
weeks, with treatment difference (due to machine dysfunction, one patient did not have an exhaled CO 
measurement at week 8 while on placebo).
Variable Atorvastatin Placebo Treatment 
difference
95% CI P value
n Median IQR n Median IQR
Exhaled 
NO (ppb) 
44 16.2 9.0, 
38.1
48 17.3 9.0, 
42.7
-1.6 -7.1, 4.0 0.559
Exhaled 
CO (ppm)
44 4.2 3.7, 4.7 47 4.1 3.6, 
5.1
-0.2 -0.6, 0.3 0.438
Figure 5.60 Box and whisker plot for exhaled nitric oxide after 8 weeks for atorvastatin and placebo. The boxes 
represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. Mean is 
indicated by +. No significant difference is seen between groups (p=0.559).
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Figure 5.61 Box and whisker plot for exhaled carbon monoxide after 8 weeks for atorvastatin and placebo. The 
boxes represent the interquartile range, with the whiskers representing 1.5×IQR. Outliers are identified by *. 
Mean is indicated by +. No significant difference is seen between groups (p=0.438).
5.13 Inflammatory markers - summary
While no changes were seen in serum markers of inflammation or exhaled gases, changes 
were seen in sputum macrophage and neutrophil counts, with an associated fall in LTB4
and a trend in reduction of CRP. This may suggest a localized reduction in inflammation, 
despite the lack of clinical effect. The implications of these changes are discussed in the 
following chapter. 
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5.14 Correlations
5.14.1 LTB4
There was no correlation in week 8-week 0 delta between sputum LTB4 and sputum IL-8, 
sputum macrophages, neutrophils or eosinophils, or with PEF (table 5.65).
Table 5.65 Pearson Correlation Coefficient in week 8-week 0 delta for LTB4 with IL-8, sputum macrophage 
neutrophil and eosinophil count, and PEF
Variable R value R2 P value Number of 
observations
Sputum IL-8 0.220 0.048 0.114 53
Macrophage 
percentage
0.277 0.077 0.076 42
Macrophage cell 
count
0.114 0.013 0.471 42
Neutrophil cell 
count
-0.166 0.027 0.295 42
Neutrophil 
percentage
-0.166 0.027 0.294 42
Eosinophil cell 
count
-0.114 0.013 0.390 46
Eosinophil 
percentage
-0.090 0.008 0.500 46
Morning PEF 0.174 0.030 0.238 48
Evening PEF -0.027 0.001 0.862 45
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5.14.2 IL-8
There was no correlation at week 8-week 0 delta between sputum IL-8 and sputum 
macrophages, neutrophils or eosinophils, or with PEF (table 5.66).
Table 5.66 Pearson Correlation Coefficient in week 8-week 0 delta for IL-8 with sputum macrophage, 
neutrophil and eosinophil count, and PEF
Variable R value R2 P value Number of 
observations
Macrophage 
percentage
0.073 0.005 0.619 49
Macrophage cell 
count
0.072 0.005 0.623 49
Neutrophil cell 
count
-0.064 0.004 0.663 49
Neutrophil 
percentage
-0.073 0.005 0.618 49
Eosinophil cell 
count
0.147 0.021 0.240 46
Eosinophil 
percentage
0.143 0.021 0.251 46
Morning PEF 0.008 0.000 0.956 56
Evening PEF -0.027 0.001 0.847 53
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5.14.3 Sputum macrophages
There was a good correlation in week 8-week 0 delta between sputum macrophage cell 
count and neutrophils (r=-0.842, p<0.0001for cell counts). There was no correlation with 
eosinophils or PEF (table 5.67).
Table 5.67 Pearson Correlation Coefficient in week 8-week 0 delta for sputum macrophage count with 
neutrophil and eosinophil count and percentage, and PEF
Variable R value R2 P value Number of 
observations
Neutrophil cell 
count
-0.842 0.918 <0.0001 50
Neutrophil 
percentage
-0.848 0.921 <0.0001 50
Eosinophil cell 
count
-0.211 0.045 0.088 46
Eosinophil 
percentage
-0.161 0.026 0.200 46
Morning PEF -0.195 0.442 0.193 46
Evening PEF -0.011 0.103 0.946 44
5.14.4 Sputum neutrophils
There was no correlation in week 8-week 0 delta between sputum neutrophil cell count or 
percentage and eosinophils or PEF (table 5.68).
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Table 5.68 Pearson Correlation Coefficient in week 8-week 0 delta for sputum neutrophil count with 
eosinophils and PEF
Variable R value R2 P value Number of 
observations
Eosinophil cell 
count
-0.092 0.009 0.458 46
Eosinophil 
percentage
-0.120 0.0.14 0.337 46
Morning PEF 0.246 0.496 0.099 46
Evening PEF 0.071 0.267 0.645 44
5.14.5 Sputum eosinophils
There was no correlation in week 8-week 0 delta between sputum eosinophil cell count or 
percentage and PEF (table 5.69).
Table 5.69 Pearson Correlation Coefficient in week 8-week 0 delta for sputum eosinophil count and PEF
Variable R value R2 P value Number of 
observations
Morning PEF 0.054 0.003 0.677 59
Evening PEF 0.132 0.017 0.310 48
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5.15 Correlations summary
No correlation was seen between the inflammatory markers tested and macrophages, 
neutrophils, eosinophils or lung function. There was a significant correlation between 
sputum macrophages and neutrophils, and a trend towards a correlation between 
neutrophils and morning PEF. 
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6. DISCUSSION
6.1 Principal findings
This randomised controlled study examined the effects on asthma control and airway 
inflammation of oral atorvastatin 40 mg daily with that of a matched placebo in adults 
with allergic asthma. The hypothesis was that atorvastatin improves asthma control and 
airway inflammation in adults with asthma. We found that atorvastatin has no effect on a 
range of clinical indices of control of chronic allergic asthma after 2 months of treatment. 
Immunological investigations showed a change in both relative and absolute sputum 
macrophage and neutrophil counts, and an associated reduction in sputum LTB4, but no 
other significant effects.
6.1.1 Clinical effects
The lack of any evidence of clinical benefit of atorvastatin in allergic asthma confirms 
and extends the findings of Menzies et al 243, who performed a crossover trial of 
simvastatin (2 weeks at 20mg, 2 weeks at 40mg vs. placebo with no washout) in 16 
subjects with asthma. In our study the statin chosen, atorvastatin, was administered at a 
higher dose and for longer duration that the earlier study 243 and to larger group of 
participants (n=54), but we still showed no evidence of an improvement in asthma 
control. 
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6.1.2 Inflammatory outcomes
In addition to the cholesterol lowering effects of statins through the inhibition of HMG 
CoA reductase, statins have posited anti-inflammatory effects 244. There is evidence that 
statins can influence the in vitro function of a range of inflammatory cells including T-
lymphocytes 245, monocytes 246, macrophages 189, eosinophils 174 and neutrophils 161. 
6.1.2.1 Eosinophils
Animal models suggest that statins decrease eosinophil survival 32 and increase 
eosinophil apoptosis 179. This would suggest that patients treated with statins should show 
a decrease in sputum eosinophils. This was not the case in this study. In addition, to 
support the evidence of a lack of effect of statins on eosinophilic inflammation, there was 
no reduction in exhaled nitric oxide, which is closely linked with sputum eosinophilia 247. 
Menzies at al 243 also failed to show any change in sputum eosinophils or eNO.
6.1.2.2 Macrophages
The reduction in sputum absolute alveolar macrophage count after atorvastatin treatment 
echoes similar findings in atherosclerosis 191. Several mechanisms, either alone or in 
combination, might explain this decrease. Reduced macrophage growth, decreased 
recruitment, antioxidant effects, decreased cell adhesion and/or an altered cytokine 
profile may all go some way towards explaining the effect on macrophages seen in this 
study.
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6.1.2.2.a Reduced macrophage growth
Statins reduce growth of both animal and human macrophages 191, 248 and possibly 
atorvastatin had a similar effect on sputum alveolar macrophage numbers. 
6.1.2.2.b Decreased macrophage recruitment
LTB4 is raised in induced sputum supernatant in asthma 249 and mediates the recruitment 
of alveolar macrophages through B leukotriene receptor 1 250. The decrease in sputum 
LTB4 concentrations within the airways by atorvastatin therapy could contribute to the 
reduction found in sputum macrophage count. Atorvastatin has also been shown to 
reduce CCL2, involved in macrophage recruitment, in the arteries of 
hypercholesterolaemic rabbits 251, human vascular cells 252, and in in vitro models of 
sepsis 134.
6.1.2.2.c Antioxidant effects
Statins possess potent antioxidative properties 154, 155. Simvastatin has been identified as 
an antioxidant in rat liver microsomes 157 and vascular smooth muscle 158, and human 
lipoprotein particles 159. The reduced production of reactive oxygen species from human 
bronchial epithelial cells 253 and endothelial cells 124, 254 by atorvastatin might also 
influence alveolar macrophage function.
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6.1.2.2.d Decreased cell adhesion
Statins could affect the chemokine and adhesion molecule-directed migration of 
inflammatory cells from blood into the airways 169, 175, 177. Statins have specifically been 
shown to interfere with cell binding and macrophage recruitment to the lung 134, 255, 256. 
Decreased monocyte to endothelial cell adhesion is due to attenuation of up-regulation of 
P-selectin on activated endothelial cells 133, and decreased expression of CCL2 receptor 
has also been seen on endothelial cells in rats 136, 137.  This reduction in binding could also 
relate to inhibition of LFA-1/ICAM-1 interaction 135, which could thus reduce 
macrophage function, although interestingly previous work suggests that expression of 
these molecules is increased by statins 256. 
6.1.2.2.e Altered cytokine profile
Finally, statins reduce the in vitro release of cytokines and mediators including TNFa
from monocytes 142, IL-6, IL-1β and endothelin-1 from endothelial cells, IL-5 and IFN-γ 
from human peripheral blood mononuclear cells (PBMC) 195, and in vivo circulating 
levels of TNFα, IL-6 170, and CCL2, a chemokine responsible for the recruitment of 
monocytes to sites of inflammation 257, 258. Similar effects on the release of these 
cytokines and mediators, including from cells within the airways could reduce the 
recruitment of alveolar macrophages to the airways. Against this latter mechanism, we 
found no reduction in sputum TNFa, or circulating IL-6, TNFa, and ICAM-1 
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concentrations following atorvastatin therapy. Future studies should examine these 
potential pathways. 
In stable asthma alveolar macrophages are activated 259, 260 and show an increased 
capacity to release pro-inflammatory cytokines 261. The absolute macrophage count in 
sputum is not elevated in asthma 262, and despite the reduction in absolute macrophage 
count by atorvastatin there was no improvement in clinical outcomes. It is not known 
whether the activation status of alveolar macrophages was impaired by atorvastatin in the 
study.
6.1.2.3 Neutrophils
In a mouse model, the neutrophilia associated with acute lung injury is markedly reduced 
with lovastatin treatment 180 and bronchoalveolar lavage neutrophil count is reduced in 
lung transplant recipients receiving statins 209. Lovastatin has been shown to inhibit 
neutrophil chemotaxis 178. Paradoxically we found a significant increase in the proportion 
of neutrophils in induced sputum with atorvastatin therapy. The absolute neutrophil 
counts were not significantly different between groups, suggesting that the increased 
proportion of neutrophils occurred because of the low macrophage proportion and the 
expression of the results as a percentage. In support of this explanation, the sputum LTB4
concentration was reduced after atorvastatin therapy, which would be more likely to be 
associated with a reduced neutrophil count. LTB4 is expressed mainly by activated 
macrophages and to a lesser extent neutrophils 250. Decreased production of LTB4 would 
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be consistent with a reduction in the numbers and activation status of sputum 
macrophage. 
IL-8 is another important cytokine involved in the recruitment of neutrophils, and 
previous studies have suggested that lovastatin inhibits human alveolar epithelial 
production of IL-8 178. In this study however, the circulation and sputum concentrations 
of IL-8 were not altered by atorvastatin. There was no correlation between LTB4
production and IL-8 production within patients in this study.
6.1.2.4 Inflammatory markers
Previous studies have shown that statins lower inflammatory markers such as CRP 91, 107 -
109 and IL-6 112, 113 in ischaemic heart disease. Interestingly, this study showed very few 
anti-inflammatory effects of statin medication in patients with asthma. Most notably, 
there was no change in IL-6, and CRP reduction was only of borderline significance. 
Menzies et al also failed to show any change in CRP in their trial of simvastatin in 
asthma 243. This contrasts with a recent study of atorvastatin in rheumatoid arthritis 164, 
where these were reduced by atorvastatin. This may be due to the fact that CRP levels 
were not high at baseline or due to lack of statistical power. Changes in CRP may also 
have been masked by concomitant use of inhaled corticosteroids.
However, a reduction in sputum LTB4 was observed. LTB4 is normally raised in 
asthma 263, and is expressed by macrophages and neutrophils. Decreased expression of 
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LTB4 would be consistent with the alteration in sputum macrophage and neutrophil 
count, discussed above.
6.1.2.5 Summary
Despite the well-established anti-inflammatory actions of statins, it seems that they are 
not appropriate for the inflammatory phenotype associated with atopic asthma.
6.1.3 Duration of treatment
We estimated that 8 weeks duration of therapy was long enough to show a clinical effect, 
on the basis that a drop in cholesterol can already be seen within 6 weeks of statin 
treatment 99, and CRP has been shown to fall within four weeks 264, possibly even in the 
first two days 265. Anti-inflammatory effects were seen in 28 days in animal models of 
allergic asthma 173. It is however possible that a longer trial would have shown clinical 
effects. Alternatively, such changes may be more apparent in disease states with raised 
CRP levels, as a reduction of borderline significance was seen in the present study. It is 
possible that the administration of atorvastatin therapy for a longer duration might 
improve different clinical outcome measures of asthma such as indices of airway 
remodelling and statins have been shown to inhibit smooth muscle proliferation in both 
vascular 114 and airway smooth muscle 184, 203and lower the expression of the 
profibrogenic cytokine transforming growth factor (TGF)-b1 185. Another possible line of 
investigation would be to measure rates of exacerbation, as previous studies have 
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suggested that statins decrease episodes of pneumonia 207 or may reduce the associated 
mortality 206.
6.1.4 Statin used
It is unlikely that using a different statin would have showed greater effects. An earlier 
trial in rheumatoid arthritis 164 used atorvastatin with success. However, the initial 
experimental work in inflammatory lung disease was using simvastatin 173 and 
pravastatin 174 with clear effect. Indeed, Kiener and colleagues 166 showed that lipophilic 
statins such as atorvastatin and simvastatin have a much greater effect on inflammatory 
responses in human and mouse models than the hydrophilic pravastatin. Additionally, 
Joukhadar et al showed no difference in effect on inflammatory parameters when 
comparing atorvastatin, simvastatin or pravastatin 266. Furthermore no therapeutic effect 
was found in a previous trial of simvastatin in asthma 243, adding further weight to the 
idea that the lack of effect is not statin-specific. 
6.1.5 Washout period
The six week washout period for this study was considered acceptable because evidence 
suggests that the anti-inflammatory effects do not last this long. Circulating levels of 
sVCAM-1 revert to normal in 2 days 267, CRP 268  and IL-6 begin to increase after at most 
3 days and have returned to baseline after 7 days’ withdrawal 187, 265, 269. In contrast, a 
study examining CRP and MMPs showed that although there was a rapid restoration of 
CRP, MMPs remained unchanged 120 days after statin withdrawal 270. In the event, 
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analysis of treatment-period interaction (Appendix 5) showed no significant results for 
any variable, indicating that the washout period selected was adequate.
6.1.6 Concomitant inhaled corticosteroid
One possible explanation for the apparent lack of efficacy in this study is that all patients 
were taking regular inhaled corticosteroid therapy. The anti-inflammatory action of this 
medication may be enough to overwhelm any modest effect from statins. This may in 
part explain why the observed reduction in CRP was of borderline significance, as 
corticosteroids have been shown to lower CRP in healthy individuals 271. Interestingly, in 
the Menzies et al study, all patients were withdrawn from inhaled corticosteroids before 
treatment began, with patients receiving a long-acting beta2-agonist instead 243. This too 
could mask a subtle anti-inflammatory action 272. They examined the effect of two weeks 
of 20mg and two weeks of 40mg simvastatin in a crossover trial of asthmatic patients 
taking LABA and SABA alone after withdrawal of corticosteroids and other anti-
inflammatory medications. The study had no washout period. Their study also failed to 
show any effect on most clinical parameters. 
An alternative would be to attempt to withdraw all long-acting medication from patients 
before starting statin therapy, but this is likely to create practical difficulties, as patients 
likely to benefit from this medication are unlikely to tolerate the withdrawal of all other 
long-acting treatments.
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6.1.7 Compliance 
Compliance with medication, as measured by tablet count, does not seem to have been 
problematic. This is borne out by the significant changes in serum lipids and liver 
function tests observed in the patients receiving atorvastatin. 
6.2 Strengths and limitations of the study
6.2.1 The introduction of the EU Clinical trial directive.
The changes to regulation of clinical trials introduced in 2005 have had a wide-reaching 
impact on research in the UK 273 - 276. In particular, the bureaucratic demands made of 
researchers have been significant. Every stage of the project has had additional delays 
due to the need to collect approval from sponsors, ethics and the MHRA. Many of these 
delays unfortunately had significant knock-on effects in terms of delays to recruitment. It 
has been argued that such cumbersome work, and particularly the demands placed on a 
sponsor, for a small-scale non-commercial trial may well hinder the implementation of 
hypothesis-testing work such as this in the future 277.
6.2.2 Recruitment issues and Generalisability
A Canadian cross-sectional study of asthma severity and prevalence 278 suggested that 
78.9% of patients could be described as having mild to moderate asthma according to the 
Canadian Asthma Consensus Guidelines, broadly comparable with the patients included 
in the current study. Consequently, studying this group of patients is appropriate. If levels 
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of co-medication (e.g. with LABAs or leukotriene receptor antagonists) increase, then 
findings in milder patients may become less generalisable in future.
6.2.3 Severity of asthma
Baseline measures of asthma severity in this study indicate relatively mild asthma (all 
spirometric measures >75% predicted), with relatively low inflammatory indices (e.g. 
geometric mean methacholine responsiveness 2.23 mg/mL, median eosinophils 1.5%). 
This is essentially a feature of available patients for recruitment – more severe patients 
tend to be on additional medications or be more poorly controlled, which would have 
excluded them from this study. It is worth noting that mean baseline reliever use was 2.3 
puffs of inhaler per day, mean ATS severity score was 3.3, and mean ACQ 1.5. There 
was thus some scope for improvement in asthma control. 
Repeat analysis of the results, using only patients with baseline sputum eosinophils above 
3% (to investigate the effect on more severe asthmatics) still showed no change in 
outcomes, and indeed the observed effects on sputum were no longer seen (Table 6.1). 
Although this subgroup analysis cannot be conclusive, particularly considering the small 
sample size (n=11), it adds weight to the argument that there is no clinical effect to be 
found. 
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Table 6.1 Reanalysis of primary end point and significant findings from main study, using only patients 
with baseline sputum eosinophils >3% (n=11). Only serum cholesterol shows a statistically significant 
effect
Variable Treatment 
difference
95% CI p 
value
Morning PEF , L/min -0.42 -33.34, 32.51 0.975
Evening PEF, L/min 4.83 -20.78, 30.44 0.648
FEV1 pre-salbutamol, L 0.08 -0.2, 0.4 0.595
FEV1 post-salbutamol, L 0.03 -0.2, 0.3 0.797
Macrophage cell count, 
x106
-4.9 -69.2, 59.4 0.842
Neutrophil cell count, 
x106
41.7 -29.7, 113.2 0.180
Eosinophil cell count, 
x106
-27.9 -79.3, 23.4 0.206
Serum CRP, mg/L -0.3 -1.3, 0.70 0.470
Serum cholesterol, 
mmol/L
-1.8 -2.7, -1.0 0.002
Sputum LTB4, ng/mL -69.8 -196.1, 56.4 0.199
6.2.4 Power of the study
The original power calculations indicated that a sample size of 44 would give 90% power 
to detect a difference in means of 20L/min in peak expiratory flow (PEF) (primary 
endpoint), assuming a standard deviation of differences of 40L/min, using a paired t-test 
with a 0.05 two-sided significance level. We recruited a total of 54 patients to ensure that 
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44 patients completed the study. Fewer patients provided sputum samples, thus limiting 
the potential of the trial to find significant differences between the groups. Secondary end 
points must this be regarded as “hypothesis-generating”, rather than definitive. 
6.3 Implications for future research
6.3.1. Mechanism of macrophage reduction
Future studies could examine the potential pathways discussed above for reduction of 
sputum macrophage count.
6.3.1 Different statins
While atorvastatin has not been shown to have any clinical effect, there might be merit in 
examining the effect of other statins in the same setting. 
6.3.2 Smoking-related inflammatory lung disease
Smoking in asthma alters the clinical picture of the disease, with resistance to normal 
therapies, especially corticosteroids 194. Most trials of asthma medications specifically 
exclude smokers, making this an area ripe for further investigation. 
Although in the present study no improvement was seen in asthma control for non-
smokers, a significant change in sputum macrophages and neutrophils was shown. This 
may have relevance to the treatment of other chronic lung diseases. Alveolar 
macrophages have been implicated in the pathogenesis of number of chronic lung 
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diseases, including COPD 279, 280. The pathogenesis of COPD seems to involve both 
increased apoptosis and decreased clearance of apoptotic cells by macrophages (a process 
known as efferocytosis) 283 - 285, as well as an imbalance of macrophage and neutrophil-
related inflammation in the lung parenchyma 286, 287 (figure 6.1). Lovastatin enhances the 
clearance of apoptotic cells by human and mouse macrophages, a statin-specific effect 
reversible with mevalonate, through modulation of Rho-GTPases 147, 148, 279, 280. 
Lovastatin and simvastatin have also been shown to block Fc receptor-mediated 
phagocytosis by cultured human monocytes 149. Macrophage expression and production 
of MMP-9 is also reduced by statins 191, which could have an impact on COPD. LTB4 is 
also increased in COPD 288, and this study suggests that statins decrease expression. 
Recent evidence may also show that statins may inhibit lung parenchymal destruction, 
and peribronchial and perivascular infiltration of inflammatory cells in a rat model of 
smoking-induced emphysema 186. Furthermore, a recent nested case-control study in 
humans has also suggested that statins may decrease respiratory mortality in patients with 
COPD 197.Taken together with the reduction in the sputum macrophage count with 
atorvastatin found in this study, these findings imply that the efficacy of statins should be 
investigated in COPD.
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Figure 6.1  Chronic inflammation in COPD is driven initially by cigarette smoking and other inhaled irritants, 
which induce a specific pattern of inflammation that predominantly involves the peripheral airways and lung 
parenchyma. This pattern of inflammation is characterized by an increase in neutrophils, macrophages and 
CD8+ T lymphocytes in small and large airways and in lung parenchyma and pulmonary vasculature. Alveolar 
macrophages have a crucial part in orchestrating this inflammation through the release of proteases, such as 
MMP-9, inflammatory cytokines, such as TNF-α, and other cytokines, such as IL-8, that attract neutrophils into 
the airways. Reprinted from Cazzola et al 286, with permission from Elsevier
6.4 Conclusion
In conclusion, we have demonstrated that atorvastatin administered for 8 weeks to adults 
with mild to moderate atopic asthma resulted in no improvement in asthma control. The 
reduction in the sputum macrophage count suggests potential areas for investigation of 
atorvastatin in chronic lung disease in which activated alveolar macrophages have been 
implicated in the pathogenesis, such as COPD.
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Appendix 1: Asthma Diary 
(from Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. 
Measurement characteristics of two asthma symptom diary scales for use in clinical 
trials. European Respiratory Journal 1997;10:646-651.)
Appendix 1
Circle year 2005/ 2006 Effect of statins on control of chronic asthma
Subject number MON TUES WED THU FRI SAT SUN
Day/Month DD/MM
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2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
4. How often did your asthma 
affect your activities today?
0     6
0=none of the time 
6=all of the time.
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1□
2□
3□
4□
5□
6□
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0□
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2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
6□
0□
1□
2□
3□
4□
5□
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Night  peak flow (best of 3)
Was blue inhaler taken within 
4 hours of night peak flow ?
Yes □
No  □
Yes □
No  □
Yes □
No  □
Yes □
No  □
Yes □
No  □
Yes □
No  □
Yes □
No  □
5. Did you wake up with 
asthma symptoms?
No = 0
Once = 1
More than once = 2
Awake “all night” =3
0□
1□
2□
3□
0□
1□
2□
3□
0□
1□
2□
3□
0□
1□
2□
3□
0□
1□
2□
3□
0□
1□
2□
3□
0□
1□
2□
3□
6. How many puffs of the blue 
inhaler did you use today? 
Have you taken your study 
tablets today?
Yes □
No  □
NA □ 
Yes □
No  □
NA □
Yes □
No  □
NA □
Yes □
No  □
NA □
Yes □
No  □
NA □
Yes □
No □ 
NA □
Yes □
No  □
NA □
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Please complete all questions by circling the number that best describes how you have been during the 
last 2 weeks as a result of your asthma.
HOW LIMITED HAVE YOU BEEN DURING THE LAST 2 WEEKS IN THESE ACTIVITIES AS A RESULT 
OF YOUR ASTHMA?
Totally Extremely Very Moderate Some A little  Not at all
Limited  Limited  Limited Limitation Limitation Limitation  Limited
1. STRENUOUS ACTIVITIES 1  2  3 4 5 6  7
(such as hurrying, exercising, 
running up stairs, sports)
2. MODERATE ACTIVITIES 1  2  3 4 5 6  7
(such as walking, housework, 
gardening, shopping, climbing stairs)
3. SOCIAL ACTIVITIES 1  2  3 4 5 6  7
(such as talking, playing with pets/children,
visiting friends/relatives)
4. WORK-RELATED 1  2  3 4 5 6  7
ACTIVITIES (tasks you have to do
at work*) *If you are not employed or self-employed, these should be tasks you have to do most days.
5. SLEEPING 1  2  3 4 5 6  7
HOW MUCH DISCOMFORT OR DISTRESS HAVE YOU FELT DURING THE LAST 2 WEEKS?
A Very  A Great  A Good Moderate Some Very  None
Great Deal Deal  Deal Amount Little
6. How much discomfort or 1  2  3 4 5 6  7
distress have you felt over the last
2 weeks as a result of CHEST 
TIGHTNESS?
IN GENERAL, HOW MUCH OF THE TIME DURING THE LAST 2 WEEKS DID YOU:
All of the Most of A Good Some of A Little Hardly any None of
time the time bit of the time of the of the  the time
the time time time
7. Feel CONCERNED ABOUT 1 2 3 4 5 6  7
HAVING ASTHMA?
8. Feel SHORT OF BREATH 1 2 3 4 5 6  7
as a result of your asthma?
9. Experience asthma symptoms1 2 3 4 5 6  7
as a RESULT OF BEING 
EXPOSED TO CIGARETTE 
SMOKE?
10. Experience a WHEEZE 1 2 3 4 5 6  7
in your chest?
11. Feel you had to AVOID A 1 2 3 4 5 6  7
SITUATION OR ENVIRONMENT
BECAUSE OF CIGARETTE SMOKE?
Appendix 2: ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ)
Appendix 2
HOW MUCH DISCOMFORT OR DISTRESS HAVE YOU FELT DURING THE LAST 2 WEEKS?
A Very A Great A Good Moderate Some Very None
Great Deal Deal Amount Little
Deal
12. How much discomfort or 1 2 3 4 5 6 7
distress have you felt over the
last 2 weeks as a result of 
COUGHING?
IN GENERAL, HOW MUCH OF THE TIME DURING THE LAST 2 WEEKS DID YOU
All of the Most of A good Some of A little Hardly None of
time the time bit of the time the time any of of the time
time the time
13. Feel FRUSTRATED as a 1 2 3 4 5 6 7
result of your asthma?
14. Experience a feeling of 1 2 3 4 5 6 7
CHEST HEAVINESS?
15. Feel CONCERNED 1 2 3 4 5 6 7
ABOUT THE NEED TO USE
MEDICATION for your asthma?
16. Feel the need to CLEAR 1 2 3 4 5 6 7
YOUR THROAT?
17. Experience asthma 1 2 3 4 5 6 7
symptoms as a RESULT OF
BEING EXPOSED TO DUST?
18. Experience DIFFICULTY 1 2 3 4 5 6 7
BREATHING OUT as a result
of your asthma?
19. Feel you had to AVOID A 1 2 3 4 5 6 7
SITUATION OR ENVIRONMENT 
BECAUSE OF DUST?
20. WAKE UP IN THE 1 2 3 4 5 6 7
MORNING WITH ASTHMA 
SYMPTOMS?
21. Feel AFRAID OF NOT 1 2 3 4 5 6 7
HAVING YOUR ASTHMA
MEDICATION AVAILABLE?
22. Feel bothered by HEAVY 1 2 3 4 5 6 7
BREATHING?
23. Experience asthma 1 2 3 4 5 6 7
symptoms as a RESULT OF 
THE WEATHER OR AIR 
POLLUTION OUTSIDE?
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24. Were you WOKEN AT 1 2 3 4 5 6 7
NIGHT by your asthma?
25. AVOID OR LIMIT GOING 1 2 3 4 5 6 7
OUTSIDE BECAUSE OF
THE WEATHER OR AIR 
POLLUTION?
26. Experience asthma 1 2 3 4 5 6 7
symptoms as a RESULT OF
BEING EXPOSED TO STRONG 
SMELLS OR PERFUME?
27. Feel AFRAID OF GETTING 1 2 3 4 5 6 7
OUT OF BREATH?
28. Feel you had to AVOID A 1 2 3 4 5 6 7
SITUATION OR ENVIRONMENT 
BECAUSE OF STRONG SMELLS 
OR PERFUME?
29. Has your asthma 1 2 3 4 5 6 7
INTERFERED WITH GETTING 
A GOOD NIGHT'S SLEEP?
30. Have a feeling of FIGHTING 1 2 3 4 5 6 7
FOR AIR?
HOW LIMITED HAVE YOU BEEN DURING THE LAST 2 WEEKS?
Most Not Several Very Few No
Done Not Done Not Done Limitation
31. Think of the OVERALL 1 2 3 4 5 6 7
RANGE OF ACTIVITIES that 
you would have liked to have 
done during the last 2 weeks.
How much has your range of 
activities been limited by your 
asthma?
HOW LIMITED HAVE YOU BEEN DURING THE LAST 2 WEEKS?
Totally Extremely Very Moderate    Some  A Little Not at all
Limited Limited Limited Limitation   Limitation  Limitation Limited
Overall, among ALL THE 1 2 3 4 5 6 7
ACTIVITIES that you have
done during the last 2 weeks, 
how limited have you been
by your asthma?
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DOMAIN CODE:
SYMPTOMS: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30
ACTIVITY LIMITATION: 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32
EMOTIONAL FUNCTION: 7, 13, 15, 21, 27
ENVIRONMENTAL STIMULI: 9, 17, 23, 26
The Asthma Quality of Life Questionnaire is copyrighted. It may not be changed, translated, or sold 
(paper or software) without the permission of Elizabeth Juniper.
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Appendix 3: ASTHMA CONTROL QUESTIONNAIRE Score
Circle the number that best describes how your asthma has been during the night and this morning. 
1 On average, during the past week, how often were you woken by your asthma during the night?
Never 0
Hardly ever 1
A few times 2
Several times 3
Many times 4
A great many times 5
Unable to sleep because of asthma 6
2 On average, during the past week, how bad were your asthma symptoms when you woke up in
the morning?
No symptoms 0
Very mild symptoms 1
Mild symptoms 2
Moderate symptoms 3
Quite severe symptoms 4
Severe symptoms 5
Very severe symptoms 6
3 In general, during the past week, how limited were you in your activities because of your asthma?
Not limited at all 0
Very slightly limited 1
Slightly limited 2
Moderately limited 3
Very limited 4
Extremely limited 5
Totally limited 6
4 In general, during the past week, how much shortness of breath did you experience because of your 
asthma?
None 0
A very little 1
A little 2
A moderate amount 3
Quite a lot 4
A great deal 5
A very great deal 6
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5 In general, during the past week, how much of the time did you wheeze?
Not at all 0
Hardly any time at all 1
A little of the time 2
A moderate amount of the time 3
A lot of the time 4
Most of the time 5
All the time 6
6 On average, during the past week, how many puffs of short-acting bronchodilator (eg Ventolin) 
have you used each day?
None 0
1-2 puffs most days 1
3-4 puffs most days 2
5-8 puffs most days 3
9-12 puffs most days 4
13-16 puffs most days 5
More than 16 puffs most days 6
To be completed by a member of the Research Team
[Record actual values in the shaded cells and score the FEV1 % predicted in the last column]
FEV1 prebronchodilator > 95% predicted 0
95-90% 1
FEV1 predicted  89-80% 2
79-70% 3
FEV1 % predicted  69-60% 4
59-50% 5
<50% predicted 6
TOTAL SCORE
SCORE / 7
The Asthma Control Diary is copyrighted. It may not be translated, adapted, or sold (paper or software) without the 
permission of Elizabeth Juniper.
APPENDIX 4: MEASUREMENT OF NEBULISER OUTPUT  -
Wright’s nebuliser
A4.1 Apparatus
Rotameter 3 ml syringe
Flow meter Needle
O2 or air supply (50 psi) Stop watch
Phosphate buffered saline Digital balance
Wright nebuliser
A4.2 Method
1. Add 3ml saline to vial
2. Attach vial to nebuliser and weigh on balance
3. Attach flow meter to rotameter
4. Adjust the flow meter until the rotameter indicates 6 l/min
5. Record the flow meter reading. (True flow rate is measured by the rotameter)
6. Disconnect the rotameter keeping the flow meter at exactly the same setting.
7. Attach the nebuliser to the flow meter for exactly 2 minutes.
8. Disconnect the flow meter and re-weight the nebuliser and vial. The difference 
in weight from Step 2 above is the nebuliser output for 2 minutes (assuming 
specific gravity of saline to be 1.0)
9. Repeat this procedure 5 times at true flow rates of 6 l/min, 7 l/min, and 8 
l/min, 9 l/min and 10 l/min.
10. Mean the 5 measurements of nebuliser output.
Plot true flow rate against nebuliser output (figure A4.1) and read off the true flow 
rate that will give an output of 0.13 ml/min.
Plot flow meter reading against true flow rate (e.g. figure A4.2) to determine the flow 
meter setting that will produce an output of 0.13 ml/min.
Use this flow rate to operate the nebuliser during methacholine inhalation tests.
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Figure A4.1 Calibration of nebuliser output: Nebuliser output versus true flow rate 
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Figure A4.2 Calibration of nebuliser output: Flow meter reading versus true flow rate 
Table A4.1 Calibration of nebuliser output: Data for calibration 
Flow 
meter 
rate
Rotameter 
rate
Weight 
before
Weight 
after 2 
minutes
Difference Mean Mean 
output/minute
Mean 
flow 
rate
5.75 6 107.33 107.21 0.12
5.75 6 107.2 107.05 0.15
6 6 107.05 106.91 0.14
5.75 6 107.47 107.33 0.14
5.75 6 107.58 107.42 0.16 0.142 0.071 5.8
7 7 108.03 107.83 0.2
7 7 107.7 107.5 0.2
7 7 107.75 107.56 0.19
7 7 107.56 107.37 0.19
7 7 107.8 107.61 0.19 0.194 0.097 7
8 8 107.77 107.54 0.23
8 8 107.73 107.52 0.21
7.5 8 107.52 107.32 0.2
7.75 8 107.82 107.59 0.23
8 8 107.91 107.69 0.21 0.216 0.108 7.85
9 9 107.88 1076.7 0.21
9 9 107.39 107.17 0.22
9 9 107.79 107.56 0.23
9 9 108.07 107.84 0.23
9 9 107.89 107.66 0.23 0.224 0.112 9
9.75 10 108.36 108.1 0.26
10 10 107.99 107.71 0.28
10 10 107.85 107.57 0.28
10 10 107.85 107.57 0.28
10 10 108.01 107.74 0.25 0.27 0.135 9.95
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Appendix 5: Treatment-period interaction analysis.
Treatment-period interaction analysis for all outcomes in the trial. The p value represents the probability of no 
difference between groups, i.e. that the null hypothesis is true and both groups are the same. No values are 
statistically significant.
Variable P value
Morning PEF 0.680
Evening PEF 0.666
Reliever inhaler use 0.887
ATS score 0.033
Asthma control Score 0.975
FEV1 pre-salbutamol 0.081
FEV1 post-salbutamol 0.167
% predicted FEV1 0.360
FEV1 reversibility 0.096
PEF (spirometry) pre-salbutamol 0.467
PEF (spirometry) post-sabutamol 0.610
% predicted PEF 0.846
FVC pre-salbutamol 0.110
FVC post-salbutamol 0.289
% predicted FVC 0.281
FEF25-75 pre-salbutamol 0.206
FEF25-75 post-salbutamol 0.407
% predicted FEF25-75 0.383
FEV1/FVC ratio pre-salbutamol 0.900
FEV1/FVC ratio post-salbutamol 0.862
Sputum total cell count 0.471
Viability 0.610
Volume of filtrate 0.243
Total number of cells recovered 
from sample
0.303
Total viable cells recovered from 
sample 
0.318
Macrophages 0.606
Neutrophils 0.198
Eosinophils 0.695
Lymphocytes 0.489
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Variable P value
Bronchial epithelial cells 0.358
Total non-squamous cells 0.674
Squamous epithelial cells 0.349
Absolute number of cells counted
per slide
0.484
% macrophages 0.327
% neutrophils 0.204
% eosinophils 0.843
% lymphocytes 0.317
% bronchial epithelial cells 0.381
% squamous cells 0.567
Serum CRP 0.178
Serum ICAM 0.661
Serum  TNFα 0.635
Serum IL-6 0.577
Serum IL-1 0.546
Serum IL-5 0.260
Serum IL-8 0.245
Serum IL-10 0.249
Serum Triglycerides 0.362
Serum Cholesterol 0.803
Serum HDL 0.595
Serum LDL 0.245
Serum Urea 0.576
Serum Potassium 0.250
Serum Sodium 0.975
Serum Bilirubin 0.395
Serum AST 0.716
Serum ALT 0.919
Exhaled NO 0.220
Exhaled CO 0.258
Quality of Life score 0.442
QOL Symptoms 0.326
QOL Activities 0.764
QOL Emotional well-being 0.213
QOL Environmental 0.850
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Variable P value
Methacholine (PC20) 0.880
Sputum supernatant MPO 0.347
Sputum supernatant LTB4 0.156
Sputum supernatant IL-1b 0.517
Sputum supernatant IL-1RA 0.584
Sputum supernatant IL-6 0.501
Sputum supernatant IL-8 0.460
Sputum supernatant IL-17 0.673
Sputum supernatant TNFα 0.387
Sputum supernatant IFNγ 0.437
Sputum supernatant GM-CSF 0.694
Sputum supernatant MIP1α 0.240
Sputum supernatant MCP1 0.596
Lymphocyte proliferation Control 0.071
Lymphocyte proliferation PHA 0.969
Lymphocyte proliferation Anti CD3/28 0.773
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2ABSTRACT 
Background
Statins have anti-inflammatory properties that may be beneficial in the treatment 
of asthma. We tested the hypothesis that atorvastatin added to inhaled 
corticosteroids treatment improves lung function and airway inflammation in 
atopic adults with asthma 
Methods 
Fifty four adults with atopic asthma were recruited to a double-blind, randomised 
controlled crossover trial comparing the effect of oral atorvastatin 40 mg daily 
with that of a matched placebo on asthma control and airway inflammation. Each 
treatment was administered for 8 weeks separated by a 6-week washout period. 
The primary outcome was morning peak expiratory flow (PEF). Secondary 
outcomes included FEV1, asthma control questionnaire score, airway 
hyperresponsiveness to methacholine, induced sputum cytology and 
inflammatory biomarkers.
Results
At 8 weeks, the change in mean morning PEF, as compared with baseline, did 
not differ substantially between the atorvastatin and placebo treatment periods 
[mean difference -0.5 L/min, 95% Cl -10.6 to 9.6, p=0.921]. Values for other 
clinical outcomes were similar between the atorvastatin and placebo treatment 
periods. The absolute sputum macrophage count was reduced after atorvastatin 
compared to placebo [mean difference -45.0x104 cells, 95% Cl -80.1 to -9.7, 
p=0.029], as was the sputum fluid leukotriene B4 [mean difference -88.1pg/ml, 
95% CI -156.4 to -19.9, p=0.014].
Conclusion 
The addition of atorvastatin to inhaled corticosteroids results in no short-term 
improvement in asthma control, but reduces sputum macrophage counts in mild 
to moderate atopic asthma. We speculate that the change in sputum 
macrophage count suggests potential areas for investigation of statins in other 
chronic lung diseases.
Clinical Trials.gov number: NCT00126048
Word count: 248
Key words
Asthma; atorvastatin; statins; inhaled corticosteroids; induced sputum; alveolar 
macrophages, leukotriene B4
Dedication
This paper is dedicated to the memory of Dr Stuart Wood, Senior Lecturer in 
General Practice at the University of Glasgow, who died in March 2006.
3INTRODUCTION 
Statins are inhibitors of 3-Hydroxymethyl-3-glutaryl Coenzyme A reductase (HMG 
CoA reductase), a rate-limiting step in cholesterol synthesis. In addition to 
clinically important cholesterol lowering properties 1, statins also have diverse 
anti-inflammatory effects 2-5. Statins prevent the isoprenylation of signalling 
molecules such as Ras and Rho, which are involved in driving many 
inflammatory processes including lymphocyte activation. Statin treatment 
therefore has the potential to modify immune-driven diseases , and this has been 
tested in experimental models of auto-immune diseases 6.  A recent trial of 
atorvastatin in rheumatoid arthritis showed improvement in clinical outcome 
measures 7 associated with reduction in blood inflammatory biomarkers such as 
erythrocyte sedimentation rate, C-reactive protein (CRP) and interleukin-6 (IL-6). 
Atopic asthma is an immune-mediated airway disease associated with 
eosinophilic airway inflammation and Th2 cytokine functional profile 8. Recent 
studies have shown that simvastatin and pravastatin can effectively reduce these 
acute changes in murine models of allergic lung inflammation 3 9 10. It has been 
postulated that the anti-inflammatory effects of statins may have relevance for the 
treatment of asthma and other respiratory disease 5. 
The aim of this study was to test the hypothesis that atorvastatin added to 
inhaled corticosteroids treatment improves lung function and sputum cell counts 
in atopic adults with asthma. We designed a randomised double blind crossover 
placebo controlled trial to investigate the effect of oral atorvastatin 40 mg daily for 
8 weeks on measures of asthma control and airway inflammation in adults with 
allergic asthma receiving inhaled corticosteroids alone. The dose and duration of 
statin therapy with atorvastatin was greater than that used in a previous placebo-
controlled crossover trial of short-term, low dose simvastatin in 16 subjects with 
steroid-naïve asthma, which showed no clinical beneficial effects on asthma 
control 11. Atorvastatin was chosen because of its favourable in vitro and in vivo
anti-inflammatory properties 7 12 13 and evidence of clinical benefit at the dose of 
40 mg daily in rheumatoid arthritis 7. 
METHODS
Subjects
Chronic symptomatic atopic asthma subjects aged 18–70 years were recruited 
from general practices and hospital clinics. Subjects were taking ≤ 1000 mcg 
beclometasone equivalent daily, no other medication for asthma other than a 
short-acting beta2-agonist and had been on stable medication for at least four 
weeks before randomisation. Atopy to common allergens was established by skin 
prick test or specific serum IgE antibody measurement. Subjects were excluded if 
they were pregnant or lactating, current smokers, ex-smokers with > 5 pack-year 
smoking history, receiving statins or had a known allergy to them, had a 
4respiratory tract infection or needed oral corticosteroids in the 6 weeks preceding 
inclusion. All participants gave written informed consent. The study was approved 
by the West Glasgow Ethics Committee.
Study design and assignment
The study was a 24-week randomised double blind crossover study comparing 
the effect of oral atorvastatin therapy (40 mg daily) with that of a matched 
placebo, on asthma control and airway inflammation. After a 2-week run-in period, 
each treatment was administered to randomised patients for 8 weeks, separated 
by a 6-week washout period. Randomisation was performed by a centralised 
telephone service in sequential blocks of 4. Researchers and participants were 
blinded to allocation and had no access to the randomisation code held by the 
Data Centre until completion of the study. 
During the two-week run-in period, subjects continued their usual asthma 
medication and recorded peak expiratory flow (PEF) and symptoms twice daily, 
in their diary. Further visits were undertaken at randomisation, and after 2, 4, and 
8 weeks (Phase 1). After a washout period of 6 weeks, Phase 2 of the crossover 
was started, with visits after 2, 4, and 8 weeks. At each visit, spirometry was 
performed. Patients recorded morning and evening PEF measurements and 
symptoms throughout the study. Before and after each treatment period, airway 
responsiveness to methacholine, a validated asthma control questionnaire (ACQ) 
score, asthma quality of life questionnaire (AQLQ) score, induced sputum and 
exhaled nitric oxide (FeNO) were recorded and blood samples were taken for 
immunological tests, lipids and liver functions.  Tablets were counted at the end 
of each treatment period as a measure of compliance.
Measurements
Patients maintained a validated diary card14, recording morning and night PEF 
(Mini-Wright; Clement Clarke, Harlow, UK), daytime symptoms, night awakenings, 
use of inhaled rescue medication, and study tablet consumption. Spirometry was 
measured with a dry spirometer (Vitalograph Ltd., Buckingham, UK)15. ACQ was 
recorded16. Methacholine airway responsiveness was measured in subjects with 
a baseline FEV1 of >  60% predicted using Cockcroft’s technique17 with 
concentrations of methacholine from 0.03 to 16 mg/ml18.  Skin prick tests for 
allergy to cat dander, house dust mite (Dermatophagoides farinae) and mixed 
grass pollen were performed (Soluprick, ALK, Horsholm, Denmark). Total IgE 
and specific IgE to house dust mite, grass pollen, and cat dander were assayed 
by the Unicap 100 system (Pharmacia UK Ltd, Milton Keynes, UK). Total IgE 
levels >120 IU/ml and specific IgE levels >0.35 AU/ml were considered raised. 
Atopy was defined when a patient had a positive skin prick test or elevated 
specific IgE level. Sputum was induced as previously described 19. Differential 
cell count was performed and the sputum supernatant fluid analyzed for 
leukotriene (LT) B4 and myeloperoxidase (MPO) using enzyme immunoassay 
5(EIA) (R&D Systems, Abingdon, UK), and IL-8, TNFα, IFN-γ  using a Luminex 
microbead fluorescence kit (Biosource, Invitrogen, Paisley, UK). FeNO was 
measured using a chemiluminescence analyzer (Logan Research Ltd., 
Rochester, UK) at a flow rate of 50 ml/s according to consensus guidelines20. 
Serum was analysed for IL-5, high sensitivity (hs) IL-6, IL-8, hsTNF-α, sICAM-1 
and hsCRP by EIA (R & D Systems). Peripheral blood concentrations of urea, 
electrolytes, lipids, liver function and full blood count were measured in the 
hospital accredited laboratories at the beginning and end of each treatment 
period.
Statistical analysis
Baseline characteristics were described by number and percentage of patients 
for categorical variables and mean (SD) for continuous variables.  Response to 
atorvastatin on lung function, diary data, induced sputum, mediator levels and 
exhaled nitric oxide versus placebo was assessed by normal linear models that 
included parameters for patient, period and treatment. 
A sample size of 44 was calculated to have 90% power to detect a difference in 
means of 20L/min in PEF (primary endpoint)21, assuming a standard deviation of 
differences of 40L/min, using a paired t-test with a 5% two-sided significance 
level. A total of 54 patients were recruited to ensure that 44 patients completed 
the study. All data was analysed using SAS version 9 (SAS Institute, Cary, NC). 
Response to atorvastatin on lung function, diary data, induced sputum, mediator 
levels and exhaled nitric oxide versus placebo was assessed by normal linear 
models that included parameters for patient, period and treatment. When 
variables were unsuitable for this, the within-patient treatment differences were 
calculated and then analysed by either t-test or Wilcoxon test, as appropriate. 
Significance at a level of 5% was accepted for the primary endpoint, the mean of
the morning PEF measurements taken from the 7 days of diary recording before 
each study visit. The mean was calculated if there were at least three days of 
completed data within that period.
RESULTS 
Recruitment and baseline characteristics
A total of 4303 asthmatic patients from 39 practices and hospital clinics were 
invited to participate (Figure 1). Of the 439 replies, screening visits were 
arranged for 137 volunteers and 54 were randomised. Baseline demographic and 
clinical characteristics of patients are listed in Table 1 and baseline inflammatory 
biomarkers in Table 2. Distributions of baseline characteristics were similar for 
patients starting with placebo and those starting with atorvastatin. All subjects 
were atopic.
6Table 1: Demographics and clinical characteristics of subjects 
Variable All Patients (n=54)
Male sex, n (%) 23 (42.6%)
Ex-smoker, n (%) 6 (11.1%)
Age, years 42.5 (13.7)
Asthma duration, years 24.9 (16.6)
Positive IgE serology (%) 89%
Equivalent beclometasone daily dose,
mcg, median (IQR) 400 (200-800)
Morning PEF, L/min 390.3 (103.5)
Evening PEF, L/min 403.3 (101.4)
FEV1 pre-salbutamol, L 2.78 (0.86)
FEV1 post-salbutamol, L 3.18 (0.84)
FEV1 % predicted 85.7 (19.3)
FEV1 %reversibility 14.9 (11.7)
Geometric mean (range) PC20 (mg/ml) 2.5 (0.9 - 6.2)
Asthma Control Questionnaire Score 1.5 (0.8)
AQLQ Score, median (IQR) 5.75 (5.03-6.19)
Definition of abbreviations: PEF, peak expiratory flow; FEV1, Forced Expiratory 
Volume in one second; AQLQ, asthma quality of life questionnaire, PC20, 
concentration of methacholine that reduces the FEV1 by 20%.
Data represented as mean (SD) unless otherwise indicated.  
Changes in clinical outcomes 
Changes in clinical outcomes after atorvastatin treatment are listed on Table 3 
and illustrated in Figure 2.  At 8 weeks, the change in mean morning PEF, as 
compared with baseline, did not differ between the atorvastatin and placebo 
treatment periods [mean difference -0.5 L/min, 95% Cl -10.6 to 9.6, p=0.921]. 
The estimated mean difference for the primary outcomes (20L/min) was much 
larger than that obtained in the study. No statistically significant effect of 
atorvastatin was seen in evening PEF, pre- and post- salbutamol FEV1 or 
methacholine responsiveness (PC20). Similarly, there was no significant 
difference in ACQ score or AQLQ score between atorvastatin and placebo 
treatment periods.
7Table 2: Baseline induced cytology and inflammatory biomarker levels. 
Variable Median (IQR)
Induced sputum cell counts and proportion (%)
Total cell count (x106) 1.4 (0.8- 4.3)
Macrophages (x104) 
Macrophages %
196.5 (101.3 - 235.0) 
49.5 (30.5 - 57.5)
Neutrophils (x104)
Neutrophils %
129.8 (60.0 - 186.5)
35.5 (14.5 - 48.3)
Eosinophils (x104)
Eosinophils %
6.4 (2.0 - 16.3)
1.5 (0.6 - 5.0)
Lymphocytes (x104)
Lymphocytes %
2.5 (1.0 - 5.5)
0.7 (0.3 - 1.1)
Bronchial epithelial cells (x104)
Bronchial epithelial cells %
44.0 (12.0 - 60.3)
10.0 (8.0 - 316.0)
Mediators
MPO (ng/mL) 179.0 (73.5 - 276.0)
LTB4 (pg/mL) 47.8 (32.6 - 80.4)
IL-8 (ng/mL) 1.9 (0.8 - 5.3)
TNFα (pg/mL) 11.4 (4.6 - 46.5)
IFN-γ (pg/mL) 19.8 (4.9 - 71.6)
Exhaled nitric oxide
FeNO ppb 18.3 (10.1 - 33.1)
Serum biomarkers
hs-CRP (mg/L) 1.68. (0.5 – 3.8).
sICAM (ng/mL) 209.4 (185.7 - 245.4)
IL-5 (pg/mL) 7.3 (1.9 - 26.4)
IL-8 (pg/mL) 14.3 (0.6 - 24.0)
TNF-α (pg/mL) 1.1 (0.7 - 1.8)
IL-6 (pg/mL) 1.1 (0.7 - 3.1)
Abbreviations: CRP, C-reactive protein; HDL, high density lipoprotein; NO, nitric oxide; 
ppb, parts per billion; sICAM, soluble inter-cellular adhesion molecule; TNFα, tumour 
necrosis factor-α; IL, interleukin; MPO, Myeloperoxidase; LT, Leukotriene; IFN, 
interferon.
Changes in inflammatory biomarkers
Induced sputum cytology
The total cell counts recovered from sputum were similar after atorvastatin 
compared to after placebo treatment (Table 3). After 8 weeks, the mean absolute 
and relative sputum macrophage count was significantly reduced after 
atorvastatin compared to placebo [mean absolute difference -44.9x104 cells, 95% 
Cl -80.1 to -9.7, p=0.029] (Table 3, Figure 3). There was a reciprocal increase in 
the relative proportion of sputum neutrophils [mean proportion difference 13.1% 
(1.8 to 24.4), p=0.025] (Table 3, Figure 3), but there were no significant changes 
in the absolute count of these cells or the counts and proportions of the other 
sputum cell phenotypes under atorvastatin treatment. 
8Table 3: Treatment differences in outcome measures after 8-weeks 
atorvastatin compared to placebo.
Variable Atorvastatin Placebo
Treatment difference, 
atorvastatin minus 
placebo (95% CI)
Clinical outcomes [mean (SD)]
Morning PEF L/min
Evening PEF L/min
FEV1 pre-salbutamol, L
FEV1 post-salbutamol, L
387.0 (106.5) 
395.3 (101.0) 
2.7 (0.8) 
3.1 (0.8)
393.9 (114.2) 
403.8 (116.3) 
2.7 (0.8) 
3.1 (0.8) 
-0.5 (-10.6, 9.6) 
4.6 (-5.8, 15.0) 
0.01 (-0.01, 0.10) 
-0.05 (-0.13, 0.03)
PC20 methacholine 
geometric mean (range), mg/ml  
2.7 (0.9, 10.3) 3.0 (0.6, 9.6) 0.05 (-1.6, - 1.7)
ACQ 1.4 (0.9) 1.5 (0.8) -0.03 (-0.28, 0.21)
AQLQ, median (IQR) 5.9 (5.4, 6.6) 5.9 (5.4, 6.4) 0.1 (-0.1, 0.3)
Sputum differential cell count and proportion (%)
Total cell count (x106) 1.7 (0.9, 2.8) 1.6 (0.6, 4.7) -0.07 (-0.14, 0.01)
Macrophage (x104)
Macrophage %
134.3 (71.0, 201.0) 
37.0 (20.5, 52.5)
171.3 (135.0, 222.8) 
45.3 (36.5, 58.5)
-44.9 (-80.1, -9.7) *
-10.9 (-20.5, -1.2) *
Neutrophil (x104) 
Neutrophil %
133.3 (81.5, 234.0) 
34.8 (22.0, 65.0)
100.0 (50.3, 167.8) 
25.0 (15.0, 41.9)
47.1 (-2.0, 96.2) 
13.1 (1.8, 24.4) *
Eosinophil (x104)
Eosinophil %
3.8 (2.0, 10.5) 
1.0 (0.5, 3.0)
5.0 (1.0, 10.5) 
1.5 (0.4, 3.0)
-12.1 (-32.9, 8.6)
-2.7 (-7.1, 1.7)
Lymphocyte (x104)
Lymphocyte %
2.0 (1.0, 4.5) 
0.6 (0.4, 1.0)
1.9 (1.0, 5.0) 
0.5 (0.3, 1.4)
0.4 (-0.9, 1.7) 
0.15 (-0.18, 0.49)
Bronchial epithelial cell (x104)
Br. epithelial cell %
38.8 (17.0, 59.0) 
10.3 (4.0, 24.0)
33.5 (18.8, 69.3) 
11.9 (5.0, 17.8)
-3.5 (-23.3, 16.3) 
0.28 (-5.32, 5.88)
Sputum mediators
Leukotriene B4 50.4 (27.6, 79.8) 68.2 (28.6, 130.2) -88.1 (-156.4, -19.9) *
Interferon-γ 23.9 (3.8, 68.0) 21.5 (3.1, 155.5) -38.4 (-175.4, 98.6)
MPO (ng/mL) 87.5 (51.0, 193.0) 112.3 (56.5, 206.0) -32.6 (-112.8, 47.7)
TNFα 12.5 (4.7, 45.3) 16.2 (4.4, 123.0) -30.3 (-111.6, 51.0)
Interleukin-8 1.5 (0.5, 3.6) 1.5 (0.6, 5.1) -1.6 (-5.7, 2.5)
Exhaled NO (ppb)
16.17 (8.99, 38.1) 17.32 (9.0, 42.69) -1.6 (-7.1, 3.9)
Serum biomarkers
hs-CRP (mg/L) 0.64 (0.45, 1.46) 1.06 (0.58, 2.48) -0.65 (-1.38, 0.09)
sICAM (ng/mL) 201 (173, 222) 204 (164, 239) -6.5 (-21.4, 8.4)
TNFα 1.03 (0.60, 1.90) 1.17 (0.77, 1.87) -0.5 (2.5, 1.4)
Interleukin-5 1.87 (1.87, 21.63) 1.87 (1.87, 27.96) -3.4 (-11.3, 4.5)
Interleukin-6 1.28 (0.74, 3.12) 1.19 (0.69, 3.56) -0.02 (-1.89, 1.85)
Interleukin-8 0.71 (0.56, 12.17) 8.06 (0.56, 17.54) -0.5 (-1.5, 0.5)
Serum biochemical markers
Triglycerides (mmol/l) 0.9 (0.6, 1.3) 1.1 (0.8, 1.6) -0.24 (-0.54,  0.05)
Cholesterol (mmol/l) 3.3 (2.9, 3.9) 5.1 (4.5, 5.7) -1.7 (-1.9, -1.5) ***
HDL-cholesterol (mmol/l) 1.2 (1.1, 1.5) 1.4 (1.1, 1.7) -0.14 (-0.26, -0.02) *
Bilirubin (μmol/l) 10.0 (8.0, 13.0) 8.0 (6.0, 10.0) 1.8 (0.7, 2.9) **
AST (IU/l) 23.0 (18.0, 27.0) 20.0 (16.0, 24.0) 2.9 (0.8, 4.9) **
ALT (IU/l) 26 (18, 35) 20 (15, 33) 5.6 (2.7, 8.5) ***
9Abbreviations: ACQ, Asthma Control Questionnaire; ALT, alanine aminotransferase;
AQoL, Asthma Quality of Life Questionnaire; AST,  aspartate aminotransferase; CRP, C-
reactive protein; diff., differential; FEV1, forced expiratory volume in one second; HDL, 
high density lipoprotein; MPO, myeloperoxisade; NO, nitric oxide; ppb, parts per billion; 
PEF, peak expiratory flow rate; sICAM, soluble inter-cellular adhesion molecule; TNFα, 
tumour necrosis factor-α. Mediator levels pg/ml unless otherwise indicated. 
Data represented as median (IQR) unless otherwise indicated.  
* = p<0.05, ** = p < 0.01, *** = p < 0.001.
Inflammatory biomarkers in sputum
The sputum concentrations of inflammatory cytokines and mediators were similar 
after atorvastatin compared to after placebo treatment (Table 3) other than 
leukotriene B4 (LTB4) which was significantly reduced [mean difference -88.1 
pg/mL (95% CI -156.4 to -19.9) p=0.014].
Exhaled nitric oxide
There was no significant change in FeNO after atorvastatin compared to placebo, 
[mean difference -1.6 ppb, 95% CI -7.1 to 3.9, p=0.559] (Table 3). 
Inflammatory biomarkers in serum
No significant difference was seen in the concentration of any serum marker of 
inflammation between atorvastatin and placebo treatment periods (Table 3). The 
change in hsCRP was of borderline significance [mean difference -0.65 mg/L, 
95% CI -1.38 to 0.09, p=0.082], but there were no changes in sICAM-1, TNF-α, 
IL-5, IL-6 and IL-8.
Change in biochemical markers 
The biochemical effects of atorvastatin therapy were reflected in significant 
reduction in concentration of serum lipids; cholesterol (mean difference -1.71 
mmol/l, 95% CI -1.94 to -1.48 p<0.0001), HDL-cholesterol (mean difference -0.14 
mmol/l, 95% CI -0.26 to -0.02 p=0.026), but not triglycerides [Table 3]. There 
were significant, albeit modest, increases in mean bilirubin, AST and ALT. 
Adverse events 
Adverse event rates were similar in patients taking atorvastatin compared with 
placebo. One patient receiving atorvastatin required oral steroid, while none in 
the placebo group did. 2 patients from each group made unscheduled visits to 
their general practitioner, and 2 patients from the atorvastatin group compared 
with one from the placebo group attended the emergency department in relation 
to their asthma during the study. Equal numbers of patients were lost to follow-up 
in both arms of the study. One patient died of unrelated causes while taking the 
placebo medication.
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Compliance 
There was no difference in compliance, assessed by number of tablets returned 
and by biochemical results. 
DISCUSSION 
This randomised controlled study tested the hypothesis that atorvastatin added to 
inhaled corticosteroids treatment could improve lung function and airway 
inflammation in adults with allergic asthma. We found that that there were no 
clinically important improvements in a range of clinical indices of asthma control 
after eight weeks of treatment with atorvastatin despite expected changes in 
serum lipids. There were, however changes in airway inflammation and in 
particular, a reduction in the absolute sputum macrophage count after 
atorvastatin compared to placebo and an associated reduction in sputum LTB4.
 
The lack of any evidence of clinical benefit of atorvastatin in allergic asthma 
confirms and extends the findings of Menzies et al 11, who performed a 
randomised placebo controlled crossover trial of simvastatin in 16 steroid-naïve 
subjects with asthma. Simvastatin was administered for 2 weeks at 20 mg daily 
and 2 weeks at 40 mg daily, with no washout between active and placebo 
treatment periods 11. In our study the statin chosen, atorvastatin, was 
administered at a higher dose and for longer duration and to a larger group of 
participants (n=54), but we found no evidence of improvement in lung function or 
airway hyperresponsiveness. We estimated that 8 weeks duration of therapy was 
long enough to show a clinical effect, on the basis that serum cholesterol levels 
fall within 6 weeks of statin treatment 22, and our own findings show a highly 
significant drop in cholesterol after 8 weeks’ treatment. Plasma CRP 
concentration has been shown to fall within four weeks , and possibly even in the 
first two days of treatment23. However, CRP reduction was only of borderline 
significance in the present study possibly because the CRP levels were not high 
at baseline or due to lack of statistical power. Changes in CRP may be more 
apparent in lung diseases with raised CRP levels which could include COPD, or 
in exacerbations, because previous studies have suggested that statins decrease 
episodes of pneumonia 24. Statins have an inhibitory effect on human airway 
smooth muscle cell proliferation 25, therefore it is possible that the administration 
of atorvastatin therapy for a longer duration of time might have improved different 
clinical outcome measures of asthma such as indices of airway remodelling.
It is unlikely that using a different statin would have shown any greater effects. A 
trial in rheumatoid arthritis 7 used atorvastatin with evidence of clinical benefit. 
Although the initial experimental work in inflammatory lung disease used 
simvastatin 3 10 and pravastatin 9, Joukhadar and colleagues showed no 
difference in effect on inflammatory parameters when comparing atorvastatin, 
simvastatin or pravastatin 12. Furthermore no therapeutic effect was found with 
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simvastatin in asthma 11. The six week washout period for the present study was 
considered acceptable because evidence suggests that the anti-inflammatory 
effects of statins do not last this long. Circulating levels of sVCAM-1 revert to 
normal in 2 days 26, and CRP 27  and IL-6 concentrations have returned to 
baseline after 7 days withdrawal 23 28. No evidence of a carry-over effect on 
clinical outcome measures was seen in the present study. 
One possible explanation for the apparent lack of clinical efficacy in this study is 
that all patients were taking regular inhaled corticosteroid therapy and had a low 
basal sputum eosinophil count. In the study by Menzies et al, all patients were 
withdrawn from inhaled corticosteroids before treatment began, with patients 
receiving a long-acting beta2-agonist instead11. The lack of efficacy with 
atorvastatin is unlikely due to insufficient room for improvement in clinical 
outcome measures since the patients group had evidence of reversibility in FEV1
of approximately 15% and has a raised mean ACQ score of 1.5. Compliance with 
medication was supported by tablet counting and by the significant changes in 
serum lipids and liver function tests observed in the patients receiving 
atorvastatin. 
There was no effect of statin therapy on any of the inflammatory biomarkers other 
than decreases in sputum macrophage count and LTB4 concentration. 
Several mechanisms, either alone or in combination, might explain these 
observations. Firstly, statins reduce growth of both animal and human 
macrophages 29 30 and possibly atorvastatin had a similar effect on sputum 
alveolar macrophage numbers. Secondly, LTB4 is raised in induced sputum 
supernatant in asthma 31 and mediates the recruitment of alveolar macrophages 
through the B leukotriene receptor-1 32. The decrease in sputum LTB4
concentrations observed in patients treated with atorvastatin could contribute to 
the reduced sputum macrophage count. Thirdly, statins interfere with cell binding 
by reducing monocyte to endothelial cell adhesion and the recruitment of 
macrophages to the lung 33 34. Finally, statins reduce the in vitro release of 
cytokines and mediators including TNFa from monocytes 35 and endothelial cells  
36 37. Similar effects on the release of these cytokines and mediators, including 
from cells within the airways could reduce the recruitment of alveolar 
macrophages to the airways. Against this latter mechanism, we found no 
reduction in sputum TNFa, or circulating IL-6, TNFa, and ICAM-1 concentrations 
following atorvastatin therapy. Future studies should examine these potential 
pathways. 
The reduction in alveolar macrophage count found in patients with allergic 
asthma may have relevance to the treatment of chronic lung diseases such as 
COPD in which alveolar macrophage function has been implicated in the 
pathogenesis 38. Lovastatin has effects on human and mouse macrophage 
function by enhancing the clearance of apoptotic cells, a statin-specific effect 
reversible with mevalonate, through modulation of Rho-GTPases 39. Production 
of MMP-9 is also reduced by statins 29, which could also have an impact on 
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COPD. Recent evidence suggests that statins may inhibit lung parenchymal 
destruction, and peribronchial and perivascular infiltration of inflammatory cells in 
a rat model of smoking-induced emphysema 40.
In a mouse model, the neutrophilia associated with acute lung injury is markedly 
reduced with lovastatin treatment 41. Paradoxically we found a significant 
increase in the proportion of neutrophils in induced sputum with atorvastatin 
therapy. The absolute neutrophil counts were not significantly different between 
groups, suggesting that the increased proportion of neutrophils occurred because 
of the low macrophage proportion and the expression of the results as a 
percentage. In support of this explanation, the sputum LTB4 concentration was 
reduced after atorvastatin therapy, which would be more likely to be associated 
with a reduced neutrophil count. 
In conclusion, we have demonstrated that short-term therapy with statins does 
not improve lung function or other indices of asthma control of patients with mild 
to moderate atopic asthma who are already receiving treatment with inhaled 
corticosteroids. The reduction in the sputum macrophage count suggests 
potential areas for investigation of atorvastatin in chronic lung disease in which 
activated alveolar macrophages have been implicated in the pathogenesis, such 
as COPD.
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FIGURE LEGENDS
Figure 1: Flow of subjects through the study
Patients invited n = 4303
Suitable for screening n = 299
Positive responses n = 439
Screened n = 137
Randomised n = 54
Competed trial n = 48
Analysed for primary endpoint n = 46
Not eligible n = 140
Declined screening n = 162
Excluded n = 83
Lost to follow-up n = 3
Discontinued n = 3
Final diary missing n = 2
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Figure 2: Mean (95% confidence interval) difference between atorvastatin and 
placebo treatment periods in morning PEF (L/min), FEV1 (L), PC20 methacholine 
(mg/ml) and ACQ score (range 0-6). 
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Figure 3: Mean (95% confidence interval) difference between atorvastatin and 
placebo treatment periods in change in absolute macrophage, neutrophil and
eosinophil counts (x104 cells) compared with baseline. * = p<0.05
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